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SUMMARY 
 
 
Cancer is a growing global health issue and many low or medium resource countries are ill-
prepared to deal with the ever-increasing cancer burden owing to lack of well-developed 
surveillance systems. This needs an inter-disciplinary approach through international 
collaborations between low, middle and high income countries. Systematic reporting of 
cancer incidence and to some extent, cancer mortality, has been done periodically for many 
decades now. Unlike in well-developed countries, cancer survival however, is not routinely 
reported from low or medium resource countries. It required special and concerted efforts 
from multiple quarters to get reliable survival statistics. 
 
Cancer survival generally refers to the lifetime of a person after the diagnosis. 
Population-based cancer survival data are essential for evaluating the development and 
distribution of and accessibility to cancer health services like treatment or screening. Since 
data from low or medium resource countries are beginning to surface in intermittent intervals, 
so have comparisons between well-developed and less-developed countries. This dissertation 
provides a stepwise methodological evaluation right from the conduct of survival study to the 
estimation of survival probability through empirical data from more than 25 registries in 
several low or medium resource countries with variable gross national income values. This is 
inevitable for a balanced interpretation of survival differences. The main material for study 
came from the SURVCAN database of the multinational study by the International Agency 
for Research on Cancer, Lyon, France, and is supplemented by several materials from India 
and Thailand.  
 
The impact of variation in patient follow-up on survival statistics is undisputed. It 
could be due to inappropriate methods employed for getting vital status information: lack of 
active methods of follow up in the presence of sub-optimal mortality ascertainment or high 
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magnitude of loss to follow up by ineffective active follow up. In both instances, it is shown 
by empirical data that application of standard methodology results in systematic bias in the 
estimate of survival. If the losses are high and result in non-random censoring due to 
correlation with outcome, say death, it is a clear indicator to improve the follow up by 
vigorous active methods and to deviate from standard life table estimation of survival and 
resort to estimation of survival by differential loss-adjustment procedures explained through 
its determinants. The magnitude of bias varied between 1-4 percent units for population-
based 5-year absolute survival and was larger between 2-7 percent units even for 3-year 
overall survival for hospital-based studies, for different cancers. 
 
In a registry data environment that warranted the employment of active methods of 
follow up and the real losses to follow up did not exceed one in five cases, the bias induced in 
actuarial survival under different assumptions of vital status of cases due to inappropriate 
choice of follow up methods revealed the following: if only passive methods were employed, 
say for convenience or out of constraints, without any active follow up component, the bias 
induced in 5-year absolute survival estimates varied between 22-47 percent units for different 
cancers; when predominantly passive methods of follow up were employed with necessary 
active component, the bias ranged between 3-10 percent units; when follow up methods were 
totally by active methods but losses to follow up cases were excluded from analysis, the bias 
induced varied between 2-8 percent units for different cancers. This provides an objective 
index of bias resulting in over-estimation or under-estimation of survival in a low or medium 
resource country setting. 
 
 In these circumstances, age-standardized survival rates might adjust for the potential 
confounders and survival data by important prognostic factors like extent of disease may still 
appear plausible or consistent. But a systematic evaluation of bias in estimating survival due 
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to methodological problems and its suitable correction are mandatory before survival 
differences could be attributed to the varied development of treatment resources and/or 
disease characteristics in low or medium resources settings. 
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1. INTRODUCTION 
 
1.1 Cancer registration principles and methods worldwide 
 
Reliable data on the magnitude of cancer problem are essential for monitoring the health of 
the community, assess the performance of the health care system and allow authorities to 
make informed decisions. Cancer registration may be defined as the process of continuing, 
systematic collection of data on the occurrence and characteristics of cancer with the purpose 
of helping to assess and control the impact of malignancies on the community. The cancer 
registry is the office or institution, which attempts to collect, store, analyze and interpret data 
on persons with cancer (Jensen et al., 1991). The potential source of reliable data has been the 
cancer registry, forming an essential part of any rational program on cancer control (Muir et 
al., 1985). Epidemiological research based on comprehensive cancer registration remains the 
most valid and efficient way to plan and evaluate cancer control activities. The value of a 
cancer registry is dependent on its quality and the extent to which it is used in research and 
health services planning. The usefulness of the data collected would be maximized by 
adopting uniform methods in all aspects of cancer registration. The data becomes useful for 
more and more purposes when they are accumulated over longer periods of time. The means 
of recording cancer cases by active or passive methods may be identical but a distinction is 
made between two major types of cancer registries: Hospital Based Cancer Registry (HBCR) 
and Population Based Cancer Registry (PBCR; Jensen et al., 1991). 
 
1.1.1 Hospital-based cancer registry 
 
A HBCR is concerned with the recording of information on all cancer patients seen in a 
single or group of hospitals, usually without the knowledge of the background population. In 
other words, all cancer patients attending the hospital(s), irrespective of the place or area they 
come form, are registered with an emphasis on clinical care and hospital administration. 
HBCRs present an opportunity to begin a documentation process to provide information on 
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clinical epidemiology of cancer (Valsecchi and Steliarova-Foucher, 2008). The establishment 
of HBCRs is historically rooted in the belief that individual patients are better served through 
the presence of a registry, since the registry will serve to ensure that patients return for 
follow-up examinations on a regular basis. The importance of a HBCR need not be stressed 
more that its existence is an indispensable requirement in the accreditation process of any 
cancer research programme of a hospital (Young, 1991). The HBCR ensures comparability of 
data between registries worldwide and over very long time period by adopting uniform 
classification of cancer diagnosis through standard international norms for disease coding 
(ICD-10, 1992, ICD-O, 2000). With the presence of a HBCR, case finding mechanisms are 
evolved so that the potential departments dealing with cancer cases and/or records are 
covered for accession and required information following a standard questionnaire format are 
collected either from patients (by direct interview with consent) and/or abstracted from 
records and/or by linkage through computers to serve as a repository of data on all cancer 
cases attending the institution (Young, 1991).  
A HBCR is also central to monitoring the patient follow-up activity. This includes 
devising ways to record several patient contact particulars before the start of initial treatment 
as a prerequisite, to systematically update data on follow up visits of patients to the hospital 
and to initiate timely reminders for those patients who default through active methods like 
postal or telephone or other inquiries or approaches. Naturally, these activities make sure that 
a HBCR is an important source of data for any survival study (Jensen et al., 1991, Young, 
1991). In most low or medium resource countries, a HBCR has usually been the starting point 
of cancer registration activity in a region before expansion into a population-based coverage 
(Valsecchi and Steliarova-Foucher, 2008). While all HBCRs under the National Cancer 
Registry Programme in India had been largely successful in achieving systematic and 
continuous registration of new cancers, the data on disease outcomes have largely been 
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deficient. This was mainly because of lack of strategy to develop follow up methods and 
documentation and integrate the same with HBCR activity. Apart from isolated reports on 
selected and small series of hospital patients, survival outcome based on large hospital series 
has been rare to come (Rao et al., 1998, Shanta et al., 2008). Chennai HBCR routinely 
publishes survival statistics on treated patients as part of the annual or biennial reports 
(Shanta et al., 2008). However, individual HBCRs in different major medical institutions 
have served as important data sources for PBCR thereby forming the nucleus of PBCR 
activity in the region. 
 
1.1.2 Population-based cancer registry 
 
The main objective of PBCR is to collect and classify information on all incident cancer 
cases occurring in a defined population, most specifically to a geographic area, in order to 
generate statistics on the occurrence of cancer in that population and to provide a framework 
for assessing and controlling the impact of cancer on the community (Jensen et al., 1991). 
The earliest population based cancer registry was commissioned in Hamburg, Germany in 
1929, with emphasis on medical, scientific, public health and economic aspects through 
active form of registration of cases from multiple sources and subsequent comparison with 
death certificates as a follow up activity on a voluntary basis. The continuous recording of 
cancer cases by patient name began in Mecklenburg in 1937 signifying a methodological 
progress of eliminating multiple registrations and determining individual outcomes. 
Population-based cancer registry of New York State in USA was established in 1940 with 
compulsory notification of cancer cases. The Danish Cancer Registry, founded in 1942 is the 
oldest serving registry covering a national population (Jensen et al., 1991). Since then, this 
activity has gradually progressed and is currently well developed in high resource countries. 
In most of the well-developed countries, cancer has been declared as a notifiable disease and 
hence registration of incident cases is predominantly done by passive method. However, 
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population-based cancer registration is still in variable levels of development in low or 
medium resource countries  
 
Unlike in the well-developed countries, cancer is not a notifiable disease in most low 
or medium resource countries and hence registration of incident cancer cases had been 
carried out predominantly by active methods as per the guidelines advocated by the 
International Agency for Research on Cancer (IARC) and the International Association of 
Cancer Registries (IACR). The location of registry is usually in the major cancer hospital 
with research facility in the region. The cancer registrars of the PBCR regularly visit multiple 
sources of data including major hospitals in government or public and private sectors, nursing 
homes, consultants, radiation centres, pathology laboratories, imaging centres, screening 
programmes, insurance firms and hospices, for data collection from patients by direct 
interview and/or from medical records or case listings or computer print-outs. A standardized 
form is used for collection of data on personal identification, disease, treatment and outcome 
variables. The mandatory data collected are as follows: patient identity (patient name and/or 
personal identity number, area of residence with particular emphasis on duration of stay of 
one or more years to avoid registering cases from a floating population, age at diagnosis 
and/or date of birth, sex) and disease related (incidence date, most valid basis of cancer 
diagnosis, cancer site and morphology, tumour behaviour and grade). Other data pertaining to 
the patient (socio-demographic, elements of socio-economic status, etc.), disease (clinical 
extent of disease and/or tumour stage) and treatment (received or not and/or type or modality, 
etc.) are collected as optional data, depending on the resources and availability. Data 
collection on deaths due to cancer, occurring in the region, is independently carried out as 
part of PBCR operations from vital statistics division as well as hospital death registers. It 
included data on deceased identity (name and/or personal identity number, age at death, sex, 
etc.) and death (all or cancer causes, date, place, etc.). The mortality data thus collected were 
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matched against all incident cancer cases in PBCR database through visual inspection of 
probable lists of similar pairs of listings manually or by electronic linkages. Data on all 
deaths, irrespective of the stated cause of death, were also utilized for this linkage to optimize 
the availability of mortality information on registered cancer cases. Matched cases were 
updated with death information in registry database. In a majority of PBCRs, unmatched 
deaths were traced back to hospitals for availability of more details on disease factors and 
registered accordingly. If no additional information is forthcoming, these deaths are 
registered in PBCR as cases on the basis of a death certificate only (DCO). Since cases are 
registered from multiple sources, elimination of duplicate notifications is done with utmost 
care. This is directly related to the quality of person identity data at registration. With the 
knowledge of background population that is giving rise to the cases, reports on incidence 
rates are published routinely. Even in low or medium resource countries, PBCRs have been 
extensively utilized in evaluating cancer screening and early detection programmes in the 
region (Swaminathan et al., 2009). 
 
PBCR operations have been carried out in a systematic manner for many decades now 
even in low or medium resource countries (Table 1). The scientific publication series from 
the IARC, Lyon, France, titled Cancer incidence in five continents (CI5C) from volumes I to 
IX, constitute a compendium of cancer incidence statistics based on good quality data from 
cancer registries worldwide (Parkin et al., 2005, Curado et al., 2007). 
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Table 1: Current status of cancer registration and survival studies in low or medium 
resource countries by continent or region 
 
Conduct of population-
based survival study 
Conduct of survival 
study on hospital series 
 
Continent/ 
Region 
Number 
of 
countries 
Number 
of 
registries 
Number of 
populations 
studied 
Year of 
starting 
registration 
– Range 
Countries Year of 1st 
publication 
Countries Year of 1st  
publication 
Africa 8 10 17 1953-1999 4 2003 1 1999 
Asia 14 52 57 1960-2000 8 1995 6 1971 
Caribbean 4 4 4 1958-1995 1 1996 0 - 
Latin 
America 
11 21 22 1958-2000 3 2006 3 1999 
 
 
Table 1 shows the status of population based cancer registration in low or medium 
resource countries by continents or regions as included in volumes I to IX of CI5C series 
(Parkin et al., 2005, Curado et al., 2007). Cancer registration activity in Africa, Asia, the 
Caribbean and Latin America had commenced in late 1950s or early 1960s: Uganda, 
Kyadondo, in 1954; Israel in 1960; India, Mumbai (formerly Bombay) in 1962; Colombia, 
Cali, in 1967 (Parkin et al., 2005). New registries in low or medium resource countries have 
started their operations in mid or late 1990s and newer ones have been added to this list as 
recent as in early or mid-2000 (Curado et al., 2007). Collective or individual reports on 
cancer incidence and mortality have been published as a routine from many of the registries 
in low or medium resource countries continuously from time to time (Sierra et al., 1988, 
Laudico et al., 1989, National Cancer Registry Programme, 1992, Vatanasapt et al., 1993, 
Parkin et al., 2003, Shanta et al., 1994). Hospital and population based cancer registries, 
being the repositories of data on cancer cases collected in a systematic manner using standard 
methods, are generally regarded as important sources of information about cancer survival 
(Black et al., 1998c). Cancer registries could also serve as a novel alternative for long-term 
clinical trial follow up (Shi et al., 2010). 
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1.2 Cancer survival studies from low or medium resource countries 
 
Long-term survival from cancer, such as surviving for five years or more after diagnosis, may 
reflect cure and is a positive sounding measure that can be used by planners, the public, 
doctors and patients to measure and discuss the outcome of cancer diagnosis and success of 
treatment. Survival analysis can be considered as a cohort study with a difference: here the 
length of follow up time is of greater interest than the occurrence of the event itself. Also, the 
rate of occurrence of the event is not constant over time and censored observations occur. 
Hence, special methods capable of dealing with such instances are necessary for undertaking 
survival analysis. 
 
Hospital based cancer registries with high resolution database form the basis for 
survival studies on selected series of cancer cases. If survival study is part of randomized 
controlled clinical trials, it represents the gold standard for the evaluation of outcomes of 
treatment. Otherwise, it aims to provide information about the outcome of cancer directed 
treatment in particular settings in formulating hypotheses on the effectiveness of treatment 
modalities or outcomes and study of prognostic factors. On the other hand, survival rates 
calculated using PBCR data, with at least minimum information on all cancer cases in 
defined areas, would provide an objective index of the effectiveness of cancer care in the 
region concerned. However, cancer survival studies have generally been sparse from low 
(with per head gross national income (GNI) less than US$ 2000) or medium (per head GNI 
between US$ 2000 and US$ 10,000) resource countries. Until early 1990s, there were only 
isolated reports of survival studies on hospital series based on locally available expertise and 
interests (Sankaranarayanan et al., 1998). Unlike in well developed countries, PBCRs in low 
or medium resource countries, with a long history of operations, have not been able to 
undertake survival studies routinely. Table 1 reveals that the earliest publications on cancer 
survival based on registry data in Africa, Asia, Caribbean and Latin America were brought 
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out between one and five decades after the commencement of registry operations. This points 
out to the general lack of good surveillance systems despite availability of long-standing 
cancer registration practices.  
 
Figure 1 shows the map of location of 32 registries from 16 low or medium resource 
countries that had conducted population-based cancer survival studies till date. The first 
collaborative study on cancer survival in developing countries initiated by the IARC, Lyon, 
France, reported data from 10 registries in five low or medium resource countries 
(Sankaranarayanan et al., 1998). The second study by IARC called SURVCAN attracted 
participation from 26 registries in 13 low or medium resource countries. The following 
registries had participated in the first or second or both the studies: Hong Kong, Qidong, 
Shanghai and Tianjin from China; national registries of Costa Rica and The Gambia; 
Bangalore, Barshi, Bhopal, Chennai, Karunagappally and Mumbai registries from India; 
South Karachi from Pakistan; Manila and Rizal from Philippines; Busan, Incheon and Seoul 
from the Republic of Korea; Riyadh from Saudi Arabia; Chiang Mai, Khon Kaen, Lampang 
and Songkhla from Thailand; Izmir from Turkey; Kampala from Uganda and Harare from 
Zimbabwe.  Singapore was an additional one from the high resource countries that also 
participated in the SURVCAN study (Sankaranarayanan and Swaminathan, 2011). The 
registries from low or medium resource countries that participated in the worldwide 
population study on cancer survival in five continents named CONCORD were Setif Wilaya 
registry from Algeria and Goania and Campinas registries from Brazil (Coleman et al., 2008). 
The national registry of Cuba had contributed data for all of the above studies.  
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2. REVIEW OF LITERATURE 
 
2.1 Hospital-based cancer survival studies 
 
Hospital-based cancer survival studies either form part of on-going clinical trials or aside 
studies on small numbers of selected cases with specific cancers pertaining to one institution 
or a small network of institutions. These studies usually involved selected cancer cases that 
completed at least one modality of cancer directed treatment following standard treatment 
protocols or by choice. The rationale of a randomized clinical trial is to eliminate even the 
effects of unknown confounders so that the only systematic differences are the treatments 
received (Black et al., 1998c). This approach is needed to establish the efficacy of the 
treatments. However, hospital-based studies on non-randomized settings are essential for the 
purposes of eliciting the effectiveness of treatment protocols that are being followed for 
different cancers in the hospital. In more developed countries, such patterns of care studies 
are mounted on HBCRs that have inherent systematic follow up procedures and transforming 
them into hospital-based clinical cancer registries (HBCCR) facilitating collection of high-
resolution data on a continuous basis at least for selected major cancers like breast and cervix 
having good prognosis. Such an initiative is already in place under National Cancer Registry 
Programme in India. 
 
The need to compute survival probability as an outcome measure of treatment was 
realized in the early 1970s in low or medium resource countries (Krishnamurthi et al., 1971). 
This was possible only because an effective follow up system was evolved and was made an 
integral function of the HBCR on a continuous basis to include major cancers. However, 
unlike in high resource countries, cancer survival studies based on hospital series were only 
sparingly available from low or medium resource countries for a long time from then: 
Pengsaa et al., 1989, Pavlovsky et al., 1992, Nair et al., 1993, Ganesh, 1995, Mathew, 1996, 
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Rao et al., 1998, to name a few. These studies dealt with varied aspects like estimating 
survival probability, eliciting prognostic factors and methodology. 
 
2.2 Population-based cancer survival studies 
 
In order to describe completely the experience of cancer in a population, it is necessary to 
know not only its incidence and mortality, but also the survival of cancer patients. 
Effectiveness of cancer services generally does not depend only on the efficacy of treatment 
but also on the context in which they are applied. Evaluating effectiveness requires estimation 
of survival in unselected groups of cancer patients and this is exactly what population-based 
survival study aims to provide (Black et al., 1998c). Unlike in high resource countries, the 
first report of survival studies from low or medium resource countries based on population 
based cancer registry series of all or selected incident cancers started emerging from the mid-
1990s (Nandakumar et al., 1995, Sriamporn et al., 1995). These were the first results of the 
initiative taken by the IARC, Lyon, France, for conducting a multi-national collaborative 
study on cancer survival in developing countries in 1994 (Sankaranarayanan et al., 1998). 
Several such projects were undertaken later with the support of different international 
agencies by including new registries from low or medium resource countries in Africa, Asia, 
the Caribbean and Latin America (Coleman et al., 2008; Swaminathan et al., 2009, 
Sankaranarayanan and Swaminathan, 2011).  
 
2.3 Factors influencing population-based survival and comparisons 
2.3.1 Host factors 
 
Age at diagnosis had emerged as an independent prognostic factor for many cancers from 
many registries with clear inverse relationships with survival (Sankaranarayanan et al., 1998). 
This could be either age may be associated with risk of dying due to particular cancer or 
dying due to other causes. This effect is often dealt by age-standardization of survival rates 
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by choosing appropriate standard methods (Brenner et al., 2004b) or populations (Black and 
Bashir, 1998a).  
 
Sex of the patient is less commonly associated with variations in survival permitting 
combined data on men and women together for estimating survival. Such disparities in head 
and neck cancer survival are removed when adjusted for potentially confounding prognostic 
variables like life styles and treatment (Roberts et al., 2010).  However, for some cancers like 
skin melanoma, sex of the patient is an independent risk factor for survival (Mervic et al., 
2011) probably due to greater recognition of early symptoms.  
 
Comorbid conditions experienced by cancer patients may vary substantially between 
registry populations. Comorbidity affects survival by presenting an additional source of risk 
of death, making it less likely that a patient will be offered curative treatment and if it is 
offered, less likely that the patient will be able to withstand the effects of treatment itself 
(Black et al., 1998c).  
 
Socio-economic differences in survival have been reported for many cancers in 
Europe (Kogevinas, 1991, Cavalli-Björkman et al., 2011), the USA (Berg et al., 1977) and a 
few low or medium resources country populations (Nandakumar et al., 1995). Socio-
economic disparities in diagnostic activity and management of large bowel cancers have been 
reported, which affect survival (Cavalli-Björkman et al., 2011). For almost all cancer sites, 
survival was consistently the highest for patients with the highest education and lowest for 
those with only basic education, showing that even in a potentially equitable society with 
high health care standards, like Finland, marked inequalities persist in cancer survival 
(Pokhrel et al., 2010, Cavalli-Björkman et al., 2011). When socio-economic conditions are 
grossly different between more-developed and less-developed countries, the inequalities in 
access to or development of cancer care are likely to be of particular significance in survival 
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studies from low or medium resource countries (Black et al., 1998c). However, many 
elements of socio-economic status are not routinely available for all cancer sites in registry 
data but are usually collected using extra efforts as a special study. 
 
2.3.2 Tumour related factors 
 
By convention, cancer registry data are aggregated within categories of anatomical sites 
defined by standard coding norms (ICD-10, 1992, ICD-O, 2000). One has to be wary of the 
differential distribution of subsites when making international comparisons on survival. This 
applies to variations in morphology types within the same cancer site. The stage or clinical 
extent of disease at diagnosis is the single most important factor determining survival. 
Therefore, variations in stage distributions of cancers in the populations being compared have 
a profound impact on survival. Variations in diagnostic technology could still prompt a 
measurement error in stage between more-developed and less-developed countries (Black et 
al., 1998c). But, when an inverse relationship between tumour stage or clinical extent of 
disease and survival were forthcoming, it would be reassuring of data quality on staging.  
 
2.3.3 Health care related factors 
 
There are numerous ways in which the development of or availability of or accessibility to 
screening or diagnostic or treatment facilities for cancer could influence cancer survival. 
Studies have shown that survival of cancer patients is prolonged after treatment in specialized 
cancer centres (Stiller, 1994). Karjalainen and Palva (1989) suggested that the use of a 
treatment protocol gave better results than that by the free choice of a physician in multiple 
myeloma. Markedly lesser survival from testicular cancer in Estonia compared to other 
regions in Europe is attributed to deficiencies in disease management like non-referral to 
oncologists after surgery, poor access to contemporary radiotherapy and general lack of 
coordination among specialised cancer centres (Aareleid et al., 2011). Survival differences 
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between Filipino-American patients and patients from Manila and Rizal registries for nine 
common cancers, higher in the former than latter, highlighted the importance of access to and 
utilisation of diagnostic and therapeutic facilities in low or medium resource countries 
(Redaniel et al., 2009). However, interpreting the differences as due to quality of care per se 
may be misleading in the absence of knowledge on selection of cases treated, which may 
explain the difference better (Black et al., 1998c). 
 
2.4 Data quality indices for population-based cancer survival study 
 
Variations in the quality of cancer registration data would complicate the interpretation of 
survival data based on routine cancer registry data (Hanai and Fujimoto, 1985). Only good 
quality result, fairly presented and with demonstrated use for cancer treatment and cancer 
control, would allow registries to continue and develop (Magrath and Litvak, 1993). 
Population-based cancer survival generally portrays a broader range of cancer control 
activities like screening or organization of treatment services (Black et al., 1998c). This is 
essentially because it is unbiased by selection of both, treated and untreated cases of specific 
or all incident cancers in the region across various sources of registration. Hence, 
completeness and accuracy of registration of incident cancer cases assume importance. If 
cases not registered represent a random sample of the total, there may not be any systematic 
bias introduced in survival results. However, the probability of getting registered is likely to 
be correlated with prognosis. Thus, frequency of cases excluded from survival analysis on 
any pretext, would have a marked impact on the survival estimate and hence have to be kept 
to the barest minimum. The measurable indices that would determine the population-based 
cancer survival data quality due to exclusion from analysis are summarized as follows 
(Sankaranarayanan et al., 1998, Sankaranarayanan and Swaminathan, 2011):  
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• Frequency of cases that were excluded from survival study owing to have been 
registered based on a death certificate only: dead cases with zero survival time and 
information on cancer known only from a death certificate. 
• Frequency of cases that were excluded from survival study owing to lack of any 
follow up: cases with zero survival time and vital status unknown or lost to follow up 
(LFU) with zero survival time. 
 
Other data quality biases concerning health related factors can also have an impact on 
the estimated survival. Over-diagnosis through population-based screening for prostate 
cancer almost certainly accounted for the changing incidence and corresponding survival in 
the USA (Howlader et al., 2011). With minimal exceptions, this phenomenon may not have 
any bearing on cancer survival statistics arising from most low or medium resource countries 
for any cancer site. Influences of diagnostic facilities on survival may be felt through 
improvements in sensitivity of accuracy, inducing stage migration and variations in stage-
specific survival (Feinstein et al., 1985). However, there would not be any problem when 
survival comparisons were done for groups of patients with tumours of all stages together. 
 
2.5 Complete and incomplete follow up 
 
Adequate and complete follow up is an important prerequisite for any survival study. This 
had remained as the greatest impediment in the conduct of cancer survival studies in most 
low or medium resource countries. The reasons included less developed routine information 
systems (like registration, documentation, etc.), lack of unique linkages of incidence and 
mortality data and less efficient follow up methods. Complete follow-up is deemed to have 
been achieved when the vital status (alive or dead) at closing date of study or follow up is 
known for an individual. If not known, then the follow-up is incomplete. The frequency of 
cases with incomplete follow up is the most important data quality index for any survival 
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study. This can be explicitly measured in variable lengths of time from the index date, say 
date of first diagnosis, in an active follow up environment (Swaminathan et al., 1998). By 
active follow up, it is meant that the registry makes efforts voluntarily, to get follow up 
information on patients whose vital status is unknown, through personal (direct approach 
through person contact) or other (indirect approach without person contact) approaches 
(given in detail in section 4.3.1). However, in a passive follow up environment, information 
on deaths is routinely received either by-law or via an arrangement with the vital statistics 
division. Using this procedure, those patients for whom no information of death has been 
received are presumed to be “alive” until that point of time. The main requirement for this 
method to work efficiently is that there must be a high quality of registration of mortality data 
and unique data linkage possibilities, say personal identity number, which ensure the follow-
up of cases to be complete with the exception of migration or rare losses. Active follow-up 
would supplement the latter in case of incomplete passive follow-up. A majority of registries 
in low or medium resource countries had resorted to active methods for follow up data 
collection on vital status owing to the absence of reliable health information system, 
especially cancer mortality registration. The magnitude of incomplete follow up instances 
occurring in survival studies from low or medium resource countries had been generally high 
up to 40% for different cancers (Swaminathan et al., 2002). The pattern of incomplete follow 
up information also displayed variation with most of that occurring within one year of 
diagnosis in most registries whereas it was after 5 years from diagnosis in very few 
(Suwanrungruang et al., 2011, Eser, 2011, Sriplung and Prechavittayakul, 2011, Garrote et 
al., 2011).  
 
2.6 Censoring: Potential withdrawals or loss to follow up 
 
Censoring is unique to lifetime data analysis. It occurs when exact lifetimes are known for 
only a portion of the individuals in the study and known to exceed certain values in the 
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remainder. It allows utilization of all information independent of the length of follow-up of 
an individual patient, so that, even recently diagnosed patients contribute to long-term 
survival (Black and Swaminathan, 1998b). It can occur in many ways. Censored cases are 
usually withdrawals, surviving at date of last follow-up: this date can be either individual for 
each patient or a common closing date for all patients. However, censorship in terms of losses 
to follow-up takes place if follow-up fails before this potential withdrawal. The date at which 
the individual is lost to follow up corresponds to the end of the period of observation. The 
available information on this date provides the status indicator (Chiang, 1968). There is a 
qualitative difference between these two groups of censored cases. It is therefore important to 
know the extent or magnitude, pattern and type of losses to follow up in any survival study.  
 
2.7 Bias due to type of loss to follow up 
 
When censoring occurs, either due to the termination of study at the closing date which is 
solely technical or due to every loss to follow-up that is unrelated to the outcome studied, say 
death, it is said to be random or non-informative censoring. When censoring occurs due to 
loss of follow-up which is related to death, it is known as non-random or informative 
censoring. Standard life table approaches for estimating survival probability such as the 
actuarial (Cutler and Ederer, 1958) or Kaplan-Meier (Kaplan and Meier, 1958) methods do 
not distinguish between these two groups of censorings and treat both of them alike. This 
may cause major bias since the estimates of absolute survival may be artificially raised if 
there are losses to follow up (Ganesh, 1995, Mathew, 1996). Little reliance can be placed on 
the estimated survival assuming random censoring when the magnitude of loss to follow-up 
is high (Swaminathan et al., 2002).  
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2.8 Ascertainment of non-randomness of censoring due to losses to follow up 
 
Death due to any cause is the common end point for estimating overall survival in hospital 
based studies and absolute survival in population based studies. Hence, mortality 
ascertainment is vital for complete follow up. Death registration system is generally not well 
developed in most low or medium resource countries. This is reflected in the paucity of 
cancer mortality data from population based cancer registries published in CI5C series 
(Parkin et al, 2005). In this situation, it is reasonable to believe that losses to follow up may 
be due to or associated with this deficiency. It would be a good starting point to examine the 
factors that are associated with the risk of dying as possible determinants of losses to follow 
up (Ganesh, 1995). For this analysis, all cases censored before closure of the study and 
having had a follow-up of say, less than three or five years, constituted the loss to follow-up 
group (outcome) and the rest of the cases who are either dead or known to be alive on the 
closing date of follow-up are treated as censored (Ganesh, 1995).  
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3. AIMS OF THE STUDY 
 
3.1 General 
 
• To develop a realistic framework for the conduct, design and analysis of hospital-
based and population-based cancer survival studies in low or medium resource 
countries. 
 
3.2 Specific 
 
• To estimate cancer survival rates in low or medium resource countries (I, VI) 
• To evaluate whether the estimated survival and differences, if any, are subject to or 
reflecting,  
o Constraints in cancer registration and/or follow up methods (II),  
o Inappropriate choice of analytical methods for estimating survival (IV, V, VII) 
and  
o Patient, disease, treatment or intervention characteristics (I, III) 
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4. MATERIAL AND METHODS 
 
4.1 Data sources 
The material for this study comprises data from both hospital and population-based cancer 
registries in several low or medium resource countries that formed the basis for the seven 
original publications cited in the appendix. The data, utilized in part or full in this 
dissertation, includes those from,  
(i) SURVCAN databases of the International Agency for Research on Cancer (IARC), 
Lyon, France, comprising 537,490 incident cases of 1-52 cancer sites or types in 27 PBCRs 
from 14 countries in Africa, Asia, the Caribbean and Central America, registered during 
1990-2001 and followed through 2003, period varying for individual registries and other 
associated material of preceding years. Studies (I) and (VI) are fully based on SURVCAN 
databases and reported the summary results.  
(ii) Population-based cancer registry in Chennai, India, comprising 22,460 cases of 10 most 
common cancers and corresponding subtypes plus all tobacco related cancers registered 
during 1990-1999 and followed through 2001 (II) 
(iii) Population-based cancer registry in Chennai, India, comprising 1,274 cases of all 
childhood cancers, aged 0-14 years at diagnosis registered during 1990-2001 and followed 
through 2003 (III) 
(iv) Population-based cancer registry in Khon Kaen province, Thailand, comprising 601 
cases of invasive cervical cancers registered during 1985-1990 and followed through 1995 
(IV) 
(v) Hospital-based cancer registry comprising 336 new cases of invasive breast cancers 
diagnosed and treated at Tata Memorial Hospital, Mumbai, India, in 1985 and followed 
through 1988 (V). 
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4.2 Classification of factors analysed 
4.2.1 Residence 
 
Data on residential status assumes significance in both hospital and population-based 
registries. Unlike in a PBCR, there are no geographic limits restricting the registration of 
patients in a HBCR. However, the nature of the residential area is expected to have an impact 
on the follow up in the context of both registries. For the data from Mumbai HBCR, the 
residential status of patients was classified into two as those from Mumbai city and its 
neighbourhood compared to other farther districts. For the data from Khon Kaen PBCR in 
Thailand, the area (district) of residence was classified as Muang or surrounding districts and 
others. Both these classifications were based on the proximity or not to the super-specialty 
cancer hospitals in their respective regions. 
 
4.2.2 Clinical extent of disease 
 
Data on clinical extent of disease has been used as a viable surrogate for stage of disease for 
selected cancers in this dissertation. It has the greatest significance in correlating local factors 
with the estimated survival. This data is routinely available or collected by most registries in 
low or medium resource countries. The broad norms adopted in classifying this variable into 
four categories are as follows: 
Localized: Tumour confined to the organ of origin, without invasion into the surrounding 
tissue or organ and without involvement of any regional or distant lymph nodes or organs;  
Regional: Tumour not confined to the organ of origin with invasion into the surrounding 
tissue or organ, with or without the involvement of the regional lymph nodes and not 
involving or spread to the non-regional lymph nodes or organs; 
Distant metastasis: Tumour involving or spread to the non-regional lymph nodes or distant 
organs; 
Unknown: The above information is unknown. 
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For Mumbai hospital-based study, staging for breast cancer was possible with 
available documentation and was done following standard norms (Hermanek and Sobin, 
1987) 
 
4.2.3 Cancer directed treatment 
 
Data on cancer directed treatment modality would be very helpful in explaining the 
differences in cancer survival in any setting. However, the availability of such data is limited 
in a PBCR than in HBCR. For the Mumbai HBCR study, data on treatment for female breast 
cancer was categorized as those receiving chemotherapy and not. For Khon Kaen PBCR 
study on cervix cancer from Thailand, data on treatment was categorized into two as those 
receiving any treatment and no treatment.  
 
4.3 Methods 
4.3.1 Follow up 
 
The follow up data on vital status (alive or dead) of a patient is indispensable in the 
estimation of absolute or overall survival. With varying development of cancer information 
systems and capabilities of providing data on follow up, the registries worldwide have 
evolved several ways to achieve this purpose. The methods and approaches towards follow 
up of patients adopted by registries in low or medium resource countries contributing data in 
this study are summarized in Table 2.  
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Table 2: Methods of follow up data collection employed by registries classified by 
different approaches 
 
Method of 
follow up 
Direct approach through contact 
with/by patient or others 
Indirect approach without any 
contact with patient or others  
Active – 
Voluntary, 
always 
seeking for 
information 
Registry personnel initiating the 
interview or contact with patient 
and/or others by any means: 
through postal or telephone or 
house visit or other inquiries for 
information on vital status 
 
 
Action: AE 
 
Registry personnel abstracting or 
linking information by repeated 
scrutiny of medical records/death 
certificates at sources of data 
(hospitals or vital statistics office) 
for updating or matching with 
registry incident cancer database 
 
Action: AP 
Passive – 
Involuntary, 
mostly 
receiving 
information 
Consultation or inquiries initiated 
by patient and/or others through 
postal or telephone or visit for 
consultation to hospital or through 
other means resulting in 
information on vital status 
 
Action: PP 
 
Automated linkage of registry 
incident cancer database with one 
or more databases on mortality, 
population, health, based on unique 
or available patient identity 
parameters (number, name, etc.) 
 
Action: PE 
 
Table 2 summarizes the general characteristics for broadly classifying the various 
approaches undertaken by the registries in low or medium resource countries to obtain vital 
status (alive or dead) information, into active or passive methods of follow up. A registry is 
classified to have undertaken follow up entirely by active method if the vital status 
information with reference to a pre-specified date is almost completely obtained by actions 
AE or AP and very negligible from actions PE or PP. A registry is categorized to have 
employed predominantly active method of follow up if the vital status information with 
reference to a pre-specified date for a majority of cases is obtained by actions AE or AP and 
for the rest by actions PE or PP. A registry is categorized to have employed predominantly 
passive method of follow up if the vital status information with reference to a pre-specified 
date for a majority of cases is obtained by actions PE or PP, to some extent by action AP and 
negligible by action AE. A registry is classified to have undertaken follow up entirely by 
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passive method if the vital status information with reference to a pre-specified date for almost 
all cases is obtained by actions PE or PP, minimally from action AP and not at all by action 
AE. Thus, active methods are characterized by voluntary action by registry personnel towards 
personal contact with patient/others with the possibility of eliciting the time at which cases 
were lost to follow up with reference to a pre-specified date. Passive methods are mostly 
involuntary and devoid of personal contact with patient/others (Swaminathan et al., 2011). 
 
4.3.2 Eliciting the determinants of non-random loss to follow up 
 
Categorical factors (like age at diagnosis, sex, etc.), each with reference and subcategory 
levels, that have potential to influence either follow up (complete or loss to follow up) or 
survival (alive or dead) were first determined using logistic regression (risk expressed as odds 
ratios in univariate or multifactorial settings) or Cox proportional hazard model (Cox, 1972; 
risk expressed as hazard ratios in univariate or multifactorial settings using survival time 
information). The outcome event studied with respect to follow up was loss to follow up 
either at 3 years or 5 years from the index date which was the date of first diagnosis of 
cancer. A differential pattern of loss to follow up (LFU), either between factors or within 
subcategories of factors would indicate that such factors emerge as determinants of LFU with 
an association of non-random type (IV, V, VII).  
 
4.3.3 Survival estimation 
 
Death due to any cause was the end point studied for overall survival data series from both 
hospital and population-based cancer registries. Survival time was calculated as the duration 
between the date of first diagnosis of cancer and the date of death or date of loss to follow up 
or the closing date of follow up, whichever was earlier. Overall or absolute survival was 
calculated by actuarial method (Cutler and Ederer, 1958) unless otherwise specified. This 
method treated all censorings as random and potential withdrawals at closing date and losses 
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to follow up, in the same grouped annual interval of follow time were not distinguished. An 
example of the life table giving the calculations is given in Table 3. 
 
Table 3: Illustration of the layout of the life table and calculation of cumulative survival 
probability by the actuarial method (VII) 
 
 
4.3.4 Relative survival and age-standardization 
 
Relative survival is defined as the ratio (Ederer et al., 1961) of observed to the expected 
survival in the general population of the same age and sex (Hakulinen, 1982) and was 
calculated to exclude the effect of competing causes of mortality and to facilitate survival 
comparisons between countries with different background mortalities. Expected survival 
probabilities for individual registries were estimated from country, age and sex specific life 
tables (Lopez et al., 2001). To account for the differences in the age structure of the cancer 
cases, relative survival was adjusted for age and reported as age-standardized relative 
survival (ASRS). For age standardization (Brenner and Gefeller, 2004a, Brenner et al., 
2004b), the weights were defined as the ratio of the proportion of patients in the respective 
age group in the standard cancer population of estimated incident cancer cases from less 
developed countries together in the year 2002 (Ferlay et al., 2004) divided by the proportion 
Interval Alive at 
beginning 
of interval 
Last known 
alive during 
interval 
(censored) 
No. of 
deaths 
during 
interval 
Effective no. at 
risk 
Conditional 
probability 
of death 
Conditional 
probability of 
survival 
Cumulative 
probability of 
survival 
(to end of 
interval) 
 
ti – ti+1 
 
ni 
 
wi 
 
di 
 
Ni = ni – (wi / 2) 
 
qi = di / Ni 
 
pi 
∏
=
+ =
i
j
ji pP
0
1
 
0-1 3289 166 365 3206.0 0.114 0.886 0.886 
1-2 2758 275 301 2620.5 0.115 0.885 0.784 
2-3 2182 37 278 2163.5 0.128 0.872 0.683 
3-4 1867 30 191 1852.0 0.103 0.897 0.613 
4-5 1646 20 106 1636.0 0.065 0.935 0.573 
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of patients in the respective age group in the study cancer population for every classified 
cancer site for every registry. Analyses were done using the publicly available macros 
(Brenner et al., 2002). All of the above methods and more are summarized in (VII). 
 
4.3.5 Loss adjusted rate 
 
Unlike traditional survival analysis which grouped withdrawals and losses together, loss 
adjusted rate (LAR) differentiated the two. Potential follow up time for all subjects was five 
years (three years) to estimate 5-year (3-year) loss adjusted survival. The choice of potential 
determinants or confounding factors and corresponding strata based on subcategories of 
chosen factors are made. Study subjects are classified into two main categories: those with 
complete follow up and those with loss to follow up. It is assumed that those lost to follow up 
in specific stratum have the same probability of death as others still remaining under 
observation and belonging to the same stratum. Accumulating over prognostic strata resulted 
in annual loss adjusted survival and cumulative loss-adjusted survival probabilities were 
calculated within the actuarial framework but different assumptions (IV, V). The method of 
calculating loss adjusted survival using logistic regression approach facilitated simultaneous 
adjustment of any number of determinants of loss to follow up and is a simplification of 
computational procedure to estimate expected deaths among those lost to follow up. The 
conditional probability of dying, conditional probability of surviving and the cumulative 
probability of surviving the current and subsequent annual intervals are done under the 
modified framework of generating life table (IV, V). 
 
4.3.6 Elucidating bias in survival in the absence of active case follow-up 
 
Different actuarial assumptions on the survival status of subjects were made during follow-up 
under active or passive or a mixture of both methods (II). Figure 2 gives the schematic 
representation of vital status of each subject under real circumstances and different actuarial 
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assumptions of follow up. Let y0, y1, …, y4 represent the calendar years. The period y0 to y2 
(say, 1990 to 1992) signifies the registration of cancer cases and y0 to y4 (say, 1990 to 1994) 
indicates the period of follow up. Subjects were designated as belonging to the following 
categories: [A] when they were matched with mortality data obtained by routine registry data 
linkage with official mortality statistics without any active follow-up; [B] when they could 
not be matched through routine registry data linkage with official mortality statistics and their 
death was ascertained through active follow-up; [C] when they were lost to follow-up but 
known to be alive until a specific date, with unknown survival status at the close of follow-
up; and [D] when they had completed follow-up and were known to be alive on the closing 
date.  
 
The follow up status was classified into four different case scenarios depending on the 
assumptions made, as follows: 
Case 1: Purely passive follow-up only – Apart from cancer cases matched with deaths 
from vital statistics division, those not matched with official mortality data were presumed to 
be alive at the close of follow-up. In this scenario, subjects in category A were treated as 
having died on their respective dates of death, while subjects B, C, and D were assumed to be 
alive on the last day of follow-up in the analysis. 
Case 2: Predominantly passive method with minimal active follow-up – Cases lost to 
follow-up were presumed to be alive on the last day of follow-up. In this scenario, subjects A 
and B were treated as having died on their respective dates of demise, while subjects C and D 
were treated as having been alive on the last day of follow-up. 
Case 3: Purely active follow-up only – Cases lost to follow-up were censored on the 
last date on which their survival status was known. Under this case scenario, subjects A and 
B were treated as having died on their respective dates of demise; subjects in category D were 
treated as having been alive on the last day of follow-up, and subjects in category C were 
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treated as having been alive until a specific date and censored thereafter for the survival 
analysis, based on actuarial assumption. 
Case 4: Predominantly active follow-up with minimal passive component – Cases lost 
to follow-up were excluded from the survival analysis. This resembles Case 3, excepting that 
subjects in category C were excluded from the survival analysis. 
 
Absolute survival probability, also known as crude survival, was estimated through an 
actuarial approach. However, the assumptions made in this study differed from those 
normally made using the routine actuarial method (II). 
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Vital status in real circumstances 
 
Subject   Calendar Time  
  y0---------------y1--------------y2--------------y3--------------y4 
   [----Period of registration----] 
   [-----------------------Period of Follow up-------------------] 
  A               i--------------------------------------matched death 
 B i----------------------------death from active follow up only 
  C          i---------------------☺lost to follow-up 
  D                                 i----------------------------------☺ alive 
 
Different assumptions on survival status under various follow up environment 
 
Case 1:  Passive follow up only with no active follow up when cases not matched with 
official mortality database were presumed as alive at closing date 
  y0---------------y1--------------y2--------------y3--------------y4 
  A               i--------------------------------------death 
 B i------------------------------------------------------------------☺ alive 
  C          i---------------------------------------------------☺ alive 
  D                                 i----------------------------------☺ alive 
 
Case 2:  Predominantly passive follow up with minimal active component, when lost to 
follow up cases were presumed alive at the closing date 
  y0---------------y1--------------y2--------------y3--------------y4 
  A               i--------------------------------------death 
 B i----------------------------death 
  C          i---------------------------------------------------☺ alive 
  D                                 i----------------------------------☺ alive 
 
Case 3:  Purely active follow up, when lost to follow up cases were censored alive  
at the last known date under actuarial assumption 
  y0---------------y1--------------y2--------------y3--------------y4 
  A               i--------------------------------------death 
 B i----------------------------death  
  C          i---------------------☺ alive 
  D                                 i----------------------------------☺ alive 
 
Case 4:  Predominantly active follow up, when lost to follow up cases (C) were excluded 
from analysis 
  y0---------------y1--------------y2--------------y3--------------y4 
  A               i--------------------------------------death 
 B i----------------------------death  
  D                                 i----------------------------------☺ alive 
 
 
 
Figure 2: Schematic representation of vital status of each subject in real circumstances 
and under different assumptions of follow up  
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5. RESULTS 
 
5.1 Descriptive statistics on characteristics of population based cancer registries from low or 
medium resource countries that had undertaken survival studies 
 
The study of characteristics of 28 population-based cancer registries in low or medium 
resource countries that have undertaken survival studies till date along with descriptive 
statistics reveal interesting differences on various parameters of cancer registration and 
survival (I, VI, Parkin et al., 2005, Curado et al., 2007). The registration of incident cancer 
cases has been done either entirely or predominantly by active methods in 19 (68%) registries 
and either entirely or predominantly by passive methods in the rest (32%). There were 15 
(54%) registries covering only urban population, 10 (36%) covering both urban and rural 
populations and 3 (10%) were national registries. 
  
The IARC evaluates the quality of data of cancer registries in a systematic and 
uniform manner by setting moderate to high standards for publication in the CI5C series. Out 
of 28 registries, data from 22 registries (78%) have been published in one or more volumes of 
CI5C without any reservation and 3 (11%) with some reservation. The common reservation 
expressed for publishing the incidence data of the latter three registries was the suspected 
excess degree of incompleteness in case finding or high proportion of cases registered on the 
basis of a death certificate only. The reasons for data from three remaining registries not 
included in CI5C series were because of either non-submission of data by registry (say 
Bhopal, India) for scrutiny by IARC or registry was of recent origin (say Dindigul from 
2003) not covered by CI5C series so far. Thus, the data quality of cancer incidence data from 
a majority of registries has been good. 
 
However, unlike morbidity data that was published in CI5C volumes for 25 registries, 
the cancer mortality data was not readily forthcoming in 9 (36%) registries while there were 
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reservations on completeness of cancer mortality data in 6 (24%) registries. Thus, it is clear 
that in a majority of the registries that had undertaken population-based cancer survival 
studies, the routine collection of cancer mortality data, though carried out as part of registry 
operations, remained constrained and the system was not fully developed or available. 
 
In this background, it requires special efforts and separate resources on the part of 
most of the registries from low or medium resource countries to obtain complete data on 
follow up that remains the key to the conduct of any survival study on cancer. From Table 4, 
of the 28 population-based registries that have conducted survival studies based on a few 
hundreds to several thousands of cases of all or selected cases of 1-52 invasive cancers, 18 
(64%) have used active follow up methods either entirely or predominantly to gather data on 
vital status of incident cancer cases. In the rest (36%), passive methods were employed for 
the purpose. The registries that practiced the same methods for cancer registration as well as 
follow up of incident cancer cases for vital status were 18 (64%): 15 were either entirely or 
predominantly by active methods and 3 were predominantly by passive methods. The 
registries that employed active methods for registration but switched to passive mode for 
follow up were 2 (7%; Tianjin, China and Incheon, Korea) while there were none vice-versa. 
Out of 15 registries for which mortality data was either not well developed or unavailable 
routinely or subject to severe incompleteness by CI5C series evaluation, 11 had augmented it 
and pursued follow up by employing active methods. It emerges very clearly that registries 
have put in extra efforts and allocated separate resources for undertaking the follow up of 
cancer cases for obtaining vital status information on incident cancer cases. 
  
The extent of complete follow up at five years from the first diagnosis of cancer 
(index date) ranged between 76-100% for registries that employed passive follow up methods 
either entirely or predominantly. This figure ranged between 30-100% for registries that 
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pursued follow up entirely or predominantly by active methods. Thus, completeness of follow 
up was differential between population-based cancer registries using passive or active 
methods in low or medium resource countries. Inter-country and intra-country differences in 
frequency of cases with complete follow up existed even when the follow up methods were 
identical and approaches were the same (I, VI).  
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Table 4: Characteristics of cancer registries from low or medium resource countries 
that have undertaken population-based survival studies, 1990-2001* 
 
Cancer registration Follow up data£ Survival study£ IARC-CI5C volumes COUNTRY/ 
Registry Method Population Method Complete 
% 
Cancers Cases Incidence 
data 
Mortality 
data 
CHINA         
   Hong Kong PP U PE 100 45 110,190 Y Y 
   Qidong AP M AP 100 33 20,167 Y YR 
   Shanghai PE U PP 100 52 70,006 Y Y 
   Tianjin AE U PP 100 51 70,005 Y N 
COSTA RICA PE C PP 74-83 2 6,297 Y Y 
CUBA PE C PP 95-99 17 8,150 YR YR 
THE GAMBIA PP C AE 81-98 6 505 Y N 
INDIA         
   Bangalore# AE U AE 85-92 8 4,781 YR N 
   Barshi AE M AE 96-100 15 1,188 YR N 
   Bhopal AE U AE 100 16 1,863 N N 
   Chennai AE U AE 79-99 20 22,618 Y Y 
   Dindigul$ AE M AE 86-96 12 1,045 N N 
   Karunagappally AE M AE 91-100 22 1,601 Y Y 
   Mumbai AE U AE 82-93 28 46,162 Y Y 
PAKISTAN         
   South Karachi AE U AE 67-76 4 677 Y N 
PHILIPPINES         
   Manila AE U AP 75-82 4 1,040 Y N 
   Rizal AE U AP 30 1 1,299 Y N 
SAUDI ARABIA         
   Riyadh PP U PP 80 1 298 N N 
SOUTH KOREA         
   Busan PP U PP 100 48 41,434 Y Y 
   Incheon AE U PP 100 42 20,563 Y Y 
   Seoul PP U PP 100 46 77,827 Y Y 
THAILAND         
   Chiang Mai AE M AE 59-100 36 7,276 Y YR 
   Khon Kaen AP M AP 40-83 13 2,253 Y N 
   Lampang PE M PP 96-100 40 11,195 Y YR 
   Songkhla AE M AE 50-86 36 6,589 Y Y 
TURKEY         
   Izmir AE M AE 79-98 12 4,381 Y YR 
UGANDA         
   Kampala AE M AE 47-87 15 1,916 Y N 
ZIMBABWE         
   Harare AE U AE 95-100 17 1,990 Y YR 
 
* Period varies for individual registries; $ Year 2003; # 1982-1989; IARC-CI5C: 
International Agency for Research on Cancer - Cancer Incidence in Five Continents;  
AE: Active method only; PE: Passive method only; AP: Predominantly active method; PP: 
Predominantly passive method; U: Urban population only; M: Mixed covering rural + urban 
populations; C: Country on a whole; Y: Yes: YR: Yes with reservation; N: No; £ SURVCAN 
database 
 
 
 45 
 
5.2 Data quality indices for population-based survival study 
 
The comparison of descriptive statistics on data quality indices of population-based cancer 
survival for lung and breast cancers between selected registries classified on methods of 
cancer registration and follow up are given in Table 5 (SURVCAN). 
 
Table 5: Data quality indices: Frequency of excluded cases expressed as proportion of 
death certificate only and no follow up cases for lung and breast cancers in 
selected registries from low or medium resource countries separately for 
passive and active methods of cancer registration and follow up, 1990-2001* 
(SURVCAN database) 
 
Lung Breast  
Country/Registry Total 
registered 
DCO% NFU% Included 
% 
Total 
registered 
DCO% NFU% Included 
% 
Passive methods of 
registration and 
follow up 
        
China, Shanghai 14,113 0.0 0.1 99.9 5,184 0.0 0.0 100.0 
Costa Rica DNA DNA DNA DNA 2,854 2.5 11.2 86.3 
Korea, Seoul 10,294 12.7 4.9 82.4 5,907 3.3 6.0 90.7 
Thailand, Lampang 3,278 7.8 0.3 91.9 842 1.4 0.0 98.6 
Range  0-13 0-5 82-100  0-3 0-11 86-100 
Active methods of 
registration and 
follow up 
        
China, Qidong 3,303 0.3 0.4 99.3 669 0.3 2.4 97.3 
India, Barshi 48 2.1 0.0 97.9 124 0.0 0.0 100.0 
India, Mumbai 3,995 13.0 0.6 86.4 7751 5.2 0.7 94.1 
Thailand, Songkhla 850 5.1 16.1 78.8 665 1.2 13.3 84.5 
Range  0-13 0-16 79-99  0-5 0-13 85-100 
DCO: Death certificate only; NFU: No follow up; DNA: Data not available 
* Period varies for individual registries 
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The figures for frequency of lung cancer cases included for survival analysis ranged 
between 82-100% for selected registries in Asia and Central America, employing passive 
methods and 79-99% for selected registries in Asia undertaking active methods (Table 5). 
The corresponding figures for breast cancer were 86-100% and 85-100% respectively. The 
range of DCOs for lung cancer was 0-13% in both groups of registries; the range for no 
follow up cases was 0-5% in registries with passive methods and 0-16% in registries with 
active methods for lung cancer. The range of DCOs for breast cancer was 0-3% in registries 
with passive methods and 0-5% in registries with active methods; the corresponding figures 
for no follow up cases were 0-11% and 0-13% respectively. The comparison of frequency of 
cases included for survival analysis out of total incident cases between the two groups of 
registries that pursued passive or active methods of case registration and follow up revealed 
minimal variation for lung and breast cancers (Table 5). This augurs well for the conduct of a 
population-based cancer survival study. 
 
However, the frequency of cancer cases excluded from survival study (owing to being 
DCOs or no follow up (NFU) with zero survival time) and the frequency of cases with 
incomplete or loss to follow up (LFU) among cases included in survival study both have to be 
considered in unison to evaluate data quality in population-based survival study. There may 
be instances when one is minimal while the other is not. The following scenarios from real 
data present the different problems encountered pertaining to data quality indices and 
reiterate their possible impact on the population-based cancer survival. 
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Table 6: Frequency of cases registered as DCO or with lack of complete follow up for 
common cancers in Cuba, 1994-1995 followed through 1999* 
 
Excluded from 
survival study 
Incomplete follow up: % lost to 
follow up- years from diagnosis 
 
Cancer/site 
 
Total 
registered DCO% NFU% 
Included 
in 
analysis 
% 
Complete 
follow up 
% <1 1-3 3-5 >5 
 
Tongue 314 25.5 0.9 73.6 95.2 3.0 0.9 0.9 0.0 
Mouth 355 25.9 0.9 73.2 93.4 3.1 1.9 1.2 0.4 
Tonsil 82 32.9 1.2 65.9 98.1 0.0 0.0 1.9 0.0 
Oropharynx 60 20.0 0.0 80.0 97.9 2.1 0.0 0.0 0.0 
Colon 2491 49.7 0.2 50.1 99.2 0.2 0.2 0.3 0.1 
Rectum 790 29.1 0.5 70.4 98.0 1.1 0.4 0.5 0.0 
Anus 106 8.5 2.8 88.7 98.9 1.1 0.0 0.0 0.0 
Larynx 1165 30.7 0.6 68.7 96.3 1.5 0.9 1.0 0.3 
Breast 2929 25.6 0.3 74.1 97.0 0.9 0.3 1.4 0.4 
Cervix uteri 1450 15.4 0.4 84.2 94.4 2.2 1.2 1.7 0.5 
Urinary bladder 1182 29.5 1.2 69.3 97.4 1.2 0.0 1.0 0.4 
Hodgkin lymphoma 320 40.3 1.6 58.1 97.4 1.6 0.5 0.5 0.0 
Non Hodgkin lymphoma 771 39.7 0.1 60.2 97.7 0.6 0.6 1.1 0.0 
 
DCO: Death certificate only; NFU: No follow up or lost to follow up with zero survival time; 
* SURVCAN database 
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Table 6 shows the frequencies of cases pertaining to all the data quality indices of 
population-based survival for selected cancers in Cuba during 1994-1995 and followed 
through 1999 (SURVCAN). Registration of cancer cases was carried out entirely by passive 
method. The frequency of cases registered as DCO ranges between 9-50% for different 
cancers. The very high figure may be the result of lack of active method of tracing back the 
cancer cases, first identified through a death certificate, to hospitals or to other sources of 
registration. On the other hand, the frequency of cases with zero survival time and vital status 
unknown were negligible ranging between 0-3%. In total, the frequency of cases included for 
survival analysis ranged between 50-89%. This is quite low and may or may not be a random 
sample or representative of the total incident cases. On the other hand, among the cases 
included for survival analysis, the complete follow up was achieved in 94-99%, which is 
adequate (Table 6). Follow up for vital status information was carried out predominantly by 
passive methods with minimal active component. Overall, despite good follow up, the 
resulting survival may not reflect the average outcome of respective cancers in the region 
owing to high degree of exclusion from the survival study thereby indicating high selection of 
cases. 
  
The other kind of problem pertaining to inadequate follow up usually encountered in 
real data from low or medium resource countries is described in Table 7 (SURVCAN).  
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Table 7: Frequency of cases registered as DCO or with lack of complete follow up for 
common cancers in Khon Kaen, Thailand, 1993-1997 followed through 2000* 
 
Excluded from 
survival study 
Incomplete follow up: % lost to 
follow up- years from diagnosis 
 
Cancer/site 
 
Total 
registered DCO% NFU% 
Included 
in 
analysis 
% 
Complete 
follow up 
% <1 1-3 3-5 >5 
Lip 88 1.1 9.1 89.8 67.1 19.0 5.1 6.3 2.5 
Tongue 57 0.0 5.3 94.7 77.8 20.3 1.9 0.0 0.0 
Mouth 120 3.3 7.5 89.2 73.8 19.6 2.8 1.9 1.9 
Nasopharynx 123 0.0 4.1 95.9 80.5 12.8 4.2 0.8 1.7 
Colon 258 1.6 4.7 93.8 79.8 6.6 6.2 5.4 2.0 
Rectum 143 0.0 2.8 97.2 80.6 10.1 6.5 0.7 2.1 
Larynx 38 0.0 5.3 94.7 80.6 19.4 0.0 0.0 0.0 
Breast 446 1.1 5.2 93.7 41.4 24.4 22.2 7.7 4.3 
Ovary 230 0.9 9.6 89.6 47.1 28.6 12.6 8.7 3.0 
Urinary bladder 114 0.0 9.6 90.4 41.7 35.9 10.7 8.7 3.0 
Hodgkin lymphoma 31 0.0 6.5 93.5 37.9 27.6 17.2 6.9 10.4 
Non Hodgkin lymphoma 191 0.0 12.0 88.0 53.0 28.0 10.1 6.0 2.9 
DCO: Death certificate only; NFU: No follow up or lost to follow up with zero survival time; 
* SURVCAN database 
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Table 7 describes both the two data quality indices pertaining to cancer registration 
and follow up as observed in survival data from Khon Kaen, Thailand, in 1993-1997 and 
followed through 2000. Both cancer registration and follow up were carried out 
predominantly by active methods. The frequency of cases registered as DCO was minimal 
ranging between 0-3% for different cancers. This possibly is due to trace-back procedures by 
active methods adopted by the registry. However, the frequency of cases excluded from 
survival study with zero survival time and vital status unknown was higher ranging between 
3-12%. In total, the frequency of cases included for survival analysis ranged between 88-
97%, which is satisfactory. Among the cases included for survival analysis, the complete 
follow up was achieved only in 38-81% for different cancers. Overall, despite minimal 
exclusions from the study, the resulting absolute survival is not likely to reflect the average 
outcome of respective cancers in the region owing to the very high degree of incomplete or 
losses to follow up (19-62%), especially due to high losses to follow up within the first year 
from diagnosis (7-36%). These data quality indices, with the exception of DCOs, are 
applicable to hospital-based survival studies also.  
 
5.3 Magnitude of loss to follow up in low or medium resource countries 
 
The magnitude of loss to follow up observed in population-based cancer registries from low 
or medium resource countries for major cancers are shown in Table 8 (SURVCAN).  
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Table 8: Frequency (%) of cases lost to follow up for major cancers in registries from 
low or medium resource countries in Africa, Asia, the Caribbean and Central 
America, 1990-2001* (SURVCAN database) 
 
Country/Registry Mouth Stomach Rectum Larynx Lung Breast Cervix Ovary Bladder 
          
China, Shanghai 2.5 0.7 1.1 0.5 0.4 1.7 1.3 1.0 1.2 
Costa Rica DNA DNA DNA DNA DNA 24.2 32.6 DNA DNA 
Cuba 6.6 DNA 2.0 3.7 DNA 3.0 5.6 DNA 2.6 
The Gambia DNA 12.8 DNA DNA 19.4 8.2 4.5 DNA DNA 
India, Barshi 3.6 4.4 DNA 3.0 4.3 4.0 0.7 DNA DNA 
India, Chennai 26.5 10.6 DNA 17.2 10.4 23.3 38.0 22.6 17.0 
India, Karunagappally 3.3 0.0 0.0 2.2 1.4 1.1 0.6 0.0 2.6 
India, Mumbai 20.4 11.6 20.9 20.2 10.1 25.1 25.8 15.6 23.5 
Pakistan, S. Karachi 28.8 DNA DNA DNA DNA DNA DNA DNA DNA 
Philippines, Manila DNA DNA DNA DNA DNA 22.4 23.6 DNA DNA 
Philippines, Rizal DNA DNA DNA DNA DNA 73.7 DNA DNA DNA 
Saudi Arabia, Riyadh DNA DNA DNA DNA DNA 21.8 DNA DNA DNA 
Thailand, Chiang Mai 29.7 17.4 25.3 26.8 11.6 34.9 29.8 30.9 27.8 
Thailand, Khon Kaen 26.2 DNA 19.4 19.4 DNA 58.6 62.1 52.9 58.3 
Thailand, Lampang 0.8 0.3 0.8 1.2 0.2 1.1 1.4 0.5 1.9 
Thailand, Songkhla 31.6 24.5 34.5 33.3 19.6 48.8 45.9 51.4 42.6 
Turkey, Izmir DNA DNA 32.5 35.6 DNA 39.3 48.4 38.7 38.2 
Uganda, Kampala DNA 25.6 20.0 DNA 12.8 40.7 47.3 27.3 DNA 
Zimbabwe, Harare DNA 1.6 3.0 5.5 0.0 3.1 1.5 0.0 2.3 
 
* Period varies for individual registries; DNA: Data not available 
 
 
 52 
The magnitude of loss to follow up (LFU) at the end or closing date of follow up is 
observed to be very high in a majority of registries that have undertaken population-based 
survival study from low or medium resource countries (Table 8). The range of LFU across 
major cancer sites exceeded 20% for most cancer sites in Costa Rica (24-33%); South 
Karachi, Pakistan (29%); Manila, Philippines (22-24%); Rizal, Philippines (74%); Riyadh, 
Saudi Arabia (22%); Chiang Mai, Thailand (12-35%); Khon Kaen, Thailand (19-62%); 
Songkhla, Thailand (20-51%); Izmir, Turkey (33-48%) and Kampala, Uganda (13-47%). It 
was intermediate in The Gambia (5-19%); Chennai, India (11-38%) and Mumbai, India (10-
26%). Excepting Costa Rica and Riyadh registries, all others had adopted active methods of 
follow up. It is likely that the high magnitude of loss to follow up would have a significant 
impact on the estimation of absolute survival in these registries. The range of LFU across 
major cancer sites was very minimal in Shanghai, China (0-3%); Cuba (2-7%) and Lampang, 
Thailand (0-2%) pursuing passive methods of follow up and Barshi, India (1-4%); 
Karunagappally, India (0-3%) and Harare, Zimbabwe (0-6%) adopting active methods of 
follow up (Table 8). 
 
5.4 Pattern of loss to follow up in Izmir, Turkey and Songkhla, Thailand 
 
The frequency of cancer cases that are lost to follow up being higher for major cancers in 
most registries from low or medium resource countries, it would be necessary to study the 
pattern of losses to follow up and its possible impact on the survival rate. The pattern of 
losses to follow up (LFU) is determined by the frequency of losses at variable lengths of time 
from the diagnosis of cancer. This is generally measurable only in registries adopting active 
methods of follow up. 
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Table 9:  Frequency (%) and pattern of loss to follow up for selected cancers in Izmir, 
Turkey (1995-1997) and Songkhla, Thailand (1990-1999)* 
 
Loss to follow up  (LFU%) – Years from diagnosis Cancer site LFU% at 
closing date <1 year 1-3 years 3-5 years >5 years 
LFU% at  
5-years 
Turkey, Izmir 
(1995-1997) 
 
      
Rectum 32.5 16.0 2.9 2.0 11.6 21.9 
Larynx 35.6 9.8 1.7 1.5 22.6 13.0 
Breast 39.3 10.9 2.3 1.8 24.3 15.0 
Cervix 48.4 10.6 3.7 2.4 31.7 16.7 
Ovary 38.7 10.9 1.3 2.6 23.9 14.8 
Bladder 38.2 13.3 2.7 1.2 21.0 17.2 
Range 32.5-48.4 9.8-16.0 1.3-2.9 1.2-2.6 11.6-31.7 13.0-21.9 
Thailand, Songkhla 
(1990-1999) 
 
      
Rectum 34.5 10.3 9.9 7.9 6.4 18.1 
Larynx 33.3 13.0 8.0 4.3 8.0 25.4 
Breast 48.8 12.1 9.8 11.0 15.8 32.9 
Cervix 45.9 13.2 12.1 8.6 12.1 33.8 
Ovary 51.4 16.2 19.7 8.1 7.5 43.9 
Bladder 42.6 11.0 11.6 9.7 10.3 32.3 
Range 33.3-51.4 10.3-16.2 8.0-19.7 4.3-11.0 6.4-15.8 18.1-43.9 
LFU: Loss to follow up; * SURVCAN database 
 
 
Table 9 shows the two different patterns of losses to follow up encountered in 
Songkhla registry in Thailand and Izmir registry in Turkey (SURVCAN). In Songkhla 
registry, the highest number of losses to follow up ranging between 10-16% had occurred at 
less than one year from diagnosis for most cancers; it ranged between 8-20% at 1-3 years 
from diagnosis, 4-11% at 3 to 5 years from diagnosis and 6-16% after 5 years from diagnosis. 
The LFU% ranged between 33-51% at the end of follow up and between 18-44% at 5 years 
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from diagnosis for different cancer sites (Table 9). Here, the impact of this pattern of LFU on 
the estimation of 5-year absolute survival would be significant. 
 
On the other hand, in Izmir registry, the highest number of losses to follow up ranging 
between 12-32% had occurred at 5 or more years from diagnosis for most cancers; it ranged 
between 10-16% at less than 1 year from diagnosis and ranged between 1-4% at 1 to 5 years 
from diagnosis (Table 9). The LFU% that ranged between 33-48% at the end of follow up got 
reduced between 13-22% at 5 years from diagnosis for different cancer sites. Here, the impact 
of this pattern of LFU on the estimation of 5-year absolute survival would be minimal. 
Hence, the pattern of losses to follow up is also an important contributing factor along with 
the magnitude of losses to follow up in the estimation of absolute survival. However, these 
are usually not estimable when registries undertake follow up based on purely passive 
methods. 
 
5.5 Determinants of non-random loss to follow up 
 
It is evident that a high proportion of censored cases in survival studies from low or medium 
resource countries are due to losses to follow up rather than being potential withdrawals. 
Also, the patterns of LFU were variable. Hence, it is essential to elicit the type of loss to 
follow up and its determinants. This is applicable to both hospital-based and population-
based survival studies.  
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5.5.1 Non-random loss to follow up – Population-based survival study 
Determinants of loss to follow up had been elicited by computing the risk of loss to follow up 
expressed as hazard ratio in multifactorial setting. 
 
Table 10:  Determinants of loss to follow up and non-random censoring by Cox 
proportional hazards model, female breast cancer (n=273), Mumbai PBCR, 
1992-1994 followed through 1999, (VII) 
 
Loss to follow up Relative hazard of loss to follow up$ Determinants of loss to followup 
No. % Hazard ratio 95% CI 
Age at diagnosis 
     <=44 years 
     45-54 
     55-64 
     65-74 
     75+ 
 
53 
75 
89 
47 
9 
 
6.9 
10.4 
16.2 
13.7 
7.4 
 
1.00 
1.63 
2.47 
2.25 
1.26 
 
- 
1.14-2.31* 
1.76-3.47* 
1.52-3.33* 
0.62-2.56 
Extent of disease 
     Localised 
     Regional 
     Distant metastasis 
     Unknown 
 
129 
98 
1 
45 
 
14.6 
8.2 
0.4 
26.9 
 
1.00 
0.54 
0.05 
2.40 
 
- 
0.41-0.71* 
0.01-0.35* 
1.70-3.38* 
% computed to respective categories; CI: Confidence interval; * p<=0.05; $ Each factor is 
adjusted for the other in the table 
 
 
 Table 10 shows the proportion and risk (hazard ratio) of loss to follow up at 5 years 
from diagnosis with respect to the prognostic factors like age at diagnosis and clinical extent 
of disease, experienced in Mumbai population-based cancer registry for invasive breast 
cancer cases registered during 1992-1994 and followed through 1999 (VII). The proportion 
of loss to follow up between sub-categories of age at diagnosis and extent of disease varied 
widely and ranged between 7-16% and 0-27% respectively. A differential risk pattern of loss 
to follow up was observed between the sub-categories of prognostic factors. One-two folds 
higher risk of loss to follow up was forthcoming for all age groups more than 45 years 
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compared to less than 45 years, which was statistically significant. The risk of loss to follow 
up was 46-95% less among those with regional or distant metastatic disease compared to 
localized category. The risk was reversed and more than two-fold higher for cases with 
unknown extent of disease. All of these were statistically significant. Both age at diagnosis 
and extent of disease have emerged as determinants of loss to follow up in Mumbai PBCR. 
The differential risk pattern of loss to follow up with respect to each of the prognostic factors 
for survival indicate that the censoring due to losses to follow up are likely to be non-random.  
 
5.5.2 Non-random loss to follow up – Hospital-based survival study 
 
Table 11: Number and proportion (%) of patients and losses at 3-years and risk (odds 
ratio) of loss to follow up with 95% confidence interval by patient 
characteristics among female breast cancer patients diagnosed in Tata 
Memorial Hospital, Mumbai India, in 1985 and followed through 1988 (V) 
 
Patients 
(n=336) 
Lost to follow up 
(n=80; 24%) 
Patient characteristics 
Number %a Number %b 
Odds ratio 
(95% CI) 
 
Age at diagnosis 
   ≤ 44 years 
   45-54 
   55-64 
   65+ years 
 
Residence 
(Mumbai city) 
   Mumbai+neighborhood 
   Other districts 
 
Stage of disease 
(TNM summary) 
   I 
   II 
   III 
   IV 
 
Treatment 
   With chemotherapy 
   Without chemotherapy 
 
 
 
101 
117 
77 
41 
 
 
 
169 
167 
 
 
 
29 
160 
126 
21 
 
 
194 
142 
 
 
30 
35 
23 
12 
 
 
 
50 
50 
 
 
 
9 
48 
37 
6 
 
 
58 
42 
 
 
22 
29 
19 
10 
 
 
 
26 
54 
 
 
 
4 
30 
40 
6 
 
 
42 
38 
 
 
22 
25 
25 
24 
 
 
 
15 
32 
 
 
 
14 
19 
32 
29 
 
 
22 
27 
 
 
1.0* 
1.2 (0.6-2.3) 
1.2 (0.6-2.5) 
1.0 (0.5-2.9) 
 
 
 
1.0* 
2.6 (1.5-4.6)$ 
 
 
 
1.0* 
1.5 (0.5-5.6) 
2.9 (0.9-10.6) 
2.5 (0.5-12.9) 
 
 
1.0* 
1.3 (0.8-2.3) 
* Reference category; $: p=0.05; CI: confidence interval; 
 
a
 percentage to total breast cancer cases; b percentage to total cases in respective categories 
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Table 11 examines the distribution and risk of losses to follow up (expressed as odds 
ratio) in Mumbai hospital-based survival study of newly diagnosed and treated female breast 
cancer cases with respect to more number of prognostic factors for survival like age at 
diagnosis, tumour stage, residence (proximity to base hospital) and cancer directed treatment 
(V). The differences in the risk estimates of loss to follow up between various categories of 
these factors compared to the corresponding reference sub-categories reflect the degree of 
association or non-randomness in the data on follow up. If differential pattern of risk of loss 
to follow up was observed with respect to any factor and was statistically significant, then 
that factor is a determinant of loss to follow up resulting in non-random censoring. The 
frequency of loss to follow up at 3 years from diagnosis was 24% but showed wide variation 
among sub-categories of every prognostic factor: LFU ranged between 22-25% for age at 
diagnosis, 15-32% for residence area, 14-32% for tumour stage and 22-27% for treatment 
groups. The risk of loss to follow up was elevated in excess of two-fold for residents living 
outside Mumbai city compared to those living in the neighbourhood and was statistically 
significant. A differential risk of loss to follow up was observed with respect to other 
prognostic factors also though not statistically significant. The risk was 2-3 folds higher for 
advanced stages of disease compared to early stage; 30% excess risk was forthcoming among 
those not treated with chemotherapy compared to those who received it and 20% elevated 
risk among those aged 45-64 years compared to less than 45 years. It is clear that differential 
loss to follow up exists and the censoring induced by these losses to follow up is likely to be 
non-random in this hospital-based study (V).  
 
5.6 Loss-adjusted survival studies in India 
  The risk differences in table 10 and table 11 correlate with the risk of death as well 
(V, VII). This signifies a differential losses to follow up indicating the presence of bias and 
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this would impact the estimation of survival probability by the traditional approach using 
actuarial assumption. This observation on follow up data on female breast cancer from both 
hospital and population-based studies from Mumbai, India, stresses the need for estimating 
overall or absolute survival by specific loss adjusted methods that accounts for the 
differential losses to follow up. 
 
5.6.1 Loss-adjusted survival in population-based studies 
 
Table 12:  Number of incident cases, proportion (%) lost to follow up and 
comparison of 5-year absolute survival with and without loss-adjustment for 
top ranking cancers in population based cancer registry, Chennai, during 
1990-96 and followed through 2001 (V) 
 
5-year survival% Cancer site/type Number of 
incident 
cases 
Lost to 
follow up % Actuarial With loss 
adjustment 
Absolute 
difference in 
survival 
 
Cervix 
 
Breast 
 
Stomach 
 
Oesophagus 
 
Lung 
 
Mouth 
 
Lymphomas 
 
Tongue 
 
Leukaemias 
 
Ovary 
 
 
3134 
 
1923 
 
1845 
 
1403 
 
1237 
 
1202 
 
768 
 
670 
 
668 
 
521 
 
21.8 
 
20.7 
 
8.0 
 
6.7 
 
7.8 
 
11.6 
 
11.5 
 
13.0 
 
8.2 
 
24.0 
 
52.1 
 
39.5 
 
9.4 
 
7.7 
 
8.2 
 
30.1 
 
26.5 
 
20.2 
 
19.8 
 
25.7 
 
50.4 
 
39.1 
 
8.7 
 
7.5 
 
8.1 
 
29.1 
 
25.6 
 
18.9 
 
19.2 
 
24.2 
 
1.7 
 
0.4 
 
0.7 
 
0.2 
 
0.1 
 
1.0 
 
0.9 
 
1.3 
 
0.6 
 
1.5 
 
 
 The magnitude of losses to follow up and the ensuing absolute survival at 5-years 
from diagnosis with actuarial assumption and specific adjustment for non-random losses to 
follow up have been extended to cover major cancers in Chennai population-based cancer 
registry, India, registered during 1990-1996 and followed through 2001 in Table 12 (V). The 
losses to follow up ranged between 7-24% for different cancers and were ascertained to be 
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non-random with respect to one or more of prognostic factors like age at diagnosis, sex, 
education, extent of disease and treatment (V). The 5-year absolute survival estimated using 
the standard actuarial assumption ranged between 8% for lung cancer and 52% for cervical 
cancer. The corresponding figures for loss adjusted survival were 8% and 50% respectively. 
The absolute differences in survival between these two approaches of estimation were 
minimal and did not exceed 2% for any cancer. Also, the loss-adjusted survival was seen to 
be lesser than the corresponding actuarial survival for all cancers (Table 12). 
 
5.6.2 Loss-adjusted survival in hospital-based studies 
 
Table 13:  Comparison of 3-year survival without loss adjustment by actuarial 
assumption, stepwise loss-adjustment of factors using stratified method 
and loss adjustment using all factors together by logistic regression for all 
female breast cancer patients diagnosed in Tata Memorial Hospital, 
Mumbai India, in 1985 and followed through 1988 (V) 
 
Loss adjustment of factors 3-year survival% 
 
Without loss adjustment and using actuarial assumption only 
 
Loss adjustment done by stratification 
 
   Residential status 
 
   Residential status and age at diagnosis 
 
   Residential status, age at diagnosis and stage of disease 
 
   Residential status, age at diagnosis, stage of disease and treatment 
 
Loss adjustment done by logistic regression 
 
   Residential status, age at diagnosis, stage of disease and treatment 
 
 
61.2 
 
 
 
 
59.5 
 
59.2 
 
57.4 
 
56.5 
 
 
 
 
54.5 
 
 
The effect of stepwise loss adjustment by its determinants like residence, age at 
diagnosis, tumour stage and treatment, in order, on overall cumulative survival compared to 
the standard actuarial method in a hospital-based survival study on female breast cancer from 
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Mumbai, India, is given in Table 13 (V). The 3-year overall survival of all breast cancers 
together by actuarial method was 61.2%. The corresponding 3-year survival, loss-adjusted for 
all the four determinants together were 54.5%. The absolute difference in survival was 6.7%. 
Stepwise loss adjustment by stratification from single to all four factors revealed a decreasing 
3-year survival after addition of every factor. This showed that there was a marked effect on 
the survival estimate by loss-adjustment in the hospital based study. 
 
5.7 Risk of loss to follow up and loss adjusted survival in Thailand 
 
The effect of differential loss-adjustment on 5-year absolute survival based on more number 
of prognostic factors as determinants of loss to follow up, taken together as well as adjusted 
for one another, in a population-based survival study of 601 invasive cervical cancer cases in 
Khon Kaen province in Thailand, during 1985-1990, is given in Table 14 (IV). The overall 
loss to follow up at five years from date of first diagnosis of cancer was 27.6%. There was 
wide variation between sub-categories of different factors under consideration: 24-30% for 
age at diagnosis; 22-38% for tumour stage; 22-40% for treatment status and 27-28% for 
residence area. Each of the factors emerged as a potential prognostic factor for survival with a 
statistically significant association with death: 2-4 fold increased risk of dying, expressed as 
odds ratio, with increasing age at diagnosis; 2-5 fold excess risk of dying for other factors. 
The risk of loss to follow up was 2-fold higher for cases not treated compared to those 
received treatment and was statistically significant. This shows that there is differential non-
random loss to follow up with respect to the prognostic factors to emerge as determinants. 
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Table 14: Number of cases, proportion and odds ratio (with 95% CI) of death and loss 
to follow up (LFU) at 5-years from index date, 5-year cumulative absolute 
and loss adjusted survival of factors studied for cervical cancer in Khon Kaen 
province, Thailand, 1985-1990 followed through 1995 (IV) 
 
Proportion at 5 years 
from index date 
Odds ratio (OR) with 95% CI 5-year absolute 
survival % 
 
Factors 
 
Number 
of cases LFU% Dead% LFU-ORa Dead-ORa Actuarial Loss 
adjusteda 
All cervix cancers 601 27.6 36.4   56.8 54.7 
Age at diagnosis        
<40 122 27.9 24.6 1.0 1.0 71.0 68.1 
40-49 194 24.2 35.1 0.9 (0.5-1.5) 1.5 (0.8-2.7) 59.7 57.8 
50-59 158 29.1 36.7 1.2 (0.7-2.0) 2.0 (1.1-3.7) 55.7 53.4 
60+ 127 29.9 49.6 1.2 (0.7-2.1) 3.5 (1.8-6.9) 38.8 37.6 
Stage of disease        
Stage I 93 23.7 20.4 1.0 1.0 77.1 74.6 
Stage II 134 28.4 29.1 1.2 (0.7-2.2) 1.8 (0.9-3.6) 65.5 63.0 
Stage III/IV 222 21.6 53.6 0.8 (0.4-1.5) 5.0 (2.7-9.5) 39.0 38.2 
   Unknown 152 37.5 27.6 1.4 (0.7-2.6) 1.5 (0.7-3.1) 63.3 59.8 
Treatment        
Received 428 22.4 36.2 1.0 1.0 59.2 57.5 
Not received 173 39.9 37.0 2.0 (1.3-3.1) 2.0 (1.2-3.4) 49.9 47.5 
Residence district        
     Muang +  
neighbourhood 
274 28.1 32.9 1.0 1.0 61.1 58.6 
Other districts 327 26.9 39.4 0.8 (0.6-1.2) 1.5 (1.0-2.3) 53.2 51.4 
a
 Each factor adjusted for other factors in the table; CI: confidence interval 
 
 
The 5-year absolute survival of all cases together by actuarial method was 56.8%. The 
corresponding 5-year survival, after differential loss-adjustment by taking all the four 
determinants together, was 54.7%. The absolute difference between these two was minimal 
(2.1%). An inverse relationship between survival and age at diagnosis or known stages of 
disease was observed: a decreasing survival with increasing age at diagnosis or stage of 
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disease. The maximum absolute difference in survival by actuarial and loss-adjustment did 
not exceed 3.5 units for any factor (Table 14). 
 
5.8 Elucidating bias in survival estimate under different assumptions on vital status 
The problems of high magnitude of loss to follow up, the pattern of high losses within the 
first year of follow up and the non-random type of losses to follow up necessitated the 
computation of loss-adjusted survival in both hospital and population-based survival studies 
in low or medium resource countries. It was clear that such loss-adjusted survival was lesser 
than actuarial survival for almost all cancer sites. This suggests that the patients who were 
lost to follow up had higher mortality than assumed in actuarial assumption of eliciting 
survival rate. In most low or medium resource countries, optimal mortality ascertainment is 
directly dependent on the methods adopted to obtain the data. Hence, it is important to study 
the effects of active or passive methods of ascertainment of vital status on the estimated 
actuarial survival. In other words, when the health information systems are generally not well 
developed, it is vital to elucidate the bias, if any, resulting from absolute survival estimates in 
the absence of active follow up and when different assumptions are made regarding the vital 
status (alive/dead) of cancer patients. 
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5.8.1 An application using Chennai PBCR data 
 
Table 15:  Number of cases variably classified as alive or dead under different 
assumptions of follow up by cancer site, Chennai PBCR, 1990-1999 (II) 
 
Number of cases by vital status included for analysis 
Passive follow up only Passive + active follow up 
Case 1 Case 2 Case 3 Case 4 
 
 
 
 
Cancer/Site 
 
 
 
Total 
 
Dead 
Presumed 
alive at 
closing 
date 
 
Dead 
Presumed 
alive at 
closing 
date 
 
Dead 
 
Alive 
 
LFU 
 
Dead 
 
Alive 
Lip 86 17 69 46 40 46 10 30 46 10 
Tongue 988 371 617 693 295 693 54 241 693 54 
Oral cavity 1662 528 1134 1052 610 1052 169 441 1052 169 
Tonsil 250 107 143 214 36 214 16 20 214 16 
Hypopharynx 1017 421 596 833 184 833 59 125 833 59 
Oesophagus 2016 1028 988 1759 257 1759 59 198 1759 59 
Stomach 2681 1392 1289 2277 404 2277 120 284 2277 120 
Pancreas 328 190 138 291 37 291 23 14 291 23 
Larynx 722 290 432 456 266 456 142 124 456 142 
Lung 1806 1069 737 1574 232 1574 45 187 1574 45 
Breast 3067 875 2192 1489 1578 1489 862 716 1489 862 
Cervix 4438 1131 3307 1874 2564 1874 878 1686 1874 878 
Ovary 808 321 487 487 321 487 138 183 487 138 
Urinary bladder 442 172 270 305 137 305 62 75 305 62 
Hodgkin lymphoma 298 92 206 171 127 171 74 53 171 74 
Non Hodgkin lymphoma 868 383 485 602 266 602 130 136 602 130 
Lymphoid Leukaemia 433 197 236 323 110 323 49 61 323 49 
Myeloid Leukaemia 465 277 188 365 100 365 35 65 365 35 
Leukaemia unspecified 85 56 29 69 16 69 5 11 69 5 
PBCR: Population Based Cancer Registry; LFU: Lost to Follow Up 
Case 1:  Passive follow up only without any active follow up with cancer cases not matched with official mortality 
database presumed to be alive on the closing date of follow up. 
Case 2:  Passive + Active follow up with lost to follow up cases presumed alive on the closing date. 
Case 3:  Passive + Active follow up with lost to follow up cases censored at the last known date. 
Case 4:  Passive + Active follow up with lost to follow up cases excluded from survival analysis. 
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Table 15 gives the distribution of cases of major cancers by vital status, variably 
classified as alive or dead, based on different assumptions made on each case following the 
method adopted for getting the outcome data on follow up (II). In the example of cervix 
cancer, there were a total of 4,438 cases included for survival analysis. Of these, in reality, 
there were 1,131 (25.5%) deaths matched from the official mortality data from vital statistics 
division, 743 (16.7%) cases were known to be dead by active follow up methods (by actions 
AE or AP as in Table 2 in section 4.3.1) yielding a total of 1874 (42.2%) deaths; 878 (19.8%) 
cases were known to be alive on the closing date of follow up on December 31, 2001; for the 
rest of 1686 (38.0%) cases, alive or dead status was not known on this date as they had been 
lost to follow up at variable times between 1990 and 2001. The vital status of cases gets 
transformed when different assumptions are made.  
 
If we assume that only passive follow up was adopted and no active follow up was 
pursued in Chennai, then we know death information on 1131 cases only, instead of 1874 
deaths in reality. By rule, under passive follow up environment, if death information is not 
forthcoming, such cases are presumed to be alive. So, 743 deaths obtained by active methods 
of follow up plus 878 cases actually alive on closing date plus 1686 cases whose vital status 
was actually unknown at closing date will all be erroneously assumed to be alive on closing 
date (Case 1-purely passive method of follow up).  
 
Suppose we assume that there is a moderately developed health information system 
functioning locally which can correctly identify all deaths occurring in the region and 
minimal active follow up with impersonal approach is adopted for follow up (by actions AP 
as in Table 2 in section 4.3.1), then at the most, 1874 deaths will be known. By rule, under 
passive follow up environment, 878 cases actually alive on closing date plus 1686 cases that 
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were actually lost to follow up at variable intervals between 1990 and 2001 would all be 
assumed to be alive on the closing date (Case 2-predominantly passive method of follow up).  
 
Suppose we assume the situation as it exists, then there would be 1874 deaths of 
cervix cancer cases, 878 cases alive on closing date and 1686 cases lost to follow up before 
closing date (Case 3-active method of follow up). Suppose we decide to exclude the cases, on 
whom, the alive or dead status was not known on closing date, then the analysis will include 
only 2752 cases: 1874 deaths and 878 alive cases, instead of 4438 (Case 4-predominantly 
active method of follow up).  
 
There is variable impact caused by above scenarios on different cancers based on the 
availability of mortality data and extent or magnitude of losses to follow up. It is evident that 
the absolute survival estimated under different assumptions as stated above will also be 
different for different cancers. It becomes important to elucidate the bias arising out of such 
different misclassification of vital status (alive or dead) of cases in the analysis for major 
cancers. 
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Table 16:  5-year absolute actuarial survival% estimated under different assumptions 
on the vital status by method of follow up, Chennai PBCR 1990-1999 cases 
followed through 2001 (II) 
 
Methods of follow up and different vital status assumptions 
Passive follow up Passive + Active follow up 
All cases not 
matched with 
official mortality 
database are 
presumed as 
alive at the 
closing date 
All cases lost 
to follow up 
are presumed 
as alive at 
closing date 
All cases lost to 
follow up are 
censored at last 
known vital 
status date 
Excluding all cases 
lost to follow up 
within five years of 
diagnosis from 
analysis 
 
 
 
Cancer site or type 
Case 1 Case 2 Case 3 Case 4 
Lip 
Tongue 
Oral cavity 
Tonsil 
Hypopharynx 
Esophagus 
Stomach 
Pancreas 
Larynx 
Lung 
Breast 
Cervix 
Ovary 
Urinary Bladder 
Hodgkin’s lymphoma 
Non Hodgkin’s lymphoma 
Lymphoid Leukemia 
Myeloid leukemia 
Leukaemia unspecified 
79.5 
62.1 
68.5 
58.5 
59.2 
48.9 
47.9 
41.8 
59.0 
40.8 
71.6 
75.5 
60.1 
61.3 
69.1 
55.6 
54.3 
40.4 
32.9 
44.6 
29.2 
37.1 
17.2 
20.0 
12.9 
15.0 
10.9 
35.1 
13.2 
51.5 
59.0 
39.5 
31.0 
42.6 
29.7 
26.5 
21.5 
17.8 
40.7 
19.4 
30.5 
13.7 
12.5 
6.9 
8.6 
7.9 
30.7 
6.5 
43.7 
54.0 
27.4 
23.2 
39.4 
21.6 
23.8 
14.7 
10.9 
39.5 
15.4 
26.4 
10.8 
9.6 
5.0 
5.6 
6.5 
28.4 
4.2 
39.6 
49.4 
21.1 
20.0 
35.9 
16.8 
15.5 
10.9 
6.2 
 67 
 
The five year absolute survival estimated by actuarial methods under different 
assumptions on the vital status of the cases based on corresponding assumption on the follow 
up environment or methods of follow up as totally passive or active or a mixture of both 
using Chennai population-based cancer registry data during 1990-1999 are given in Table 16 
(II). The survival estimated by following case 1 was the highest and by following case 4 was 
the lowest for all cancers. Case 3, which treats vital status of subjects as is, is taken as 
standard. The absolute difference in estimated survival by case 1, case 2 and case 4, 
compared to case 3 represents the bias. In the absence of active follow up (case 1), 5-year 
absolute survival was estimated to be higher by 22% (in leukaemia unspecified) to 47% (in 
hypopharyngeal cancer) than when cases were actively followed and were lost to follow up at 
a known point in time (case 3). The bias ranged between 3 (for pancreas) and 10 (for tongue) 
percent units for case 2 vs. case 3. When follow up methods were totally by active methods 
but losses to follow up cases were excluded from analysis, the bias induced varied between 2-
8 percent units for different cancers. The more losses to follow up the greater are the 
uncertainty and potential for bias, in the actuarial estimate. Cases 2 and 4 represent the two 
extremes of a survival spectrum, with the actuarial estimate assuming random withdrawal 
(case 3) falling in between. The absolute differences in 5-year survival between cases 2 and 4 
were substantial for cancers of the tongue (13.8%) and ovary (18.4%). 
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6. DISCUSSION 
 
6.1 Cancer survival differences in less developed and more developed countries 
 
Documentation of cancer cases has to be perceived as a substantial part of cancer control 
programme than as a bureaucracy component (Valsecchi and Foucher, 2008). The 
fundamental step in carrying out an end-result study is to ensure adequate complete follow 
up. If the vital status (alive or dead) of all the cases included in the study is known at the 
closing date, excepting for rare losses and random drop outs as experienced in well developed 
country setting, the estimation of survival probability by standard life table methods is 
straightforward and unbiased. Every registry contemplating a survival study strives hard to 
achieve optimal level of complete follow up. However, in low or medium resource countries, 
it is difficult to obtain complete follow up information for all patients for various reasons: 
less-developed health information systems, especially mortality, that limit the data linkage 
possibilities; restrictions in active data collection through personal contact owing to data 
confidentiality agreement with multiple data sources; requirement of additional resources 
encompassing expertise, personnel, funding, etc. Hence, a high magnitude of loss to follow 
up and a marked variation in the completeness of follow up data between registries is on the 
expected lines from most registries in less developed countries. Information from all cases is 
used, including cases whose follow up ends due to closure of the study and those lost to 
follow up before closure in the estimation of survival. This differentiation has an impact on 
the survival statistics from these registries and should be borne in mind while interpreting 
survival differences between any two registries between or within countries or regions, 
especially in low or medium resource setting.  
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Table 17:  5-year Age Standardised Relative Survival (ASRS%; 0-74 years) of major cancers 
by country in low or medium resource settings (I):c Comparison with US-SEER 
White (1996-2002),a EUROCARE-4 (1995-99),b and Singapore (1993-1997)c survival 
 
5-year Age standardized relative survival (0-74 years of age) 
Median (Minimum-Maximum) of values if more than one registry are contributing 
 
Country 
(Registries) Lung Stomach Large 
bowel 
Breast Cervix Bladder Ovary Larynx Oral 
cavity 
Tongue 
 
US-SEER White* 
 
EUROCARE-4$ 
 
Singapore† 
 
China 
(Hong Kong (U)/ 
Qidong (R)/ 
Shanghai (U)/ 
Tianjin (U)) 
 
Costa Rica† 
 
Cuba† c 
 
The Gambia† 
 
India 
(Barshi (R)/ Bhopal 
(U)/ Chennai (U)/ 
Karunagappally 
(M)/ Mumbai (U)) 
 
Pakistan 
(Karachi (U)) 
 
Philippines 
(Rizal(U)/Manila(U) 
 
Saudi Arabia 
(Riyadh (U)) 
 
South Korea 
(Busan (U)/ Incheon 
(U)/ Seoul (U)) 
 
Thailand 
(Chiang Mai (M)/ 
Khon  Kaen (M)/ 
Lampang (M)/ 
Songkhla (M)) 
 
Turkey 
(Izmir (M)) 
 
Uganda 
(Kyadondo (M)) 
 
Zimbabwe c 
(Harare (U)) 
 
 
15 
 
12 
 
09 
 
21 
(6-32) 
 
 
 
 
NA 
 
NA 
 
20 
 
7 
(1-13) 
 
 
 
 
 
NA 
 
 
NA 
 
 
NA 
 
 
20 
(14-21) 
 
 
9 
(5-12) 
 
 
 
 
NA 
 
 
00 
 
 
11 
 
 
22 
 
24 
 
27 
 
39 
(20-44) 
 
 
 
 
NA 
 
NA 
 
03 
 
6 
(4-15) 
 
 
 
 
 
NA 
 
 
NA 
 
 
NA 
 
 
49 
(46-50) 
 
 
12 
(9-20) 
 
 
 
 
NA 
 
 
00 
 
 
23 
 
 
65 
 
54 
 
52 
 
44 
(36-63) 
 
 
 
 
NA 
 
21 
 
04 
 
28 
(6-31) 
 
 
 
 
 
NA 
 
 
40 
 
 
NA 
 
 
60 
(57-64) 
 
 
35 
(31-44) 
 
 
 
 
52 
 
 
08 
 
 
28 
 
90 
 
82 
 
76 
 
82 
(58–90) 
 
 
 
 
70 
 
70 
 
12 
 
52 
(31-54) 
 
 
 
 
 
NA 
 
 
47 
(40-55) 
 
64 
 
 
79 
(78-81) 
 
 
63 
(57-66) 
 
 
 
 
77 
 
 
46 
 
 
58 
 
 
71 
 
67 
 
66 
 
67 
(48-79) 
 
 
 
 
53 
 
56 
 
22 
 
46 
(34-60) 
 
 
 
 
 
NA 
 
 
37 
 
 
NA 
 
 
79 
(76-79) 
 
 
61 
(54-63) 
 
 
 
 
63 
 
 
13 
 
 
39 
 
 
82 
 
71 
 
72 
 
78 
(47-81) 
 
 
 
 
NA 
 
69 
 
NA 
 
39 
(10-48) 
 
 
 
 
 
NA 
 
 
NA 
 
 
NA 
 
 
76 
(72-79) 
 
 
48 
(33-60) 
 
 
 
 
71 
 
 
NA 
 
 
37 
 
44 
 
37 
 
62 
 
56 
(35-67) 
 
 
 
 
NA 
 
NA 
 
NA 
 
25 
(19-29) 
 
 
 
 
 
NA 
 
 
NA 
 
 
NA 
 
 
59 
(54-62) 
 
 
47 
(45-58) 
 
 
 
 
60 
 
 
09 
 
 
34 
 
 
66 
 
63 
 
66 
 
68 
(49-73) 
 
 
 
 
NA 
 
58 
 
NA 
 
28 
(16-38) 
 
 
 
 
 
NA 
 
 
NA 
 
 
NA 
 
 
62 
(59-76) 
 
 
36 
(26-49) 
 
 
 
 
71 
 
 
NA 
 
 
30 
 
60 
 
49 
 
49 
 
67 
(44-71) 
 
 
 
 
NA 
 
44 
 
NA 
 
37 
(26-45) 
 
 
 
 
 
41 
 
 
NA 
 
 
NA 
 
 
52 
(48-54) 
 
 
36 
(22-42) 
 
 
 
 
NA 
 
 
NA 
 
 
NA 
 
58 
 
45 
 
44 
 
67 
(64-68) 
 
 
 
 
NA 
 
39 
 
NA 
 
23 
(12-30) 
 
 
 
 
 
39 
 
 
NA 
 
 
NA 
 
 
53 
(52-60) 
 
 
32 
(24-33) 
 
 
 
 
NA 
 
 
NA 
 
 
NA 
* 5-year relative survival; $ area weighted 5-year relative survival among adults; # includes anus; NA: Not available; † 
National registries; R: Rural; U: Urban; M: Mixed; a Ries et al., 2006; b Sant et al., 2009; 
c
 SURVCAN database 
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The 5-year age standardized (0-74 years) relative survival for major cancers by 
country from medium or low resource settings are compared with corresponding survival in 
regions from high resource settings in Table 17. The countries from low or medium resource 
settings can be grouped into three tiers based on observed survival. Survival was the highest 
in Hong Kong (in China), South Korea and Turkey, where health services are well developed 
with advanced diagnostic and treatment centres and high per head Gross National Income 
(GNI) values. Survival was intermediate in Costa Rica, mainland China, Thailand, India, 
Pakistan, Philippines and Zimbabwe, where cancer health services are moderately developed 
with diagnostic and treatment facilities centred in and around urban cities and with medium 
per head GNI. Survival was the lowest in The Gambia and Uganda, with poorly developed 
health services, as indicated by limited availability of cancer diagnostic and treatment 
facilities and with very low per head GNI. The 5-year survival reported for most low or 
medium resource countries in SURVCAN study were lower than that reported for the white 
patients in the United States Surveillance Epidemiology End Results (US-SEER) program for 
most cancers (Ries et al., 2006). The country-weighted 5-year relative survival data from 23 
European countries (Sant et al., 2009) and 5-year ASRS in Singapore (Chia, 2011) were on 
par with one or more registries from China, South Korea and Turkey for cancers of the breast, 
cervix, large bowel, head and neck. The level of development of health services and their 
efficiency in providing early diagnosis, treatment and clinical follow up care can have a 
profound effect on cancer survival. However, a meaningful interpretation is possible only 
after taking into account the differences in data quality between registries, especially when 
they are from a wide range of economic development levels.  
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6.2 Data quality indices – Implications of lack of active follow up 
 
The fact that 25 out of 28 registries from low or medium resource countries that have 
undertaken population-based survival studies had contributed data to IARC CI5C publication 
series (Parkin et al., 2005, Curado et al., 2007) at one time or other, stands testimony to the 
data quality on cancer incidence. However, in 15 registries, the mortality data were not 
published as they were not routinely available or were included with considerable 
reservation. Thus, the important data quality issue in a survival study is achieving adequate 
follow up to get vital status data whether the patient is alive or dead at the end of the study. In 
a low or medium resource setting, with demonstrated less-developed mortality registration 
systems, achieving adequate complete follow up is possible only if registries undertook 
special efforts by evolving a variety of active methods suiting the conditions. Survival 
reported by most registries that pursued follow up entirely by active methods, tended to 
reflect the average outcome from the different cancers studied, keeping with the advanced 
stages at presentation, standards of health care development in their regions, inequities in 
accessibility to services especially cancer directed treatment and compliance to it and 
minimal or no cancer screening facilities. Interestingly, the countries that achieved the 
highest survival in this study have pursued follow up of cases predominantly by passive 
means with minimal active components. 
 
Box plots have been employed to examine the relationship, if any, between the 
estimated 5-year ASRS and four categories of registries classified based on methods (AE, AP, 
PE and PP according to Table 4) adopted for follow up data collection for vital status. The 
published five-year age-standardized relative survival (ASRS) percent values for cancers of 
the breast (Figure 3a) and cervix (Figure 3b) were utilized from registries that contributed 
data registered during 1990-2001 and period varying for individual registries 
(Sankaranarayanan and Swaminathan, 2011). The median, quartiles and range of ASRS (0-74 
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years) values showed a gradual ascendancy from entirely active to entirely passive methods 
of follow up. This phenomenon was true for most cancers with high lethality as well 
(Sankaranarayanan and Swaminathan, 2011). This suggests a possible methodological 
problem of follow up, especially in the ascertainment of deaths, as demonstrated in Chennai 
registry data, resulting in substantial bias in the actuarial survival estimate under standard 
assumptions.  
 
 
 
 
 
Figure 3a: Breast cancer 5-year Age Standardised Relative Survival (ASRS; 0-74 years) 
by classified methods of follow up in 26 registries, 1990-2001
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Figure 3b: Cervix cancer 5-year Age Standardised Relative Survival (ASRS; 0-74 years) 
by classified methods of follow up in 23 registries, 1990-2001 
 
High level of completeness of both cancer incidence and ascertainment of mortality 
data are important prerequisites for valid cancer survival estimates and when such 
completeness cannot be assured, survival rates and their comparisons should be carefully 
interpreted. Even modest levels of under-registration of deaths may lead to severe 
overestimation of long-term cancer survival estimates (Brenner and Hakulinen, 2009). 
Mortality ascertainment will be sub-optimal in a passive follow up environment if the data 
linkages between mortality and incident cancer registry databases are not based on a unique 
personal or national identification number and not backed by a sound death registration 
system. Such deficiencies result in incomplete follow up. This is even more accentuated by 
the fact that death registration is generally done based on place of occurrence of death and not 
necessarily on usual place of residence. The registries generally have access only to official 
mortality data of the region covered by the registries. This discounts the possibility of 
knowledge of deaths of cancer patients occurring outside of the registry coverage area if 
deaths obtained from linkages alone are accounted. This purportedly suggests re-examining 
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the definition of location of death in health services research and death registration system. 
Hence, such defective linkages effectively means that the extent of incompleteness in follow-
up is unknown, especially mortality and such dead cases would have been erroneously 
classified as alive at the closing date of follow up. Therefore, the reported survival from some 
of the registries in the study may clearly be over estimated.  
 
Aside studies have been carried out in the past to estimate the completeness of follow 
up, especially mortality, in a passive environment by extra active follow up for selected 
cancers, which revealed missing of deaths through routine linkages (Berrino et al., 1995). The 
present study has extended the elucidation of the bias in the estimation of absolute survival 
under different assumptions on vital status of patients depending on purely or predominantly 
active or passive methods of follow up for major cancers using Chennai registry data from 
India. This analogy is applied to cover the age-standardized relative survival rates for the 
same cancers in Table 18.  
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Table 18: Absolute increase in Age Standardised Relative Survival (0-74 years)% between 
treating loss to follow up as is and assuming them as alive at closing date in the 
absence of active follow up in Chennai, India, 1990-1999 
 
% lost to follow up: Years from 
diagnosis 
Age Standardised Relative 
Survival (0-74 years) % 
 
 
Cancer site/type Up to 5 
years 
<1 yr 1-3 yrs 3-5 yrs 
 
 
Dead% With loss 
to follow 
up (LFU) 
LFU as 
alive on 
closure 
Absolute 
increase 
Lip 
Tongue 
Oral cavity 
Tonsil 
Hypopharynx 
Oesophagus 
Stomach 
Pancreas 
Larynx 
Lung 
Breast 
Cervix 
Ovary 
Bladder 
Hodgkin’s 
Non Hodgkin’s 
Lymphoid leukaemia 
Myeloid leukaemia 
Leukaemia unspecified 
9.3 
16.9 
14.4 
5.6 
10.0 
8.0 
9.1 
3.7 
7.8 
8.9 
17.4 
17.2 
20.8 
12.7 
9.1 
12.8 
9.5 
10.3 
10.6 
7.0 
13.1 
10.3 
4.8 
9.0 
6.7 
7.3 
3.1 
6.7 
8.0 
12.4 
11.0 
14.7 
10.9 
6.4 
10.9 
2.8 
8.6 
10.5 
2.3 
2.6 
2.2 
0.8 
0.7 
0.9 
0.9 
0.3 
0.8 
0.7 
2.9 
3.7 
4.6 
1.6 
1.7 
1.3 
3.2 
1.3 
0.0 
0.0 
1.2 
1.8 
0.0 
0.3 
0.4 
0.9 
0.3 
0.3 
0.3 
2.0 
2.5 
1.4 
0.2 
1.0 
0.6 
3.5 
0.4 
0.0 
53.5 
70.1 
63.3 
85.6 
81.9 
87.3 
84.9 
88.7 
63.2 
87.2 
48.5 
42.2 
60.3 
69.0 
57.4 
69.4 
74.6 
78.5 
81.2 
49.0 
23.4 
36.7 
15.6 
15.0 
8.6 
10.3 
8.7 
38.0 
7.1 
47.7 
59.6 
28.5 
32.0 
37.8 
23.2 
16.4 
14.9 
11.2 
53.6 
34.1 
44.0 
20.2 
23.4 
15.4 
17.7 
11.9 
43.4 
14.6 
56.2 
64.9 
41.8 
41.9 
41.4 
32.2 
20.6 
21.9 
17.1 
4.6 
10.7 
7.4 
4.6 
8.4 
6.8 
7.4 
3.2 
5.4 
7.5 
8.5 
5.3 
13.3 
9.9 
3.6 
9.0 
4.2 
7.0 
5.9 
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The implications of lack of active follow up on population based survival in Chennai, 
India, under two assumptions on the survival status of patients for major cancers registered 
during 1990-1999 and followed through 2001 in Chennai, India, are given in Table 18. It 
shows the 5-year ASRS% values by assuming that all loss to follow up cases in reality, as 
alive on 31st December 2001 (Case 2 in methods section 4.3.6; figure 2) and by treating all 
losses to follow up cases with actuarial assumption (Case 3 in methods section 4.3.6; figure 
2). An upward bias ranging between 3-13% under 5-21% of losses to follow up for different 
cancers was detected. Extending the same analogy to other registries that pursued 
predominantly passive methods of follow up to get vital status information, if the losses to 
follow up did not exceed one in five and they were not correlated with survival, the over-
estimation of 5-year ASRS would have conformed to the upper limit of 13%. The more the 
losses, the higher would be the bias. The bias would be much more if the mortality 
ascertainment by passive follow up was poorer than anticipated. Therefore, it is imperative 
for registries from low or medium resource countries to evolve suitable methods of active 
follow up before embarking on survival studies. 
 
6.3 Loss to follow up – Implications of loss-adjusted survival 
 
The magnitude of the bias depends on the extent of loss to follow up: the lesser the loss 
implies lesser bias. This holds true, if the losses are common and correlated with the patient 
prognosis or survival. In most low- or medium-resource countries, such losses are common 
due to deficiencies in health infrastructure and recording of health statistics, especially 
mortality. The losses are also likely to be related to the patient's chance of survival. 
Differential losses may be encountered for a variety of prognostic factors: low socio-
economic status may be responsible for lack of continuous patient surveillance; stage or 
extent of disease and/or age at diagnosis may be related to the motivation of follow-up, are a 
few examples. Furthermore, the direction of bias is unpredictable and gets accentuated in 
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case of non-random nature of losses to follow up or informative censoring. In such instances, 
it is desirable to investigate deviation from randomness of censoring using the information on 
all available factors associated with survival. 
The losses to follow up have been of high magnitude and common to both hospital 
and population-based registries that pursued a variety of active methods of follow up. The 
patterns of losses have also been different: high losses within a year or 1-5 years or more than 
5-years from index date, for various registries, causing variable impact on survival estimate. 
When differential losses to follow up were further detected with respect to potential 
determinants, either of losses or survival, it became necessary to make specific loss-
adjustment for correcting the ensuing bias otherwise estimated by standard methods. Large 
differences between loss-adjusted and actuarial survival from female breast cancer were 
found in hospital-based series of patients coming from wide geographic area, where follow 
up of patients, no longer attending the hospital, by house visits was impractical (Ganesh, 
1995). However, in another study from Trivandrum hospital study of ovarian cancer, the 
differences between loss-adjusted survival before active follow up and survival by life table 
approach after perseverant postal enquiries were small (Mathew, 1996). The response was 
directly dependent on the effort expended by individual registries to collect vital status 
information. In contrast, an international comparison of actuarial and loss adjusted survival of 
cervix cancer incident cases from population-based registries in developing countries 
(Swaminathan et al., 2002) found a maximum difference of 4.1% with a loss to follow up to 
44% but indicating practically a random pattern. The difference was 2.1 units in Khon Kaen 
registry in Thailand for cervix cancer. These minimal differences are mainly due to the 
integration of mortality data collection into the case-finding operations of any population-
based registry, routinely done on an annual basis and their matching with incident cancer 
database. This is carried out for all cases registered irrespective of any selection. This induces 
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the randomness in cases on whom, the vital status is unknown. Loss adjusted survival was 
lesser than actuarial one, which suggests that under ascertainment of deaths among loss to 
follow up cases is the problem. The only exception were patients with localized or early stage 
breast cancer wherein, the loss-adjusted survival exceeded the actuarial survival indicating 
that non-tracing of alive patients till closing date was the problem (Ganesh, 1995). Hence, 
data source seems to affect the need for loss-adjustment and the problem can be more 
substantial in hospital-based cancer registries and clinical series. The loss-adjusted approach 
is likely to be useful especially when hospital-based cancer registry data from a low or 
medium resource country are used to evaluate the outcome of cancer patients. If routine 
follow up is poor, first priority is to increase the actual follow up visits and the second is to 
institute rigorous active follow up measures for eliciting the vital status. 
 
6.4 Intra-country variation in cancer survival – Methodological implications 
 
Comparing the maximum and minimum survival by registries in the same country in Table 
17, there were marked variations for all cancers in China, most cancers in India, a few 
cancers in Thailand and laryngeal cancer in South Korea. In India, marked differences were 
observed between rural (Barshi) or semi-urban (Karunagappally) or small urban (Bhopal) 
registries while the differences were minimal for most cancers between the metropolitan 
cities of Chennai and Mumbai, where more developed and accessible cancer care services are 
available. The follow up data was obtained entirely by active methods in all registries from 
India and hence the differences in survival due to methodological bias are likely to be 
minimal. In South Korea, the survival differences between registries were negligible for all 
cancers excepting larynx. Follow up was carried out predominantly by passive follow up 
methods, primarily by data linkages using unique national identity numbers issued to citizens 
and scrutiny of hospital records. Hence, the mismatches are likely to be lesser and so would 
be the methodological bias. However, the registries from China and Thailand have adopted 
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different follow up methods. In China, cancer survival from rural area of Qidong was 
consistently lower than from big cities like Shanghai and Tianjin for all cancers. In Thailand, 
the differences between registries were limited to a few cancers only. These survival 
differences are likely to reflect the differences in early diagnosis and the impact of inequities 
in health care infrastructure development, availability and accessibility to health services, but 
the differences due to bias in estimating survival following methodological problems are 
inherent but unknown. It is encouraged that future studies address this important issue and 
facilitate objective measurement of possible bias in the estimated survival owing to 
inappropriate choice of methods of follow up for vital status information. 
 
6.5 Survival differences – Implications of treatment or disease characteristics 
 
The success of cancer treatment is, as a rule, measured by survival. The variable level of 
development of cancer health services certainly impacts the survival from different 
populations in low or medium resource countries calling for adequate and sincere investments 
in improving awareness, health-services infrastructure and accessibility. Cancer survival from 
both hospital or population series have different perspectives but serve as the main indicator 
of outcome of cancer health services or treatment and an important component in maintaining 
cancer control activities. Reliable statistics devoid of methodological bias in eliciting vital 
status are required from low or medium resource countries for specifically interpreting any 
survival differences in the region or institution as due to treatment related attributes or 
resources.  
 
 80 
 
 
Table 19: Comparison of 5-year observed survival (%) of major cancers in rural 
Dindigul registrya, urban Chennai registry (II) and treated cases from 
hospital cancer registry in Cancer Institute (WIA), Chennaic  
 
 Five-year observed survival % 
Dindigul rural 
PBCR 
Chennai urban 
PBCR 
Treated cases only 
from HBCR 
 
Cancer site/type 
2003 1990-99 2000-01 
 
Cervix 
 
Breast 
 
Stomach 
 
Mouth 
 
Oesophagus 
 
Tongue 
 
Lung 
 
All leukaemias 
 
All lymphomas 
 
Larynx 
 
Ovary 
 
Large bowel 
 
 
35 
 
38 
 
7 
 
33 
 
6 
 
27 
 
4 
 
19 
 
25 
 
25 
 
30 
 
16 
 
54 
 
44 
 
9 
 
31 
 
7 
 
19 
 
7 
 
20 
 
29 
 
31 
 
27 
 
NP 
 
62 
 
67 
 
41 
 
35 
 
14 
 
37 
 
8 
 
44 
 
61 
 
70 
 
45 
 
42 
 
All cancers 
 
 
26 
 
NP 
 
NP 
PBCR: Population based cancer registry – comprises all incident cases treated or not 
HBCR: Hospital based cancer registry – comprises all cases that completed one treatment 
modality at the Cancer Institute (WIA), Chennai, India; NP: Not published; 
a
 Swaminathan et al., (2009); c Shanta et al., (2008) 
 
 
Table 19 gives the comparison of survival estimates arising from rural (Dindigul, 
India) and urban (Chennai, India) population-based registries and hospital series of treated 
cases (Cancer Institute (WIA), Chennai, India) of various cancers, from the same state of 
Tamil Nadu in South India. Cancer follow-up places a significant burden on hospital 
outpatient clinics and hence alternative models need to be developed to provide the same. 
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The follow up for vital status information on patients was carried out entirely by active 
methods in all three registries. The data quality indices like losses to follow up have all been 
addressed and were uniform in the three registries. Hence, survival differences, if any, could 
be attributed to non-methodological factors like treatment or disease characteristics. Hospital-
based survival studies generally suffer from high degree of selection of patients with 
favourable prognosis and hence usually lack representativeness, thereby not always suitable 
for generalization to a larger population in the region. However, analysis of overall or event-
free survival need not be a sterile exercise if it contrives on improving clinical practice, which 
would translate into ultimate benefit at the population level. Population-based survival in 
rural Dindigul district (Swaminathan et al., 2009) characterized by all cases treated or not was 
either on par or lower than in metropolitan Chennai and other urban registries in India 
(Sankaranarayanan and Swaminathan, 2011). Small differences in survival between rural and 
metropolitan Chennai registries are not reflective of wide differentials in availability or 
development of or accessibility to cancer related health services in these two places. This 
brings to the fore, the necessity of collecting basic data on prognostic factors (like extent of 
disease, treatment, etc.) even in a population based series of cancer cases to explain the 
survival differences meaningfully. This extra data would also help to understand and enhance 
the data quality issues on survival estimation. 
 
Though cancer treatment, including chemotherapy, is given free of cost in all public 
or government hospitals in Tamil Nadu state, patient compliance and completeness of 
treatment are significant prognostic factors for survival. This view is strengthened since 
survival witnessed among all patients receiving complete treatment in Cancer Institute 
(WIA), Chennai, a comprehensive cancer centre with state of art facilities, was two-fold 
higher than in rural Dindigul district and was either on par or higher than population-based 
survival in Europe for most cancers (Sant et al., 2009, Swaminathan et al., 2009). While the 
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survival in public hospitals was less than in non-government sector for patients who received 
complete treatment, the reverse was true for incomplete treatment, as demonstrated in the 
present study on population series of childhood cancers from Chennai. This probably reflects 
the impact of stage of disease, socioeconomic status, type of treatment received and 
compliance and supportive care on survival. Unlike in other developed countries, it is 
possible that economic constraints in living conditions may affect completeness of treatment 
more than cost of treatment itself at the population level in rural or urban India. 
Commissioning of special cancer registries as an extension of HBCRs to address the 
variations in absolute survival is one thoughtful solution. This would ensure data collection 
on a variety of important treatment and disease characteristics. Population based trials 
focusing on technologically and economically viable early detection programs for major 
cancers allied to accessible treatment facilities are the way forward to improve cancer 
outcome.  
 
 Tumour stage is one of the important disease characteristics that impacts survival and 
provides the basis for differences in survival. Information on clinical extent of disease was 
available for selected cancers in a few population-based registries from low or medium 
resource countries. This was utilized to examine and compare the survival differences by 
stage between registries classified into two groups: possessing well (W) or moderately (M) 
developed cancer health services based on per head GNI values. Since data collection was 
from heterogeneous sources, misclassification in extent of disease categories is a distinct 
possibility. To minimize this, the data from individual registries in respective groups were 
pooled and analyzed for comparison (Table 20).  
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Table 20:  5-year absolute survival% and frequency% distribution by clinical extent of disease of 
selected cancers based on two sets of pooled data from contributing countries (I) 
 
5-year survival% by clinical extent of disease 
(Frequency% by clinical extent of disease) 
Well developed health services (W) vs. moderately developed 
(M): Cancer site and countries (Pooled number of cases) 
Localised Regional Distant 
Metastasis 
Unknown 
Tongue 
W. Survival: Singapore (120) 
 
48·4 
 
23·3 
 
20·0 
 
33·1 
    Frequency (26) (25) (4) (45) 
M. Survival: India, Pakistan, Thailand (3,844) 54·3 14·5 3·1 25·3 
    Frequency (23) (65) (5) (7) 
 
    
Oral cavity 
W. Survival: Singapore (135) 
 
52·3 
 
26·5 
 
- 
 
28·9 
    Frequency (28) (22) (2) (48) 
M. Survival: India, Pakistan, Thailand (5,592) 60·2 23·8 3·3 28·8 
    Frequency (22) (66) (5) (7) 
 
    
Large bowel 
W. Survival: Singapore, Turkey (4,969) 
 
64·1 
 
45·7 
 
8·6 
 
41·8 
    Frequency (26) (27) (18) (29) 
M. Survival: India, Philippines, Thailand (4,742) 49·8 32·0 2·4 34·7 
    Frequency (29) (34) (23) (14) 
 
    
Larynx 
W. Survival: Singapore, Turkey (789) 
 
69·6 
 
40·7 
 
41·8 
 
54·6 
    Frequency (34) (19) (5) (42) 
M. Survival: India, Thailand (3,161) 54·4 22·3 4·7 26·9 
    Frequency   (25) (60) (8) (7) 
 
    
Breast 
W. Survival: China (Hong Kong), Singapore, Turkey (14,645) 
 
89·6 
 
75·4 
 
26·7 
 
79·7 
    Frequency (17) (32) (2) (49) 
M. Survival: Costa Rica, India, Philippines, Saudi Arabia,     
Thailand (17,640) 
 
76·3 
 
47·4 
 
14·9 
 
47·1 
    Frequency   (26) (47) (14) (13) 
 
    
Cervix 
W. Survival: Singapore, Turkey (1,230) 
 
69·5 
 
52·2 
 
18·6 
 
57·5 
    Frequency (42) (13) (5) (40) 
M. Survival: Costa Rica, India, Philippines, Thailand (14,536) 73·2 47·2 7·4 45·7 
    Frequency   (20) (64) (6) (10) 
 
    
Ovary 
W. Survival: Singapore, Turkey (948) 
 
84·1 
 
39·7 
 
28·1 
 
56·7 
    Frequency (40) (4) (27) (29) 
M. Survival: India, Thailand (3,666) 63·8 34·5 4·2 36·8 
    Frequency (22) (27) (38) (13) 
 
    
Bladder 
W. Survival: Singapore, Turkey (1,062) 
 
61·3 
 
34·8 
 
16·4 
 
54·0 
    Frequency (53) (7) (5) (35) 
M. Survival: India, Thailand (2,476) 43·8 24·9 2·3 35·6 
    Frequency   (42) (33) (10) (15) 
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There was an inverse relationship between stage of disease or extent of disease and 
survival in both groups for all cancers which added strength to data quality (Table 20). The 
pattern of survival by clinical extent of disease in the study provides striking evidence for the 
need for early diagnosis and effective treatment. The higher survival observed for group W 
countries for localized large bowel, larynx, breast, ovary and bladder cancers (which largely 
require radical surgical treatment) and for regional spread diseases (which require multimodal 
treatment) may largely due to the difference in the development and accessibility of 
diagnostic and treatment services. 
 
Cancer survival studies from low or medium resource countries would not have been 
possible without the availability of reliable population-based cancer registries. Such studies 
form the first step towards indentifying the elements of cancer control, including primary 
prevention, early detection initiatives and treatment, which are most likely to contribute to the 
reduction of cancer mortality in these countries. These studies are also pointers towards 
realization that cancer survival in many low-income or middle-income countries that are yet 
to undertake such studies is likely to be on par or lower than discussed here. The survival 
rates observed in many countries have also provided a definite alternative to the deficient 
official cancer mortality statistics from those areas. Extreme caution must be exercised when 
survival figures from local area registries are used to extrapolate for the entire country. For 
instance, in India, the coverage of PBCRs is about 7% of national population. The PBCRs are 
predominantly covering metropolitan or urban populations. With few registries covering rural 
populations, even pooled data analysis of all registries would result in erroneous estimates, 
mostly representing experiences in urban areas only. However, the striking differences in 
cancer survival between countries emphasize the need for urgent and adequate investments 
on cancer control. 
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It must be kept in mind that in a PBCR, using data from specialized and non-
specialized medical institutions of varying standards (heterogeneous) could lead to unrealistic 
comparisons between registries. However, methodological issues on estimating survival, 
including follow up data acquisition, are entirely within the control of individual registries. A 
simple guide to PBCRs for getting vital status data of registered cases in the conduct of 
survival studies is given in figure 4.  
  
It cannot be reiterated more that cancer survival studies based on registry data from 
low or medium resource countries do need suitable correction for possible inherent 
methodological bias, arising due to inappropriate employment of follow up methods (like 
relying on passive methods under sub-optimal mortality registration) and/or non-specific 
methods for estimation of survival (like standard actuarial instead of loss-adjusted ones). It 
can then stated with overwhelming confidence that these survival data generated from low or 
medium resource countries provided a baseline for sincere investments in developing 
infrastructure for sustainable improvements in cancer health services in the future.  
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Figure 4: A guide for choosing follow up methods for conducting population-based 
survival study in low or medium resource settings 
 
I. Ascertainment of mortality of cancer cases from official vital statistics offices 
Is the existing official mortality data 
reliable enough (on completeness, 
certification of cause, etc.) to emerge as 
an independent source of cancer data? 
Resulting mortality data of registered 
cancer cases would be sub-optimal; 
Resorting to active follow up methods for 
mortality ascertainment is mandatory 
Is linkage of mortality data with registry 
database automated, systematic, adequate 
and based on unique person identifiers? 
Resulting mortality data of registered 
cancer cases is expected to be optimal;  
Confining to passive follow up methods 
for mortality ascertainment is sufficient 
II. Ascertainment of vital status of presumably alive or all registered cancer cases  
Is linkage of registry database with other 
databases (like population health register, 
hospitals, etc.) automated, possible and is 
based on unique person identifiers? 
Resulting vital status of cases would be 
complete with random censoring; 
Confining to passive follow up methods 
for getting vital status is sufficient; 
Active follow up of random sample for 
any bias in survival estimation is optional 
Resulting vital status would be incomplete 
with or without random censoring; 
Resorting to active follow up methods for 
getting vital status data is mandatory 
Differentiating loss to follow up cases 
among those censored is necessary 
No 
No 
Yes 
Yes 
No 
Yes 
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7. CONCLUSIONS 
 
• The execution of survival studies in low or medium resource countries setting requires 
special efforts and resources in terms of personnel, expertise and funding. Unlike in 
more developed countries, survival studies could not always be routinely carried out, 
given the less developed health information systems. 
 
• In less developed health information systems, mortality ascertainment by passive 
means would be grossly inadequate or incomplete, inducing a serious bias in survival 
estimation, if standard vital status assumptions were followed (like cases always 
presumed to be alive until receiving death notification). 
 
• To avoid this upward bias in survival estimation, the maximum ranging between 22-
47% for different cancers as shown in this study, a variety of suitable active methods 
have to be evolved and pursued for collecting vital status information. 
 
• If active methods are impractical to implement owing to registry operational 
constraints, active follow up of representative subset of cases should be systematically 
undertaken to elucidate the bias in estimated survival under different assumptions on 
the vital status as done in this study. 
 
• If high magnitude of non-random loss to follow up exists, its determinants have to be 
elicited and survival estimation done through differential loss-adjustment procedures. 
The impact could be variable: minimal for population-based but would be pronounced 
for hospital-based studies as shown in this study. 
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• A systematic evaluation of biases in estimating survival due to methodological 
problems and their suitable corrections are mandatory before survival differences 
could be attributed to the varied development of treatment resources and/or disease 
characteristics in low or medium resources settings.   
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Summary
Background Population-based cancer survival data, a key indicator for monitoring progress against cancer, are not 
widely available from countries in Africa, Asia, and Central America. The aim of this study is to describe and discuss 
cancer survival in these regions.
Methods Survival analysis was done for 341 658 patients diagnosed with various cancers from 1990 to 2001 and 
followed up to 2003, from 25 population-based cancer registries in 12 countries in sub-Saharan Africa (The Gambia, 
Uganda), Central America (Costa Rica), and Asia (China, India, Pakistan, Philippines, Saudi Arabia, Singapore, South 
Korea, Thailand, Turkey). 5-year age-standardised relative survival (ASRS) and observed survival by clinical extent of 
disease were determined. 
Findings For cancers in which prognosis depends on stage at diagnosis, survival was highest in China, South Korea, 
Singapore, and Turkey and lowest in Uganda and The Gambia. 5-year ASRS ranged from 76–82% for breast cancer, 
63–79% for cervical cancer, 71–78% for bladder cancer, and 44–60% for large-bowel cancers in China, Singapore, 
South Korea, and Turkey. Survival did not exceed 22% for any cancer site in The Gambia; in Uganda, survival did not 
exceed 13% for any cancer site except breast (46%). Variations in survival correlated with early detection initiatives 
and level of development of health services. 
Interpretation The wide variation in cancer survival between regions emphasises the need for urgent investments 
in improving awareness, population-based cancer registration, early detection programmes, health-services 
infrastructure, and human resources. 
Funding Association for International Cancer Research (AICR; St Andrews, UK), Association pour la Recherche sur le 
Cancer (ARC, Villejuif, France), and the Bill & Melinda Gates Foundation (Seattle, USA).
Introduction
Cancer survival estimates from population-based cancer 
registries include all cases diagnosed in a given population. 
These estimates reﬂ ect diﬀ erent socioeconomic factors, 
health-care seeking behaviours, natural histories, and the 
eﬃ  ciency of the health-care services to provide early 
diagnosis, prompt treatment, and follow-up care. 
Population-based survival represents the average 
prognosis of a cancer and is useful for assessing progress 
in cancer control, including the eﬀ ect of early detection, 
diagnosis, treatment, and follow-up on cancer outcomes. 
These data are also helpful in making informed decisions 
to ensure improved and equitable cancer care. The 
International Agency for Research on Cancer (IARC) has 
been collating data on worldwide cancer incidence for ﬁ ve 
decades,1,2 in collaboration with the International 
Association of Cancer Registries and registries in various 
countries, with a particular focus on low-income (per 
head Gross National Income [GNI] <US$2000) and 
middle-income countries (per head GNI US$2000–10 000). 
Such eﬀ orts have been complemented by WHO mortality 
databases and population-based survival studies that 
systematically analysed survival outcomes of patients in 
Europe,3 the USA,4 and other developed countries.5–7 
Cancer survival statistics from ten developing countries 
were made available for the ﬁ rst time, to our knowledge, 
in 1995 through a collaborative initiative by IARC,8,9 but 
such data are not widely available from many countries of 
low to middle income. Here, we report the results from a 
collaborative survival study by IARC with a wider 
geographical coverage of countries and populations. 
Methods
Registries
31 population-based cancer registries in 17 countries 
provided data for this study; six population-based cancer 
registries from ﬁ ve countries were excluded from 
participation. The methods used in each geographical 
region to identify and register all diagnosed cases are 
described in the technical reports from the individual 
registries and in the Cancer Incidence in Five Continents 
(CI5) series published by the IARC.1,2 The registries used 
a mix of passive notiﬁ cation and active registration to 
register all cancer cases diagnosed in their area, and used 
quality assurance procedures, as advocated by IARC, to 
validate the quality and completion of cancer registration 
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in the target population.10 Uniform criteria3 and the 
disease codes of the International Classiﬁ cation of 
Diseases and Related Health Problems, tenth revision 
(ICD-10)11 were used for coding the collected data. 
An overview of this study is given in the ﬁ gure. 
Participating registries initially submitted data during 
2002–05, which was assessed for quality by IARC using 
standard methods and criteria.12,13 Validation checks were 
done for errors such as unusual combinations of cancer 
sites, morphology, sex, or age at diagnosis, and for in-
consistencies and completeness of follow-up infor ma-
tion. The registries were then contacted for clariﬁ cations 
and were advised on measures to improve data quality and 
on further active and passive follow-up methods to 
ascertain patients’ vital status. Data were subsequently 
updated and received until 2008. 25 population-based 
cancer registries covering an entire nation, city, or rural 
district from 12 countries were included (table 1). 16 of the 
registries provided data on clinical extent of disease. 
Patients
Of the 615 636 total cases of incident cancers (ICD-10: 
C00-96) registered in 1990–2001 from 25 cancer registries, 
a subset of 366 357 patients diagnosed with cancers of 
tongue, oral cavity, stomach, large bowel, larynx, lung, 
breast, cervix, ovary, and bladder were analysed in this 
study (ﬁ gure). 13 registries contributed cases for ten cancer 
sites, and the others contributed data for one to nine sites 
(table 1). Cases excluded were those registered on the 
basis of information from a death certiﬁ cate but with no 
traceable hospital record (11 733), those with no follow-up 
information on vital status after diagnosis (9584), and 
cases rejected on validation checks (3382). 341 658 cases 
were eligible for ﬁ nal analysis. The ﬁ nal diagnosis of 
these cases was mainly by histology, but some were 
diagnosed by clinical, biochemical, imaging, or endoscopic 
methods. The necessary minimum required data for this 
study are in the webappendix. 
Procedures
The survival status of patients at or within 5 years from the 
date of diagnosis was obtained by active and passive 
methods (table 1).13 Passive follow-up relied on matching 
cancer cases with all-cause death information collected 
from death registration systems and hospital records using 
unique person numbers (in countries where such 
information is available—eg, South Korea) or by using a 
combination of personal identiﬁ ers from national 
population registers (ﬁ rst and last name, address and date 
of birth, etc) for record linkage. However, death registration 
is often incomplete in countries such as India, Philippines, 
Thailand, The Gambia, Uganda, and Pakistan, and 
assuming patients to be alive unless a death certiﬁ cate was 
available would lead to a large underestimation of deaths. 
Therefore, in these countries, the following active measures 
were undertaken to establish the survival status of patients 
without death records: repeated visits to hospitals to 
scrutinise clinical follow-up notes; visits to death-registry 
oﬃ  ces, churches, and mosques to collect information from 
their death registers; telephone or reply-paid postal 
enquiries; investigations in work places or neighbourhoods; 
and house visits for personal enquiries. Registries from 
countries that use passive methods, such as China, Costa 
Rica, Singapore, Saudi Arabia, and South Korea, were 
advised to use repeated matching with data sources to 
update follow-up.
The endpoint in this study was death, regardless of the 
cause. Survival for each cancer site (all clinical stages 
combined) is described in terms of 5-year age-standardised 
relative survival (ASRS). For countries providing data from 
more than one cancer registry, the median value of 
individual survival estimates and the minimum and 
maximum for the diﬀ erent registries are reported. Survival 
by clinical extent of disease at 5 years from diagnosis was 
reported for eight cancer sites; for any site, data from 
10–15 registries in four to eight countries were used for 
analysis. Categories of clinical extent of disease were 
deﬁ ned as follows: localised, for tumours conﬁ ned to the 
organ of origin without invasion into the surrounding 
tissue or organ and without involvement of any regional or 
distant lymph nodes or organs; regional, for tumours that 
had invaded surrounding tissue or organ, with or without 
the involvement of the regional lymph nodes, but not 
involving non-regional lymph nodes or organs; distant 
metastasis, if the tumour had spread to the non-regional 
lymph nodes or distant organs; or unknown. 
Statistical analysis
To limit chance variation, survival estimates were based 
on at least 100 cancer cases in total and at least 30 cases in 
each subgroup of country and cancer site. Given the 
paucity of data from Africa and the rarity of distant 
metastasis in patients with head and neck cancers, 
exceptions were made for the survival estimates reported 
from African countries and survival by clinical extent of 
disease for oral cavity and tongue cancers. Observed 
survival was computed by actuarial method14 following 
the semi-complete approach.15 Relative survival16 was 
calculated as the ratio of observed to expected survival 
in the general population of the same age and sex,17 to 
exclude the eﬀ ect of competing causes of mortality and to 
facilitate survival comparisons between countries with 
diﬀ erent background mortalities. Expected survivals for 
individual registries were estimated from abridged life 
tables according to country, age, and sex.18 Relative survival 
was reported as ASRS to account for diﬀ erences in the 
age of cancer cases.19 Estimated incident cancer cases 
from developing countries in 2002 were used as standard 
cancer populations.20 Analyses were done using SAS 
software version 9.1.21
Role of the funding source
The funding source had no role in study design, data 
collection, analysis, interpretation, or writing of the article. 
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Results
The range of values of data quality indices for diﬀ erent 
cancer sites by individual registries is given in table 1. 
Cases registered based on a death certiﬁ cate only and 
excluded from survival analysis ranged from 0 to 16%, 
and the percentage of registered cases included for 
survival analysis varied from 65 to 100%. Vital status 
(alive or dead) was known at the closing date of follow-up, 
or after 5 years from the date of diagnosis, for 30–100% 
of cases. Active eﬀ orts resulted in the availability or 
improvement of data on clinical extent of disease for 
Response to invitation to participate
31 population-based cancer registries from 17 countries 
Participated in the study
25 population-based cancer registries from 12 countries
615 636 cases
Database for this study
10 cancers: 366 357 cases
Registration: 1990–2001*
Follow-up: 1990–2003*
Included for analysis
341 658 incident cancers (93%)
Survival analysis by site*
Data from 25 population-based cancer registries, 
12 countries, 1–10 sites per registry
Survival analysis by clinical extent 
of disease and site*
79 555 cases
Data from 16 population-based cancer registries, 
nine countries, 1–8 sites per registry
Tongue
5610 cases
 1527 alive
 3575 dead
 508 lost
Oral cavity
7580 cases
 2159 alive
 4635 dead
 786 lost
Stomach
65722 cases
 21391 alive
 43724 dead
 607 lost
Large bowel
55520 cases
 25461 alive
 29160 dead
 899 lost
Larynx
8449 cases
 3547 alive
 4477 dead
 425 lost
Lung
91172 cases
 14931 alive
 75461 dead
 780 lost
Breast
53849 cases
 33832 alive
 16136 dead
 3881 lost
Cervix
29711 cases
 15362 alive
 11443 dead
 2906 lost
Ovary
9367 cases
 3913 alive
 4794 dead
 660 lost
Tongue
3964 cases
 920 localised
 2514 regional
 207 distant 
  metastasis
 323 unknown
Oral cavity
5727 cases
 1296 localised
 3690 regional
 279 distant 
  metastasis
 462 unknown
Large bowel
9711 cases
 2677 localised
 2943 regional
 2005 distant 
  metastasis
 2086 unknown
Larynx
3950 cases
 1056 localised
 2051 regional
 288 distant 
  metastasis
 555 unknown
Breast
32285 cases
 7171 localised
 12877 regional
 2837 distant 
  metastasis
 9400 unknown
Cervix
15766 cases
 3410 localised
 9471 regional
 900 distant 
  metastasis
 1985 unknown
Ovary
4614 cases
 1210 localised
 1014 regional
 1635 distant 
  metastasis
 755 unknown
Bladder
3538 cases
 1603 localised
 896 regional
 301 distant 
  metastasis
 738 unknown
Bladder
14678 cases
 7428 alive
 6716 dead
 534 lost
Excluded from participation
6 population-based cancer registries from ﬁve countries
    4 data quality: incomplete follow-up
    2 data repetition: published already
Excluded: 24 699 cases (7%)
Death certiﬁcate only: 11  733 (3%)
No follow-up: 9584 (3%)
Other: 3382 (1%)
Figure: Overview of the survival study
*Varies for individual population-based cancer registries.
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5–15% of cases and on vital status for 5–35% of cases in 
diﬀ erent registries. The number of patients included for 
survival analysis and median age, by cancer site and by 
country, are given in table 2. The ﬁ gure shows the 
number of patients with vital status known on the last 
date of follow-up, the number lost to follow-up, and the 
number of patients in diﬀ erent clinical stages of disease. 
Table 3 gives the 5-year ASRS (0–74 years) according to 
country for the ten cancer sites. In China, Singapore, 
South Korea, and Turkey, the median relative survival 
rates were 76–82% for breast cancer, 63–79% for cervical 
cancer, 71–78% for bladder cancer, and 44–60% for 
large-bowel cancer. Survival was lowest in The Gambia, 
where ASRS did not exceed 22% for any cancer site, and 
in Uganda, where ASRS did not exceed 13% for any site 
except for breast cancer (46%). Comparing the maximum 
and minimum survival by registries in the same country 
showed marked variations for all cancers in China, most 
Registration 
period
Population Follow-up Number of 
sites
Data quality indices  (% of cases)
Period Method* Death 
certiﬁ cate 
only
Histological 
veriﬁ cation
Included for 
survival 
analysis
Complete 
follow-up 
at 5  years
Africa
The Gambia 1993–97 National 1993–99 A 4 0–6 12–40 65–75 81–96
Uganda
Kyadondo 1993–97 Mixed 1993–99 A 6 0–2 48–64 70–88 53–87
Asia
China
Hong Kong 1996–2001 Urban 1996–2003 P 10 0–1 77–94 92–96 100
Qidong 1992–2000 Rural 1992–2000 A+P 9 0–3 10–94 94–99 100
Shanghai 1992–95 Urban 1992–2000 P+A 10 0–1 40–93 99–100 100
Tianjin 1991–99 Urban 1991–2000 P+A 10 0–1 39–78 99–100 100
India
Barshi 1993–2000 Rural 1993–2003 A 8 0–3 71–95 98–100 96–100
Bhopal 1991–95 Urban 1991–2000 A 10 0–2 60–90 66–89 100
Chennai 1990–99 Urban 1990–2001 A 9 0–5 64–86 86–94 83–92
Karunagappally 1991–97 Mixed 1991–99 A 10 0–8 50–94 89–100 97–100
Mumbai 1992–99 Urban 1992–2003 A 10 4–13 63–86 86–95 84–93
Pakistan
Karachi 1995–99 Urban 1995–2003 A 2 0–1 98–99 92–93 72–74
Philippines
Manila 1994–95 Urban 1994–2002 A+P 3 0–1 82–88 74–83 78–80
Rizal 1996–97 Urban 1996–2002 A+P 1 6 90 83 30
Saudi Arabia
Riyadh 1994–96 Urban 1994–2001 P+A 1 0 99 93 80
Singapore 1993–97 National 1993–2001 P 10 0–2 82–100 91–98 100
South Korea
Busan 1996–2001 Urban 1996–2003 P+A 10 2–12 64–93 85–97 100
Incheon 1997–2001 Urban 1997–2002 P+A 10 2–16 64–91 84–97 100
Seoul 1993–97 Urban 1993–2001 P+A 10 2–13 68–88 82–91 100
Thailand
Chiang Mai 1993–97 Mixed 1993–2000 A 10 0–10 61–97 77–91 72–89
Khon Kaen 1993–97 Mixed 1993–2000 A+P 8 0–5 59–84 85–95 40–82
Lampang 1990–2000 Mixed 1990–2003 P+A 10 0–13 66–93 81–100 98–100
Songkhla 1990–99 Mixed 1990–2003 A 10 0–5 78–94 78–86 56–82
Turkey
Izmir 1995–97 Mixed 1995–2003 A 6 0–1 88–96 98–99 82–87
Central America
Costa Rica 1995–2000 National 1995–2003 P+A 2 2–3 91–92 82–86 74–83
P=passive follow-up. A=active follow-up. Mixed=urban+rural. *P+A=predominantly passive; A+P=predominantly active.
Table 1:  Registration period, population covered, follow-up period and method, number of cancer sites, and data quality indices for registries in each country 
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Tongue Oral cavity Stomach Large bowel Larynx Lung Breast Cervix Ovary Bladder Total
Africa
The Gambia
N ·· ·· 39 34 ·· 31 61 202* ·· ·· 367
MA ·· ·· 60 50 ·· 56 47 42 ·· ·· ··
Uganda
N ·· ·· 90 101 ·· 47 162 283 66 ·· 749
MA ·· ·· 54 53 ·· 48 46 43 40 ·· ··
Asia
China
N 1086 1128 28 384 31 762 2920 59 917 21 810 3883 2335 7610 160 835
MA 60 65 68 68 67 68 51 61 55 70 ··
E ·· ·· ·· ·· ·· ·· 10 112 ·· ·· ·· 10 112
India
N 3376 4821 5098 3056 2763 5754 11 013 10 034 2967 1864 50 746 
MA 56 55 60 56 59 60 50 50 50 63 ··
E 3307 4726 ·· 2943 2708 ·· 10 812 9376 2932 1833 38 637
Pakistan
N 180 413 ·· ·· ·· ·· ·· ·· ·· ·· 593
MA 55 50 ·· ·· ·· ·· ·· ·· ·· ·· ··
E 180 413 ·· ·· ·· ·· ·· ·· ·· ·· 593
Philippines
N ·· ·· ·· 248 ·· ·· 1714 ·· ·· ·· 2339 
MA ·· ·· ·· 62 ·· ·· 50 ·· ·· ·· ··
E ·· ·· ·· 248 ·· ·· 1714 ·· ·· ·· 2339
Saudi Arabia
N ·· ·· ·· ·· ·· ·· 298 ·· ·· ·· 298
MA ·· ·· ·· ·· ·· ·· 45 ·· ·· ·· ··
E ·· ·· ·· ·· ·· ·· 298 ·· ·· ·· 298
Singapore
N 120 135 2100 4254 311 4253 3204 984 718 496 16 575
MA 61 65 68 66 67 69 50 52 48 69 ··
E 120 135 ·· 4254 311 ·· 3204 984 718 496 10 222
South Korea
N 437 523 29 156 13 418 1488 15 844 9442 8919 2317 3396 84 940
MA 58 59 59 60 62 65 47 50 48 63 ··
Thailand
N 411 560 855 1932 489 5326 2354 3298 734 746 16 705
MA 64 66 62 62 67 63 48 49 49 66 ··
E 357 453 ·· 1551 453 ·· 2354 3298 734 643 9843
Turkey
N ·· ·· ·· 715 478 ·· 1329 246 230 566 3564
MA ·· ·· ·· 62 59 ·· 52 52 55 64 ··
E ·· ·· ·· 715 478 ·· 1329 246 230 566 3564
Central America
Costa Rica
N ·· ·· ·· ·· ·· ·· 2462 1485 ·· ·· 3947
MA ·· ·· ·· ·· ·· ·· 52 47 ·· ·· ··
E ·· ·· ·· ·· ·· ·· 2462 1485 ·· ·· 3947
Total
N 5610 7580 65 722 55 520 8449 91 172 53 849 29 711 9367 14 678 341 658
E 3964 5727 ·· 9711 3950 ·· 32 285 15 766 4614 3538 79 555
N=total number of cases. MA=median age at diagnosis. E=number of cases included for extent-of-disease analysis. ··=data not available. *Random sample of total incident cases. 
Table 2: Number of cases included for survival analysis, median age, and number included for extent-of-disease analysis by cancer site and country
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cancers in India, a few cancers in Thailand, and laryngeal 
cancer in South Korea (table 3). 
Observed 5-year survival and the proportion of cases 
presenting with diﬀ erent categories of clinical extent of 
disease were compared for countries with more 
developed versus less developed health-care services, for 
eight cancer sites (table 4). Data on clinical extent of 
disease were not available from any country in Africa. 
Among the countries with more developed health-care 
services, data on clinical extent of disease were available 
from Singapore for all sites, Turkey for most sites, and 
Hong Kong for breast cancer only. Available data on 
clinical extent of disease from these countries were 
pooled together for each site and classiﬁ ed as group A. 
Similarly, data on clinical extent of disease from 
countries with less developed health-care services were 
pooled together as group B. A decrease in survival with 
advanced stages of disease was seen for all cancers in 
both groups. For localised cancers of the breast, large 
bowel, larynx, ovary, and urinary bladder, and for all 
regional diseases at all sites, survival was higher among 
group A than group B. 
Discussion
The countries in this study can be grouped into three 
tiers based on observed survival. Survival was highest 
in Hong Kong (data not included), South Korea, 
Singapore, and Turkey, where health services are well 
developed with advanced diagnostic and treatment 
centres and high per head GNI values. Survival was 
intermediate in Costa Rica, mainland China, Thailand, 
India, Saudi Arabia, Pakistan, and Philippines, where 
cancer health services are moderately developed with 
diagnostic and treatment facilities centred in and 
around urban cities, and with medium per head GNI. 
Survival was lowest in The Gambia and Uganda, with 
poorly developed health services, as indicated by limited 
availability of cancer diagnostic and treatment facilities, 
and with very low per head GNI. 
The level of development of health services and their 
eﬃ  ciency to provide early diagnosis, treatment, and 
clinical follow-up care have a profound eﬀ ect on cancer 
survival. We studied survival of patients with cancer in 
countries with a range of economic development levels. 
The interpretation of our results should take into account 
diﬀ erences in the quality of data among registries in each 
country, and the wide diﬀ erences in health awareness, 
socioeconomic development, human resources, health-
services investment, and health-care accessibility between 
countries. Poorly developed and inaccessible health 
services result in inconsistencies in early diagnosis, 
adequate treatment, and follow-up care. 
Survival results in our study were based on a suﬃ  cient 
number of cases, except for some cancer sites in patients 
in The Gambia and Uganda. Because the registries used 
passive or active methods of follow-up to varying extents, 
the possibility of overestimation of survival should be 
addressed. A recent study22 indicated that 5-year survival 
can be overestimated by up to 6% when ascertainment of 
deaths is up to 5% incomplete. Mortality ascertain ment 
is likely to be incomplete with passive follow-up if the 
data linkage is not based on a unique personal 
identiﬁ cation number backed by a reliable death 
registration system. Therefore, an underestimation of 
deaths cannot be ruled out in some of the populations 
included in our study, despite our active eﬀ orts to 
ascertain such events. 
A study of the implications of lack of active follow-up 
for various cancers in a registry in Chennai, India, showed 
an upward bias in population-based survival of 3–13% in 
Tongue Oral cavity Stomach Large bowel Larynx Lung Breast Cervix Ovary Bladder
Africa
The Gambia ·· ·· 3 4 ·· 20 12 22 ·· ··
Uganda ·· ·· 0 8 ·· 0 46 13 9 ··
Asia
China 67 (64–68) 67 (44–71) 39 (20–44) 44 (36–63) 68 (49–73) 21 (6–32) 82 (58–90) 67 (48–79) 56 (35–67) 78 (47–81)
India 23 (12–30) 37 (26–45) 6 (4–15) 28 (6–31) 28 (16–38) 7 (1–13) 52 (31–54) 46 (34–60) 25 (19–29) 39 (10–48)
Pakistan 39 41 ·· ·· ·· ·· ·· ·· ·· ··
Philippines ·· ·· ·· 40 ·· ·· 47 (40–55) 37 ·· ··
Saudi Arabia ·· ·· ·· ·· ·· ·· 64 ·· ·· ··
Singapore 44 49 27 52 66 9 76 66 62 72
South Korea 53 (52–60) 52 (48–54) 49 (46–50) 60 (57–64) 62 (59–76) 20 (14–21) 79 (78–81) 79 (76–79) 59 (54–62) 76 (72–79)
Thailand 32 (24–33) 36 (22–42) 12 (9–20) 35 (31–44) 36 (26–49) 9 (5–12) 63 (57–66) 61 (54–63) 47 (45–58) 48 (33–60)
Turkey ·· ·· ·· 52 71 ·· 77 63 60 71
Central America
Costa Rica ·· ·· ·· ·· ·· ·· 70 53 ·· ··
Data are median percentage of individual registries (minimum–maximum, if more than one registry). ··=data not available.
Table 3: 5–year age standardised (0–74 years) relative survival for cancers by country
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the presence of 5–21% random losses to follow-up.23 This 
bias was estimated by assuming that patients lost to 
follow-up were alive at the closing date. For the registries 
that mainly used passive follow-up in our study, the 
overestimation of 5-year ASRS is likely to be no higher 
than 13%, if such misclassiﬁ cation of patients as alive at 
closing date does not exceed one in ﬁ ve.
In this study, a few registries using active methods 
reported substantial losses to follow up. However, studies 
using loss-adjusted survival methods with such data have 
shown that overestimation of population-based survival 
was small.24,25 We made considerable eﬀ orts to improve 
data quality for each registry; the survival estimates from 
our study are reliable and can serve as baseline for 
comparisons and for assessing improvements in survival 
outcome. The observed diﬀ erences in survival between 
countries seem to be largely a result of diﬀ erences in 
the availability and accessibility of early diagnosis and 
treatment, and, to a lesser extent, to data quality and 
reliability issues.
Populations followed up mainly with passive methods 
had consistently higher survival than those with mainly 
active follow-up. The registries in South Korea, Hong 
Kong, Singapore, and Costa Rica, that mostly used 
passive follow-up, had well developed health-information 
systems, with unique data linkage facilities and individual 
identity numbers or networking of hospitals. The wide 
availability and accessibility of screening programmes, 
early detection services, and cancer treatment facilities in 
these regions probably largely contributed to the high 
survival observed. 
The survival patterns for regions in this study correlate 
well with the level of development and accessibility of 
health-care services. High survival rates for large-bowel, 
breast, cervical, and ovarian cancers in South Korea, 
Singapore, Izmir (Turkey), and Hong Kong are due to 
established screening and early detection programmes, 
and well developed and accessible diagnostic and treatment 
services in the public domain. The possibility of 
pathological misclassiﬁ cation between borderline and 
invasive ovarian cancers might partly explain the high 
survival observed for ovarian cancer in South Korea, China, 
Singapore, and Turkey. Cancer diagnosis and treatment 
services are underdeveloped in The Gambia and Uganda. 
Survival in most sub-Saharan African countries, and in 
some low-income countries in Asia and Central America 
that were not included in this study, is likely to be much 
lower than the survival observed in our study, due to the 
inadequacy or absence of cancer health services.
The large variations in survival within populations in 
regions of China, India, and Thailand reﬂ ect varying 
levels of development of cancer health services, 
particularly in urban versus rural areas. Higher survival 
in urban versus rural areas in India and China is the 
result of better cancer services in urban areas, with more 
accessibility for diagnosis and treatment. In China, 
survival for all cancers was consistently lower in the rural 
area of Qidong than in big cities like Shanghai and 
Tianjin (data not shown). In India, marked diﬀ erences in 
survival for most cancers were noted between rural 
(Barshi), semi-urban (Karunagappally), or small urban 
(Bhopal) registries, whereas diﬀ erences were small 
between the metropolitan cities of Chennai and Mumbai, 
where more developed and accessible health-care services 
are available  (data not shown). In Thailand, the 
diﬀ erences between registries were limited to a few 
cancers only. The data quality indices among registries 
within the same country did not show any major diﬀ er-
ences. Therefore, the diﬀ erences in survival reﬂ ect 
diﬀ erences in early diagnosis and the eﬀ ect of inequalities 
in health-care infrastructure development, availability, 
and accessibility to health services. All three registries in 
South Korea showed no major diﬀ erences in survival for 
any cancer (data not shown), possibly reﬂ ecting equitably 
developed and accessible health-care services across the 
country. The poor survival observed in The Gambia and 
Uganda emphasises the urgent need for government 
investments to improve health services. 
Pooled 
number 
of cases
5-year survival (frequency)
Localised Regional Distant 
metastasis
Unknown
Tongue
Group A: Singapore 120 48·4 (26) 23·3 (25) 20·0 (4) 33·1 (45)
Group B: India, Pakistan, Thailand 3844 54·3 (23) 14·5 (65) 3·1 (5) 25·3 (7)
Oral cavity
Group A: Singapore 135 52·3 (28) 26·5 (22) ·· (2) 28·9 (48)
Group B: India, Pakistan, Thailand 5592 60·2 (22) 23·8 (66) 3·3 (5) 28·8 (7)
Large bowel
Group A: Singapore, Turkey 4969 64·1 (26) 45·7 (27) 8·6 (18) 41·8 (29)
Group B: India, Philippines, Thailand 4742 49·8 (29) 32·0 (34) 2·4 (23) 34·7 (14)
Larynx
Group A: Singapore, Turkey 789 69·6 (34) 40·7 (19) 41·8 (5) 54·6 (42)
Group B: India, Thailand 3161 54·4 (25) 22·3 (60) 4·7 (8) 26·9 (7)
Breast
Group A: China (Hong Kong), Singapore, Turkey 14 645 89·6 (17) 75·4 (32) 26·7 (2) 79·7 (49)
Group B: Costa Rica, India, Philippines, 
Saudi Arabia, Thailand 
17 640 76·3 (26) 47·4 (47) 14·9 (14) 47·1 (13)
Cervix
Group A: Singapore, Turkey 1230 69·5 (42) 52·2 (13) 18·6 (5) 57·5 (40)
Group B: Costa Rica, India, Philippines, Thailand 14 536 73·2 (20) 47·2 (64) 7·4 (6) 45·7 (10)
Ovary
Group A: Singapore, Turkey 948 84·1 (40) 39·7 (4) 28·1 (27) 56·7 (29)
Group B: India, Thailand 3666 63·8 (22) 34·5 (27) 4·2 (38) 36·8 (13)
Bladder
Group A: Singapore, Turkey 1062 61·3 (53) 34·8 (7) 16·4 (5) 54·0 (35)
Group B: India, Thailand 2476 43·8 (42) 24·9 (33) 2·3 (10) 35·6 (15)
Data are n or %. ··=data not available.
Table 4: 5-year survival and frequency distribution for cancers by clinical extent of disease, based on data 
from countries with more developed (group A) vs less developed (group B) health services
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China and South Korea, which reported the highest 
survival for most cancers, did not collect data on clinical 
extent of disease on a routine basis. Such information 
was available for selected cancer sites from Singapore 
and Turkey, with high survival reported, and for Costa 
Rica, India, Pakistan, Philippines, Saudi Arabia, and 
Thailand, with intermediate survival. Since data col-
lection was from heterogeneous sources, misclassi-
ﬁ cation of extent of disease, especially in localised or 
regional categories, was possible. Also, using data from 
specialised and non-specialised medical institutions 
could lead to unrealistic comparisons between 
registries. To minimise this problem, we classiﬁ ed 
countries into two groups based on survival results and 
the level of development of cancer health care (according 
to per head GNI values). The pooled data for each group 
showed decreasing survival with increasing stage at 
presentation for all cancers, which added strength to 
the data quality in this study. The higher survival 
observed for group A countries for localised large-bowel, 
larynx, breast, ovarian, and bladder cancers (which 
largely require radical surgical treatment) and for 
regional disease (which require multimodal treatment) 
are largely due to the diﬀ erences in the development 
and accessibility of diagnostic and treatment services. 
The high survival observed for advanced (distant 
metastasis) laryngeal cancer in Singapore and Turkey 
might reﬂ ect misclassiﬁ cation between regional and 
distant metastatic disease. 
This study would not have been possible without the 
availability of reliable population-based cancer 
registries. It is important to organise such information 
systems in regions that lack them. It is likely that 
survival in many low-income and middle-income 
countries that were not included in this study, 
particularly in sub-Saharan Africa, would be lower than 
reported here. The striking diﬀ er ences in cancer 
survival between countries emphasises the need for 
urgent and adequate invest ments in comprehensive 
cancer control. In addition to equitable accessibility to 
health services, eﬀ orts are needed to improve public 
and professional awareness, early detection and prompt 
treatment using locally feasible yet eﬀ ective regimens, 
health-services infrastructure, human-resources 
develop ment, and referral pathways. In many 
sub-Saharan African countries, such invest ments in 
health services have never been made, and national 
cancer-control policies should focus on balanced 
investments in prevention and early detection and 
treatment of common cancers. Further study of 
survival patterns in developing countries should 
address the limitations for follow-up and devise 
strategies to improve completeness by use of 
complementary active methods. In conclusion, our 
results largely reﬂ ect the diﬀ erences in availability and 
accessibility of health care. These data can be used as 
the baseline for sustainable improvements in the 
future, through adequate and sincere investments in 
improving awareness, health-services infrastructure, 
and accessibility.
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Lack of active follow-up of cancer patients in Chennai, India: 
implications for population-based survival estimates
Rajaraman Swaminathan,a Ranganathan Rama,a & Viswanathan Shanta a
Objective To measure the bias in absolute cancer survival estimates in the absence of active follow-up of cancer patients in 
developing countries.
Methods Included in the study were all incident cases of the 10 most common cancers and corresponding subtypes plus all 
tobacco-related cancers not ranked among the top 10 that were registered in the population-based cancer registry in Chennai, 
India, during 1990–1999 and followed through 2001. Registered incident cases were first matched with those in the all-cause 
mortality database from the vital statistics division of the Corporation of Chennai. Unmatched incident cancer cases were then actively 
followed up to determine their survival status. Absolute survival was estimated by using an actuarial method and applying different 
assumptions regarding the survival status (alive/dead) of cases under passive and active follow-up.
Findings Before active follow-up, matches between cases ranged from 20% to 66%, depending on the site of the primary tumour. 
Active follow-up of unmatched incident cases revealed that 15% to 43% had died by the end of the follow-up period, while the 
survival status of 4% to 38% remained unknown. Before active follow-up of cancer patients, 5-year absolute survival was estimated 
to be between 22% and 47% higher, than when conventional actuarial assumption methods were applied to cases that were lost to 
follow-up. The smallest survival estimates were obtained when cases lost to follow-up were excluded from the analysis.
Conclusion Under the conditions that prevail in India and other developing countries, active follow-up of cancer patients yields the 
most reliable estimates of cancer survival rates. Passive case follow-up alone or applying standard methods to estimate survival is 
likely to result in an upward bias.
Bulletin of the World Health Organization 2008;86:509–515.
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Introduction
In recent decades, incident cancer cases 
have been systematically and continu-
ously registered all over the world us-
ing both active and passive methods. 
Passive registration methods, which 
may or may not be facilitated by the 
law, are those in which incident can-
cer cases are notified and the data are 
involuntarily received by the registry 
from the respective sources. Active 
cancer registration methods consist of 
collecting data from other sources vol-
untarily. Data from 53 registries in 25 
developing countries were published in 
2002 by the International Agency for 
Research on Cancer in Lyon, France.1 
Cancer was a notifiable disease in 49% 
of the 53 registries, while data on inci-
dent cancers were collected entirely by 
passive methods in 34%. In less than 
one-third of the registries practis-
ing passive registration, data linkages 
were based on unique identification 
numbers.1
In India, cancer is not a notifiable 
disease. Hence, cancer cases are primar-
ily registered through active methods.2–6 
The population-based cancer registry 
(PBCR) in Chennai, known as the 
Madras Metropolitan Tumour Registry 
(MMTR), is based at the Cancer Insti-
tute (Women’s India Association) and 
has been a part of the National Cancer 
Registry Program of the Indian Council 
of Medical Research, a government en-
tity, since 1981.
Official cancer mortality data from 
the vital statistics division is generally 
integrated into the PBCR. However, in 
most developing countries, including 
India, death certificates are often inac-
curate, so that all-cause mortality data 
should be used to supplement cancer 
mortality statistics.7
Having reliable information on 
survival from cancer has long been rec-
ognized as important for cancer control 
activities. Monitoring population-based 
survival rates is useful for patient care 
and health care planning. Such rates are 
free from case selection bias and reflect 
average cancer-related outcomes in a 
given region. Population-based cancer 
survival estimates have been increas-
ingly available in developing countries 
since the early 1990s, but at least one-
third of them are based exclusively on 
passive follow-up.8 The present study 
aims to measure the bias resulting from 
absolute survival estimates in the ab-
sence of active case follow-up and when 
different assumptions are made regard-
ing the survival status of cancer patients 
in developing countries.
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Methods
Included in the study were all incident 
cases of the 10 most common broadly-
defined cancers and corresponding 
subtypes (for cancers of the oral cav-
ity, lymphomas and leukaemias), plus 
tobacco-related cancers not ranked 
among the top 10 (such as pancreas 
and urinary bladder), that were regis-
tered in the MMTR in Chennai during 
1990–1999 and followed through 31 
December 2001.
Data on incident cancer cases in 
the MMTR were obtained by direct 
interview of patients by cancer regis-
trars at selected source hospitals at the 
time of registration and/or by perusal 
of medical records at those hospitals 
using a validated, standardized ques-
tionnaire common to all registries in 
India. Interviewers were trained by 
senior investigators of the registry proj-
ect at the base institution where the 
registry is physically located.3 Data on 
cancer deaths through 1991 and on 
all-cause mortality since 1992 were 
extracted from death certificates main-
tained at the vital statistics division of 
the Corporation of Chennai.3,7 Incident 
cancer cases in the MMTR were then 
matched with cases in the mortality da-
tabase primarily using each individual’s 
personal identity details. Cancer cases 
for which no matches were found in 
the mortality database were actively 
followed to determine their survival 
status. Medical records at source hospi-
tals that imposed restrictions on active 
follow-up were examined once every 3 
years or less in order to track patients’ 
attendance at clinical follow-up visits. 
Postal or telephone enquiries among 
patients or their relatives and friends 
and other contacts were carried out by 
cured cancer patients from the locality, 
volunteer service organizations, and 
health workers. House visits, which 
make it possible to interrogate neigh-
bourhood residents, are the most com-
mon active follow-up method pursued 
by patient registries in India to effec-
tively determine the survival status of 
patients who have migrated (common 
in urban areas).
Different actuarial assumptions 
on the survival status of subjects were 
made during follow-up for the purpose 
of this study. Subjects were designated 
as belonging to the following catego-
ries: (A) when they were matched with 
mortality data obtained by routine reg-
istry data linkage with official mortality 
statistics without any active follow-up; 
(B) when they could not be matched 
through routine registry data linkage 
with official mortality statistics and 
their death was ascertained through 
active follow-up; (C) when they were 
lost to follow-up but known to be alive 
until a specific date, with unknown 
survival status at the close of follow-
up; and (D) when they had completed 
follow-up and were known to be alive 
on the closing date.
The follow-up status was classi-
fied into four different case scenarios 
depending on the assumptions made, 
as follows:
Case 1: Passive follow-up only of 
cancer cases not matched with official 
mortality data but presumed to be 
alive at the close of follow-up. In this 
scenario, subjects in category A were 
treated as having died on their respec-
tive dates of death, while subjects B, C, 
and D were treated as having been alive 
on the last day of follow-up.
Case 2: Passive and active follow-
up, with cases lost to follow-up pre-
sumed to be alive on the last day of 
follow-up. In this scenario, subjects A 
and B were treated as having died on 
their respective dates of demise, while 
subjects C and D were treated as having 
been alive on the last day of follow-up.
Table 1. Survival status of incident cancer cases registered in 1990–1999 and followed through 2001, PBCR, Chennai, India
Tumour site/type Cases 
included in 
survival 
analysis
Passive follow-up Active follow-up
Matched  
deaths (%)
Additional deaths 
identified (%)
Cases alive at 
closing date (%)
Survival status 
unknown at closing 
date (%)
Lip 86 19.8 33.7 11.6 34.9
Tongue 988 37.6 32.5 5.5 24.4
Oral cavity 1662 31.8 31.5 10.2 26.5
Tonsil 250 42.8 42.8 6.4 8.0
Hypopharynx 1017 41.4 40.5 5.8 12.3
Oesophagus 2016 51.0 36.3 2.9 9.8
Stomach 2681 51.9 33.0 4.5 10.6
Pancreas 328 57.9 30.8 7.0 4.3
Larynx 722 40.2 23.0 19.6 17.2
Lung 1806 59.2 28.0 2.4 10.4
Breast 3067 28.5 20.0 28.2 23.3
Cervix 4438 25.5 16.7 19.8 38.0
Ovary 808 39.7 20.5 17.2 22.6
Urinary bladder 442 38.9 30.1 14.0 17.0
Hodgkin lymphoma 298 30.9 26.5 24.8 17.8
Non-Hodgkin lymphoma 868 44.1 25.2 15.0 15.7
Lymphoid leukaemia 433 45.5 29.1 11.3 14.1
Myeloid leukaemia 465 59.6 18.9 7.5 14.0
Leukaemia, type unspecified 85 65.9 15.3 5.9 12.9
PBCR, population-based cancer registry.
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Case 3: Passive and active follow-
up, with cases lost to follow-up cen-
sored on the last date on which their 
survival status was known. Under this 
case scenario, subjects A and B were 
treated as having died on their respec-
tive dates of demise; subjects in cat-
egory D were treated as having been 
alive on the last day of follow-up, and 
subjects in category C were treated 
as having been alive until a specific 
date and censored thereafter for the 
survival analysis, based on actuarial as-
sumption.
Case 4: Passive and active follow-
up, with cases lost to follow-up ex-
cluded from the survival analysis. This 
resembles Case 3, excepting that sub-
jects in category C were excluded from 
the survival analysis.
Absolute survival probability, also 
known as crude survival, was esti-
mated through an actuarial approach.9 
However, the assumptions made in 
this study differed from those nor-
mally made using the routine actuarial 
method.
Findings
Table 1 gives the survival status of inci-
dent cancer cases, for primary tumours 
of different types, in accordance with 
the follow-up method used. Deaths 
in the all-cause mortality database 
that were matched with cases in the 
incident cancer database without any 
active follow-up ranged between 20% 
(lip cancer) and 66% (leukaemias, type 
unspecified). Of those cancer cases hav-
ing no match in the mortality database 
and actively followed, 15% (leukaemia, 
type unspecified) to 43% (cancer of the 
tonsil) had died, and 3% (oesophageal 
cancer) to 28% (female breast cancer) 
were alive by the end of the follow-up 
period. Survival status was unknown in 
4% (pancreatic cancer) to 38% (cervi-
cal cancer) of the cases on the last day 
of follow-up. As shown in Table 2, a 
variable number of cases, depending on 
survival status, was used to estimate ab-
solute survival under different actuarial 
assumptions at follow-up.
Table 3 shows the frequency (%) 
of losses to follow-up at varying time 
intervals from the time of diagnosis: 
< 1 year, 1–3 years, 3–5 years and > 5 
years. This information can be obtained 
only through active follow-up. For most 
primary tumour sites, the highest pro-
portion of losses to follow-up occurred 
within the first year from diagnosis, 
with figures ranging from 3% for lym-
phoid leukaemia to 15% for ovarian 
cancer cases. From about 1% of pan-
creatic cancer to 26% of lip cancer cases 
were lost to follow-up after 5 years 
from diagnosis. Very small proportions 
Table 2.  Incident cancer cases included in the survival analysis, among those registered in 1990–1999 and followed through 2001, 
PBCR, Chennai, India
Tumour 
site/type
Number of cases included in survival analysis
Total Passive follow-up only Passive and active follow-up
Case 1a Case 2b Case 3c Case 4d
Dead Presumed
alive at 
closing date
Dead Presumed 
alive at 
closing date
Dead Alive Lost to 
follow-up
Dead Alive
Lip 86 17 69 46 40 46 10 30 46 10
Tongue 988 371 617 693 295 693 54 241 693 54
Oral cavity 1662 528 1134 1052 610 1052 169 441 1052 169
Tonsil 250 107 143 214 36 214 16 20 214 16
Hypopharynx 1017 421 596 833 184 833 59 125 833 59
Oesophagus 2016 1028 988 1759 257 1759 59 198 1759 59
Stomach 2681 1392 1289 2277 404 2277 120 284 2277 120
Pancreas 328 190 138 291 37 291 23 14 291 23
Larynx 722 290 432 456 266 456 142 124 456 142
Lung 1806 1069 737 1574 232 1574 45 187 1574 45
Breast 3067 875 2192 1489 1578 1489 862 716 1489 862
Cervix 4438 1131 3307 1874 2564 1874 878 1686 1874 878
Ovary 808 321 487 487 321 487 138 183 487 138
Urinary bladder 442 172 270 305 137 305 62 75 305 62
Hodgkin lymphoma 298 92 206 171 127 171 74 53 171 74
Non-Hodgkin 
lymphoma
868 383 485 602 266 602 130 136 602 130
Lymphoid leukaemia 433 197 236 323 110 323 49 61 323 49
Myeloid leukaemia 465 277 188 365 100 365 35 65 365 35
Leukaemia, type 
unspecified
85 56 29 69 16 69 5 11 69 5
PBCR, population-based cancer registry.
a  Case 1: Passive follow-up only, with cancer cases not matched with those in the official mortality database presumed to be alive on the closing date.
b  Case 2: Passive and active follow-up, with cases lost to follow-up presumed to be alive on the closing date.
c  Case 3: Passive and active follow-up, with cases lost to follow-up censored on the last date their survival status was known.
d  Case 4: Passive and active follow-up, with cases lost to follow-up excluded from survival analysis.
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Table 3.  Distribution of incident cancer cases lost to follow-up, among those 
registered in 1990–1999 and followed through 2001, PBCR, Chennai, India
Tumour site/type Losses to follow-up by years from diagnosis (%)
< 1 1–3 3–5 > 5
Lip 7.0 2.3 0.0 25.6
Tongue 13.1 2.6 1.2 7.5
Oral cavity 10.3 2.2 1.8 12.2
Tonsil 4.8 0.8 0.0 12.4
Hypopharynx 9.0 0.6 0.0 2.3
Oesophagus 6.7 0.9 0.4 1.8
Stomach 7.3 0.9 0.9 1.5
Pancreas 3.1 0.3 0.3 0.6
Larynx 6.7 0.8 0.3 9.4
Lung 8.0 0.7 0.3 1.4
Breast 12.4 2.9 2.0 6.0
Cervix 11.0 3.7 2.5 20.8
Ovary 14.7 4.6 1.4 1.9
Urinary bladder 10.9 1.6 0.2 4.3
Hodgkin lymphoma 6.4 1.7 1.0 8.7
Non-Hodgkin lymphoma 10.9 1.3 0.6 2.9
Lymphoid leukaemia 2.8 3.2 3.5 4.6
Myeloid leukaemia 8.6 1.3 0.4 3.7
Leukaemia, type unspecified 10.5 0.0 0.0 2.4
PBCR, population-based cancer registry.
were lost to follow-up between 1–3 
years and 3–5 years from diagnosis.
Table 4 gives the 5-year absolute 
survival (%) estimated by actuarial 
methods under different assumptions 
on the survival status of subjects that 
were followed passively, actively, or 
both. The differences in 5-year abso-
lute survival, in percentages, between 
cases 1 and 2 were smallest among 
cases of leukaemia (type unspecified) 
(15.1%), cervical cancer (16.5%), and 
myeloid leukaemia (18.9%), and high-
est among patients with cancers of the 
tonsil (41.3%), hypopharynx (39.2%), 
and lip (34.9%). In the absence of active 
follow-up (case 1), 5-year absolute sur-
vival was estimated to be higher by 22% 
(leukaemia, type unspecified) to 47% 
(hypopharyngeal cancer) than when 
cases were actively followed and were 
lost to follow-up at a known point in 
time (case 3). In relative terms, odds ra-
tios (OR) reflecting survival differences 
were largest for oesophageal cancer 
(OR: 12.9) and smallest for leukaemia 
(type unspecified) (OR: 4.0). Cases 2 
and 4 represent the two extremes of a 
survival spectrum, with the actuarial 
estimate assuming random withdrawal 
falling somewhere in between. The 
more losses to follow-up, the greater 
the uncertainty and potential for bias 
in the actuarial estimate. The absolute 
differences in 5-year survival between 
cases 2 and 4 were substantial for can-
cers of the tongue (13.8%) and ovary 
(18.4%).
Discussion
Survival estimates of unselected groups 
of cancer patients from population-
based cancer registries can serve as an 
important index for evaluating cancer 
diagnosis and treatment and the effec-
tiveness of overall cancer services in a 
given region.8 Of the 53 registries from 
25 developing countries that published 
data on cancer incidence and mortality 
in 2002, less than half have published 
data on cancer survival despite their 
long history of cancer registration.1,8 
In India, only six out of more than 
20 registries have undertaken survival 
studies.2,8
Unlike mortality data collection, 
follow-up is not usually integrated 
with routine population-based cancer 
registration practices. In most devel-
oped countries, passive follow-up of 
cancer patients is carried out through 
the use of a personal identification 
number (PIN) matched with mortality 
databases. In making survival analyses, 
cancer cases are presumed to be alive 
when no information on death has 
been traced by a particular reference 
date. For losses to follow-up, non-
informative or random censoring is an-
ticipated (i.e. the losses to follow-up are 
assumed to be independent of the risk 
of death). However, in most develop-
ing countries, including India, unique 
citizen identifiers (such as PINs) do not 
exist; mortality registration systems, es-
pecially medical certification of deaths, 
are deficient, and the identity particu-
lars of deceased individuals are often 
inaccurate. Thus, passive means of 
follow-up alone may not be sufficient to 
perform a meaningful survival analysis.
Ten registries from five developing 
countries contributed data on survival 
for the first time to the International 
Agency for Research on Cancer mono-
graph on Cancer survival in developing 
countries,8 and four of them (Qidong 
and Shanghai registries from China; 
Cuba; and Rizal from the Philippines) 
relied either entirely or predominantly 
on passive follow-up methods. All four 
registries from India (Bangalore, Barshi, 
Bombay and Madras) that contributed 
data to that monograph had employed 
active follow-up. In the forthcoming 
second volume of the same publication, 
many more registries submitted data on 
survival and several of them adhered to 
passive methods of follow-up. Thus, ac-
tive methods are needed and the effect 
of passive registry follow-up on survival 
estimates should be ascertained. The 
authors have done this by using data 
from the Chennai registry in India and 
generalizing their conclusions to other 
developing countries.
The Chennai registry has collected 
data on all-cause mortality from the 
vital statistics division of the Corpo-
ration of Chennai since 1992. The 
general mortality-to-cancer incidence 
ratio was 45% in 1992–2001 and 23% 
before 1992, when only cancer mortal-
ity data were available.7 However, this 
did not account for all the deaths that 
had occurred among the incident can-
cer cases in the Chennai cancer registry. 
The active follow-up of cancer cases 
that could not be matched with cases in 
the all-cause mortality database revealed 
additional deaths, ranging from 15% 
more deaths among patients with leu-
kaemia (type unspecified) to 43% more 
deaths among patients with cancer of 
the tonsil. The main reasons deaths 
could not be unambiguously matched 
with cases in the cancer registry data-
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Table 4.  Five-year absolute survival under different assumptions regarding survival 
status among incident cancer cases registered in 1990–1999 and followed 
through 2001, PBCR, Chennai, India
Tumour site/type 5-year absolute survival (%)
Passive follow-up Active follow-up
Case 1a Case 2b Case 3c Case 4d
Lip 79.5 44.6 40.7 39.5
Tongue 62.1 29.2 19.4 15.4
Oral cavity 68.5 37.1 30.5 26.4
Tonsil 58.5 17.2 13.7 10.8
Hypopharynx 59.2 20.0 12.5 9.6
Oesophagus 48.9 12.9 6.9 5.0
Stomach 47.9 15.0 8.6 5.6
Pancreas 41.8 10.9 7.9 6.5
Larynx 59.0 35.1 30.7 28.4
Lung 40.8 13.2 6.5 4.2
Breast 71.6 51.5 43.7 39.6
Cervix 75.5 59.0 54.0 49.4
Ovary 60.1 39.5 27.4 21.1
Urinary bladder 61.3 31.0 23.2 20.0
Hodgkin lymphoma 69.1 42.6 39.4 35.9
Non-Hodgkin lymphoma 55.6 29.7 21.6 16.8
Lymphoid leukaemia 54.3 26.5 23.8 15.5
Myeloid leukaemia 40.4 21.5 14.7 10.9
Leukaemia, type unspecified 32.9 17.8 10.9 6.2
PBCR, population-based cancer registry.
a  Case 1: Passive follow-up only, with cancer cases not matched with those in the official mortality 
database presumed to be alive on the closing date.
b  Case 2: Passive and active follow-up, with cases lost to follow-up presumed to be alive on the closing date.
c  Case 3: Passive and active follow-up, with cases lost to follow-up censored on the last date their survival 
status was known.
d  Case 4: Passive and active follow-up, with cases lost to follow-up excluded from survival analysis.
base were: (i) incomplete identity in-
formation about the deceased in death 
certificates/records; (ii) migration of 
cases within the registry area before 
death, and (iii) inaccurate details given 
by persons reporting the death. These 
factors are difficult to overcome de-
spite the full availability of cause-specific 
mortality data in the region under 
study.
If invalid actuarial assumptions are 
made, deaths are underreported and 
the impact on absolute survival is large. 
Studies from developed countries em-
ploying unique case identifiers to link 
data passively have acknowledged the 
need to correct for survival status (alive/
dead) through active follow-up, as well 
as the potential impact of active follow-
up on survival.10,11
In our study, losses to follow-up 
were most frequent within 1 year of di-
agnosis.12–16 A different pattern has been 
observed in Thailand, with the highest 
losses occurring more than 5 years from 
diagnosis.8 Losses to follow-up at vary-
ing times thus affect actuarial survival 
estimates under passive follow-up. The 
highest dropout rates within the first 
year of cancer diagnosis are often due 
to death, while the long-term losses to 
follow-up occur mainly among survi-
vors. Many studies exclude cases that 
are lost to follow-up from survival 
analyses.8,13,15 As shown by our case 
4 scenario, such exclusions may result 
in a substantial bias whose magnitude 
depends on the number of losses to 
follow-up, with losses not occurring 
randomly or independently of the risk 
of death. Loss-adjusted survival meth-
ods have been proposed17 and applied 
to survival studies, with many losses to 
follow-up considered non-random.13,18 
After adjusting for cases lost to follow-
up in these studies, only minimal dif-
ferences were noted, ranging from 1% 
to 5% based on the data obtained from 
the population-based cancer registry, 
indicating that the losses were practi-
cally random. However, the same could 
not be said of survival studies using 
hospital cancer registry data, with 
differences in the order of 15%.13,17 
These differences typically represent 
the advantages of using population-
based cancer registry data rather than 
hospital series.
The study clearly shows that in a 
population-based cancer registry series, 
passive follow-up, as represented by 
our case 1 approach, is unidirectional 
and leads to potentially biased survival 
estimates. Our case 3 scenario – ap-
plying an actuarial approach after im-
proving the follow-up data by using 
an active method – provides a closer 
estimate of true survival. Cases 2 and 
4 yield the largest and smallest residual 
bias, respectively, when the follow-up 
data ascertained by the active method 
is incomplete. Using a loss-adjusted 
survival approach is meaningless if the 
missing data is associated with the risk 
of death and with prognostic factors. 
A more complete analysis would bring 
out whether true differences existed 
between the four case scenarios.
Conclusion
Under the conditions that prevail in 
India and other developing countries, 
with incomplete mortality registration, 
no unique case identifiers for linking 
data and poor health information sys-
tems, active follow-up of cancer patients 
yields the most reliable estimates of 
cancer survival rates. Passive follow-up 
alone and standard methods of estimat-
ing survival are likely to result in an 
upward bias.  ■
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Résumé
Manque de suivi actif des patients cancéreux à Chennei, en Inde: implications pour les estimations du taux de 
survie en population
Objectif Mesurer le biais affectant les estimations du taux de 
survie absolue au cancer en l’absence de suivi actif des patients 
cancéreux dans les pays en développement.
Méthodes Ont été inclus dans l’étude tous les cas incidents 
des 10 cancers les plus courants et des sous-types 
correspondants, plus tous les cancers liés au tabac non 
classés parmi les 10 premièrs recensés dans le registre des 
cancers de la population de Chennei, en Inde, au cours de la 
période 1990-1999, et suivis jusqu’en 2001. Les cas incidents 
enregistrés ont d’abord été appariés avec ceux figurant dans la 
base de données de mortalité toutes causes confondues de la 
division statistiques vitales de la Corporation de Chennei. Les 
cas de cancer incidents non appariés ont ensuite fait l’objet d’un 
suivi actif pour déterminer leur statut de survie. Le taux de survie 
absolue a été estimé en utilisant une méthode actuarielle et en 
appliquant différentes hypothèses concernant le statut de survie 
(vivant/mort) des cas, dans les situations de suivi passif et actif.
Résultats Avant le suivi actif, l’appariement obtenu allait de 20 à 
66 %, selon le site de la tumeur primaire. Un suivi actif des cas 
incidents non appariés a révélé que 15 à 43 % d’entre eux étaient 
décédés à la fin de la période de suivi et que le statut de survie 
de 4 à 38 % de ces cas restait inconnu. Avant le suivi actif des 
patients cancéreux, on estimait que le taux de survie absolue à 5 
ans se situait entre 22 et 47 %, soit plus qu’après l’application aux 
cas perdus pour le suivi de méthodes actuarielles hypothétiques 
classiques. Les estimations les plus faibles des taux de survie 
ont été obtenues en excluant les cas perdus pour le suivi de 
l’analyse.
Conclusion Dans les conditions qui prévalent en Inde et dans 
d’autres pays en développement, le suivi actif des patients 
cancéreux fournit les estimations les plus fiables des taux de 
survie au cancer. Le suivi passif seul ou l’application de méthodes 
classiques pour estimer la survie sont susceptibles d’entraîner 
un biais haussier.
Resumen
Falta de seguimiento activo de los pacientes con cáncer en Chennai, India: implicaciones para las 
estimaciones de supervivencia basadas en la población
Objetivo Medir el sesgo de las estimaciones absolutas de 
la supervivencia de los enfermos de cáncer en ausencia de 
medidas de seguimiento activo de esos pacientes en los países 
en desarrollo.
Métodos El estudio abarcó todos los casos nuevos de los 10 
cánceres más comunes y sus distintos subtipos, más todos los 
cánceres relacionados con el tabaco y no clasificados entre los 
10 principales, que habían sido incluidos en el registro de cáncer 
basado en la población en Chennai, India, durante 1990–1999, 
y sometidos a seguimiento durante 2001. Los casos nuevos 
registrados se aparearon con los de la base de datos de mortalidad 
por todas las causas de la división de estadísticas vitales de 
la corporación municipal de Chennai, y los casos nuevos no 
apareados fueron sometidos luego a seguimiento activo para 
determinar su grado de supervivencia. La supervivencia absoluta 
se estimó mediante un método actuarial, aplicando diferentes 
supuestos respecto al estado de supervivencia (vivo/muerto) de 
los casos sometidos a seguimiento pasivo y activo.
Resultados Antes del seguimiento activo, el apareamiento entre 
casos osciló entre el 20% y el 66%, según la localización del tumor 
primario. El seguimiento activo de los casos nuevos no apareados 
reveló que entre un 15% y un 43% habían fallecido al final del 
periodo de seguimiento, y no se conocía el estado de supervivencia 
de un 4%-38% de los casos. Antes del seguimiento activo de los 
enfermos de cáncer, su supervivencia absoluta a los 5 años era según 
las estimaciones un 22%-47% superior a la determinada al aplicar 
los supuestos actuariales tradicionales a los casos perdidos para 
el seguimiento. Las estimaciones de supervivencia más bajas fueron 
las obtenidas al excluir de los análisis los casos perdidos para el 
seguimiento.
Conclusión En las condiciones reinantes en la India y en otros 
países en desarrollo, el seguimiento activo de los enfermos 
de cáncer es el método más fiable para estimar las tasas de 
supervivencia del cáncer. El simple seguimiento pasivo de los 
casos o la aplicación de los métodos habituales de estimación 
de la supervivencia tienden a ocasionar un sesgo por exceso.
صخلم
ةيناكسلا ايقُبلا تاريدقت يرثأت :دنهلا ،ياّنش في ناطسرلا ضىرلم ةلا َّعفلا ةعباتلما دقف
 ىدل ةقلطلما )ةايحلا ديق لىع ءاقبلا( اَيْقُبلا تاريدقت في زُّيحتلا سايق :فدهلا
.ةيمانلا نادلبلا في هاضرلم ةلا َّعفلا ةعباتلما دقف دنع ناطسرلا ضىرم
 ناطسرلا  طانمأ  نم  تعقو  يتلا  تلااحلا  عيمج  ةساردلا  تلمش  :ةقيرطلا
 ةطبترلما تاناطسرلاو ،اهب ةقلعتلما ةيعرفلا طانملأا عم ًاعويش ثركلأا ةشرعلا
 نياكس لجس في تل ِّجُسو ،ةشرعلا طانملأا كلت نمض فَّنصت لم يتلاو غبتلاب
 اهتعباتم تتمو ،1999 – 1990 ةترفلا للاخ في كلذو ،دنهلا ،ياّنش في ناطسرلل
 ينبو  ًلاوأ  ةلجسلما  تلااحلا  ينب  ةنراقم  نوثحابلا  ىرجأو  .2001  ماع  للاخ
 بابسلأا عيمج نع ةمجانلا تايفولل تايطعم ةدعاق في ةدوجولما تلااحلا
 نوثحابلا  يرجأ مث  .ياّنش ةسسؤم في ةيويحلا  ةيندلما  تاءاصحلإا  مسق في
 عم ةقفاوتم نكت لم يتلا تلااحلا عاضوأ لىع فرعتلل ةلاّعف ةعباتم كلذ دعب
 لدعلما نوثحابلا رّدقو .ةايحلا ديق لىع اهئاقب ثيح نم ،تايطعلما ةدعاق
 ةفلتخم  تاضاترفاو  )ةيراوتكإ(  ةيباسح  ةقيرط  مهمادختساب  ايقبلل  قلطلما
 ةلا َّعفلا ةعباتلما اهيلع قبط يتلا تلااحلل )تاومأ/ءايحأ( ايقبلا عاضوأب قلعتت
.ةلعافلالاو
 %20 ينب تلااحلا ينب قفاوتلا حوارت ،ةلا َّعفلا ةعباتلماب مايقلا لبق :تادوجولما
 عوقول ةلا َّعفلا ةعباتلما تلد مايف .ئيدبلا مرولا عقوم لىع كلذ دمتعيو %66و
 ةياهن لولح لبق اوتام دق %43و %15 ينب حواتري ام نأ ةقفاوتلما يرغ تلااحلا
 .ةفورعم يرغ مهنم %38 لىإ %4 ىدل ايقبلا ةلاح تيقب مايف ةعباتلما ةترف
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 قلطلما اَيْقُبلا لدعم نأ نوثحابلا ردق ،ناطسرلا ضىرلم ةلا َّعفلا ةعباتلما لبقو
 دنع هيلع نوكيس ام لىع %47و %22 ينب حواتري رادقبم ديزي تاونس 5 ةدلم
 نم تدقف يتلا تلااحلا لىع ةيراوتكلإا ةيباسحلا ةيديلقتلا  قرطلا قيبطت
 داعبتسا دنع اَيْقُبلا تاريدقت نم ردق لقأ لىع نوثحابلا لصح دقو .ةعباتلما
 .ليلحتلا ءانثأ ةعباتلما نم تدقف يتلا تلااحلا
 تدأ ،ىرخلأا ةيمانلا نادلبلا فيو دنهلا في ةدئاسلا فورظلا لظ في :جاتنتسلاا
 ثركلأا يه ناطسرلا تايفو لدعلم تاريدقت لىع لوصحلا لىإ ةلا َّعفلا ةعباتلما
 ريدقتل  ةيرايعلما  قرطلا  قيبطت  وأ  تلااحلل  ةلعافلالا  ةعباتلما  امأ  .ةيقوثوم
.ةدايزلل لييم زُّيحت لىإ بلاغلا في يدؤتف اَيْقُبلا
Childhood cancers in Chennai, India, 1990–2001: Incidence and survival
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Childhood cancers (age at diagnosis: 0–14 years) comprise a vari-
ety of malignancies, with incidence varying worldwide by age, sex,
ethnicity and geography, that provide insights into cancer etiol-
ogy. A total of 1,334 childhood cancers registered in population-
based cancer registry, Chennai, India, during 1990–2001 and cate-
gorized by International Classiﬁcation of Childhood Cancer
norms formed the study material. Cases included for survival
analysis were 1,274 (95.5%). Absolute survival was calculated by
actuarial method. Cox proportional hazard model was used to
elicit the prognostic factors for survival. The age-standardized
rates for all childhood cancers together were 127 per million boys
and 88 per million girls. A decreasing trend in incidence rates
with increasing 5-year age groups was observed in both sexes. The
top 5 childhood cancers were the same among boys and girls: leu-
kemias, lymphomas, central nervous system neoplasms, retino-
blastomas and renal tumors. The highest 5-year absolute survival
was observed in Hodgkin’s disease (65%) followed by Wilm’s tu-
mor (64%), retinoblastomas (48%), non-Hodgkin’s lymphomas
(47%), osteosarcomas (44%), acute lymphoid leukemia and astro-
cytoma (39%). Multifactorial analysis of age at diagnosis and sex
showed no differences in the risk of dying for all childhood can-
cers. Completeness of treatment and type of hospital combination
emerged as a prognostic factor for survival for all childhood can-
cers together (p < 0.001), acute lymphoid leukemia (p < 0.001) and
non-Hodgkin’s lymphoma (p 5 0.04). A Childhood Cancer Regis-
try with high-resolution data collection is advocated for in-depth
analysis of variation in incidence and survival.
' 2008 Wiley-Liss, Inc.
Key words: population-based cancer registry; childhood cancer;
incidence; survival; childhood cancer registry
The network of cancer registries called National Cancer Regis-
try Program of Indian Council of Medical Research, Government
of India, has been in existence since 1981.1 The Madras Metropol-
itan Tumor Registry (MMTR), a population-based cancer registry
(PBCR), based at the Cancer Institute (WIA), Chennai, collects
data on all incident cancer cases occurring in Chennai city and
publishes reports on incidence and cancer survival to serve as ref-
erence material for oncologists involved in clinical work and
research.2–4 Childhood cancers (age at diagnosis 0–14 years) com-
prise a variety of malignancies, with incidence varying worldwide
by age, sex, ethnicity and geography, that provide insights into
cancer etiology.5,6 Publications on childhood cancer incidence
and, especially, survival are sparse from India.7,8 This paper anal-
yses the incidence of and survival from childhood malignancies in
Chennai during the period 1990–2001.
Material and methods
Cancer is not a notiﬁable disease in India. Hence, registration of
cases is done by active method.2 The MMTR covers an entirely
urban population (all ages) estimated at 4.1 millions in 1996 in the
ratio of 960 females to 1,000 males. The corresponding childhood
population ﬁgures were 1,067,425 in the ratio of 964 girls to 1,000
boys. Childhood cancers are categorized by International Classiﬁ-
cation of Childhood Cancer norms5 using ICD-O II edition codes.9
A total of 1,334 childhood cancers registered in MMTR during
1990–2001 formed the study material. Comparative measures of
incidence like age-speciﬁc rate and age-standardized rate per mil-
lion and cumulative risk expressed as ratio at risk were calculated
to describe the data on cancer incidence for both boys and girls.6
Data on mortality were routinely collected from the vital statis-
tics division.10 Deaths occurring in Chennai were routinely
matched with the incident cancer database. The incident cancer
cases that were not matched with the mortality database were sub-
jected to follow-up by active methods: repeated scrutiny of medi-
cal records, postal/telephone enquiry and/or house visits. The clos-
ing date of follow-up was December 31, 2003. Cases registered
based on a death certiﬁcate only (1.8%) and those with no infor-
mation on follow-up apart from the incidence date (2.7%) were
excluded from survival analysis. Thus, 1,274 cases were included
for survival analysis (95.5%). Data on treatment was routinely
abstracted 6 months to 1 year from diagnosis. Complete treatment
signiﬁed those who had received at least 1 full ﬁrst course of can-
cer-directed treatment independent of the type of treatment.
Incomplete treatment referred to starting of cancer treatment, but
failure to complete it at the time of abstracting this information.
Type of hospital was broadly classiﬁed into 2 categories in this
study: (i) public hospitals in government sector and (ii) hospitals
including comprehensive cancer centers in nongovernment sector.
The survival time was calculated as the duration between the inci-
dence date and the date of death or date of loss to follow-up or
closing date, whichever was earlier. Absolute survival was calcu-
lated by actuarial method.11 Log rank test was used to compare
the survival curves.12 Cox proportional hazard model was used to
elicit the main effects in multifactorial analysis of prognostic
factors for survival.13
Results
Data quality indices for the study of incidence and survival
from childhood cancers are given in Table I. Among the 1,334
childhood cancers studied for computing measures of incidence,
histologically veriﬁed cancer diagnosis comprised 1,272 (95%),
and cases included for survival study constituted 1,274 (95%).
Complete follow-up achieved with deﬁnite knowledge of alive/
dead status was 85% at 5 years from diagnosis and 74% at 10
years from diagnosis.
Descriptive statistics on childhood cancer morphology groups
by 5-year age groups and sex are given in Table II. A preponder-
ance of boys in the incidence was forthcoming for majority of
morphology and 5-year age groups. The age-speciﬁc incidence
rates per million of all childhood cancers together in the age
groups 0–4 years, 5–9 years and 10–14 years were 143, 128 and
104 among boys and 112, 76 and 68 among girls, respectively. A
decreasing trend in incidence rates with increasing 5-year age
groups was observed, with the peak incidence occurring at 0–4
years of age in both sexes. The age-standardized rates per million
for all childhood cancers together were 127 for boys and 88 for
girls. The ratio at risk of acquiring cancer in the pediatric age
group was 1 in 534 among boys and 1 in 780 among girls. The top
5 morphology groups in childhood cancers based on number of
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cases were the same among boys and girls: leukemias, lympho-
mas, central nervous system neoplasms, retinoblastomas and renal
tumors. Acute lymphoid leukemia (76%) was the commonest
among leukemias; Hodgkin’s disease accounted for half of all
lymphomas together among boys and lesser among girls. Retino-
blastomas were evenly distributed among both sexes.
Absolute survival from all incident childhood cancers in Chen-
nai, both treated and untreated ones, at one, three, 5 and 10 years
from diagnosis were 65%, 46%, 40% and 35%, respectively. The
highest 5-year absolute survival among morphology groups and
subgroups was observed in Hodgkin’s disease (65%) followed by
Wilm’s tumor (64%), retinoblastomas (48%), non-Hodgkin’s lym-
phomas (47%), osteosarcomas (44%), acute lymphoid leukemia
and astrocytoma (39%). The poorest survival was seen in hepatic
tumors (11%) preceded by Ewing’s sarcoma (23%; Table III).
However, the differences in survival between 5-year age groups in
both sexes were not statistically signiﬁcant for any cancer.
The 5-year absolute survival (%) and multifactorial analysis of
prognostic factors for survival from all childhood cancers together
and selected childhood cancers in Chennai are given in Table IV.
The factors analyzed were as follows: 5-year age group at diagno-
sis (3-levels: 0–4, 5–9 and 10–14 years), sex (2-levels: boys and
girls) and treatment status1type of hospital (4-levels): (i) Com-
pleted treatment in nongovernment hospitals, (ii) completed treat-
ment in public hospitals in government sector, (iii) registered but
received incomplete or no treatment in public hospitals in govern-
ment sector and (iv) registered but received incomplete or no treat-
ment in nongovernment hospitals). The differences in survival by
treatment status1type of hospital were statistically signiﬁcant for
all childhood cancers together, acute lymphoid leukemia and non-
Hodgkin’s lymphoma. In multifactorial analysis of prognostic fac-
tors, the combination of completeness of treatment and type of
hospital emerged as a signiﬁcant prognostic factor for survival
from all childhood cancers together (p < 0.001). A 2- to 5-fold
increased risk of dying among acute lymphoid leukemia cases (p
< 0.001) was observed for those who received complete treatment
in public hospitals in government sector and for those with incom-
plete or no treatment in any hospital compared to receiving com-
plete treatment in nongovernment hospitals. The risk of dying
among non-Hodgkin’s lymphoma cases was 4-fold higher (p 5
0.01) for those not treated or received incomplete treatment in
public hospitals in government sector compared to those receiving
complete treatment in nongovernment hospitals. No statistically
signiﬁcant differences in the risk estimates were forthcoming
TABLE I – DATA QUALITY INDICES: INCIDENCE OF AND SURVIVAL FROM
CHILDHOOD CANCERS, CHENNAI, 1990–2001
Number %
Data quality indices
Incidence data
Total cases 1,334 –
Histological veriﬁcation 1,272 95.4
Excluded from survival analysis
Death certiﬁcate only cases 24 1.8
Cases with no follow-up 36 2.7
Cases included for survival analysis 1,274 95.5
Follow-up data of included cases
Cases with complete follow-up
at 10 years from diagnosis
942 73.9
Alive 230 18.0
Dead 712 55.9
Partial or lost to follow-up 332 26.1
Know alive <1 year from diagnosis 83 6.5
1–3 years from diagnosis 74 5.8
3–5 years from diagnosis 30 2.4
5–10 years from diagnosis 145 11.4
TABLE II – DESCRIPTIVE STATISTICS ON CHILDHOOD CANCER INCIDENCE BY MAJOR MORPHOLOGY GROUPS AND SEX: CHENNAI, 1990–2001
Childhood cancer classiﬁcation:
morphology groups
Average annual rates per million and risk
Boys (B) Girls (G)
All cases Age-speciﬁc rates
ASR Ratio at risk
Age-speciﬁc rates
ASR Ratio at risk
Number
of cases
G:B 0–4 5–9 10–14 0–4 5–9 10–14
Leukemia 463 1:1.7 50.8 50.0 34.5 45.8 1:1,478 41.3 24.3 18.8 29.3 1:2,369
Lymphoid leukemia 353 1:1.8 40.1 40.0 25.3 35.7 1:1,899 34.3 17.3 11.4 22.2 1:3,175
Acute lymphoid leukemia 351 1:1.8 40.1 39.5 24.8 35.5 1:1,915 34.3 17.3 11.4 22.2 1:3,175
Acute nonlymphoid leukemia 63 1:1.3 4.6 7.3 4.6 5.5 1:12,102 3.2 4.2 5.3 4.1 1:15,772
Acute myeloid leukemia 60 1:1.2 4.1 6.4 4.6 5.0 1:13,242 3.2 4.2 5.3 4.1 1:15,772
Chronic myeloid leukemia 7 1:0.8 0.5 0.5 0.4 0.5 1:143,970 0.5 0.5 0.9 0.6 1:106,386
Lymphomas and
reticuloendothelial neoplasm
271 1:2.7 14.9 42.3 32.0 28.7 1:2,244 4.8 16.8 12.3 10.9 1:5,897
Hodgkin’s disease 126 1:3.5 5.6 24.1 14.3 14.1 1:4,540 1.6 6.5 4.8 4.1 1:15,419
Non-Hodgkin lymphoma 112 1:2.4 7.2 13.6 14.7 11.5 1:5,624 2.7 8.4 4.4 5.0 1:12,925
CNS and misc intracranial and
intraspinal neoplasms
142 1:1.4 12.3 15.0 10.5 12.7 1:5,284 8.0 14.5 6.1 9.6 1:6,978
Astrocytoma 70 1:1.1 6.7 5.0 5.5 5.8 1:11,662 4.8 7.5 3.5 5.3 1:12,653
Sympathetic nervous system tumors 56 1:0.8 7.7 2.3 2.1 4.3 1:16,554 10.7 4.2 0.9 5.8 1:12,655
Neuroblastoma and
ganglioneuroblastoma
54 1:0.8 7.7 2.3 1.7 4.2 1:17,152 10.7 3.7 0.9 5.6 1:13,041
Retinoblastoma 82 1:1.0 15.9 4.1 0.4 7.6 1:9,789 16.1 4.7 0.4 7.9 1:9,437
Renal tumors 72 1:1.1 14.4 3.6 0.4 6.9 1:10,848 14.5 3.3 0.4 6.8 1:10,999
Wilm’s tumor 65 1:1.0 13.4 3.2 0.0 6.2 1:12,096 13.9 2.8 0.0 6.3 1:11,946
Hepatic tumors 20 1:0.8 4.1 0.5 0.0 1.7 1:43,830 5.4 0.5 0.0 2.2 1:34,315
Malignant bone tumors 52 1:1.3 1.0 4.1 7.6 3.9 1:15,752 0.0 1.4 8.8 3.0 1:19,671
Osteosarcoma 26 1:1.2 0.5 0.9 4.6 1.8 1:33,033 0.0 1.4 3.9 1.6 1:37,409
Ewing’s sarcoma 20 1:1.2 0.5 2.3 2.1 1.5 1:40,887 0.0 0.0 3.9 1.1 1:50,703
Soft tissue sarcoma 62 1:1.6 8.2 3.2 6.3 6.0 1:11,290 4.8 2.8 3.9 3.9 1:17,282
Rhabdomyosarcoma 43 1:1.4 6.2 2.7 2.9 4.1 1:16,896 4.8 1.9 2.2 3.1 1:22,509
Germ cell, trophoblastic and other
gonadal neoplasms
45 1:0.6 8.2 0.5 0.0 3.3 1:23,064 3.8 0.9 8.3 4.2 1:15,368
Other carcinoma and unspeciﬁed
malignant neoplasm
69 1:1.3 5.1 2.7 9.7 5.7 1:11,398 2.7 2.8 8.3 4.4 1:14,481
All childhood cancers together 1,334 1:1.5 142.8 128.2 103.6 126.7 1:534 112.1 76.2 68.4 87.8 1:780
ASR, age-standardized rate.
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between treatment status1types of hospitals for the rest of child-
hood cancers. Age at diagnosis and sex did not emerge as signiﬁ-
cant risk factors for any of the childhood cancers studied.
Discussion
The MMTR is one of the oldest cancer registries in the network
of PBCRs in India. The data on cancer incidence have been pub-
lished in several volumes of the International Agency for Research
on Cancer Scientiﬁc Publication series on ‘‘Cancer Incidence in 5
Continents,’’ without any reservation that stands testimony to the
data quality.6 Completeness of coverage of the Chennai registry is
estimated as 96%.14 This registry was the ﬁrst to initiate active fol-
low-up of cancer cases in a PBCR in India, and the loss to follow-
up encountered in this study is the least among all PBCRs in
India.15 The population-based survival estimation is unbiased by
selection, as it pertains to all cancers that are treated as well as not
treated in the registry area, thus portraying an average outcome
from the disease in Chennai city. Also, exclusion of cases from
survival analysis has been very minimal in this study. Loss-
adjusted survival rates16 were estimated to conﬁrm that the con-
ventional estimates were not biased because of the frequent losses
to follow-up (26% at 10 years from diagnosis). Hence, the data on
childhood cancer incidence and survival from Chennai are fairly
reliable for any population-based comparison with other registries.
The age-standardized rate of all childhood cancers and both
sexes together in Chennai was 108 per one million children, which
is the highest among urban registries in India.1 The trend of age-
standardized rates of all childhood cancers together during the two
decades between 1982 and 2001 in Chennai showed an average
annual increase of 2% among boys and 1% among girls. The varia-
tion in the increase in cancer incidence among boys and girls in
the last two decades in Chennai may have been due to the decreas-
ing trend in the background childhood population at risk, espe-
cially girls, in Chennai.17–19 The increase in the childhood cancer
incidence in general might be consequent to the advent of newer
facilities for diagnosis of a majority of childhood cancers in Chen-
nai, which also ensures completeness of cancer registration. How-
ever, noticeable increase was observed only in lymphoid leukemia,
brain, renal and soft tissue tumors. A decrease was forthcoming in
non-Hodgkin’s lymphoma and retinoblastoma, which may indicate
that changes also in etiological exposures had taken place.
TABLE III – ABSOLUTE SURVIVAL FROM ALL AND MAJOR CHILDHOOD CANCERS CHENNAI, 1990–2001, CASES FOLLOWED THROUGH 2003
No. of cases
Absolute survival
1 year 3 year 5 year 10 year
Leukemia 446 58.6 40.5 36.3 29.8
Lymphoid leukemia 345 59.4 43.5 38.7 35.4
Acute lymphoid leukemia 343 59.4 43.5 38.7 35.3
Acute nonlymphoid leukemia 60 55.2 31.0 31.0 16.1
Acute myeloid leukemia 58 53.6 30.3 30.3 15.7
Chronic myeloid leukemia 7 71.4 25.7 25.7 –
Lymphomas and reticuloendothelial neoplasm 270 72.4 60.7 55.3 49.3
Hodgkin’s disease 126 83.5 72.1 65.0 65.0
Non-Hodgkin lymphoma 111 61.7 49.3 46.6 35.7
CNS and misc intracranial and intraspinal neoplasms 134 56.6 30.2 26.8 25.0
Astrocytoma 68 66.9 43.6 38.7 34.9
Sympathetic nervous system tumors 55 65.1 36.3 25.7 25.7
Neuroblastoma and ganglioneuroblastoma 64 45.7 34.6 36.9 26.9
Retinoblastoma 72 87.0 59.6 48.1 45.0
Renal tumors 66 74.4 61.0 58.0 46.9
Wilm’s tumor 61 77.6 67.6 64.2 52.0
Hepatic tumors 19 21.1 15.8 10.5 10.5
Malignant bone tumors 46 64.8 44.1 30.6 30.6
Osteosarcoma 22 58.1 43.6 43.6 43.6
Ewing’s sarcoma 19 73.7 46.9 23.4 –
Soft tissue sarcoma 61 66.7 45.4 36.3 36.3
Rhabdomyosarcoma 42 68.3 47.1 36.4 36.4
Germ cell, trophoblastic and other gonadal neoplasms 45 71.4 54.5 38.0 38.0
Other carcinoma and speciﬁed malignant neoplasm 60 70.0 47.6 35.1 –
All childhood cancers together 1,274 64.9 46.4 40.0 35.3
TABLE IV – FIVE-YEAR ABSOLUTE SURVIVAL AND MULTIFACTORIAL ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVAL FROM
CHILDHOOD CANCERS, CHENNAI: 1990–2001
Factors
All childhood cancers together Acute lymphoid leukemia Non-Hodgkin’s lymphoma
n 5-yr survival HR1 n 5-yr survival HR2 n 5-yr survival HR2
Age group (in years)
00–04 460 40.0 1.03 139 43.3 1.03 19 52.6 1.03
05–09 431 43.5 0.9 (0.8–1.1)4 120 37.2 1.2 (0.8–1.6) 48 46.0 1.3 (0.6–2.8)
10–14 383 36.1 1.0 (0.9–1.2) 84 33.4 1.3 (0.9–1.8) 44 44.1 1.0 (0.4–2.2)
Sex
Male 772 39.2 1.03 218 37.6 1.03 78 44.1 1.03
Female 502 41.4 1.9 (0.8–1.1) 125 41.1 1.0 (0.8–1.3) 33 51.2 0.7 (0.4–1.3)
Treatment1type of hospital
Complete1nongovernment 284 54.3 1.03 65 60.0 1.03 20 71.4 1.03
Complete1government 797 40.1 1.4 (1.2–1.8)5 254 37.4 1.7 (1.1–2.5)5 72 44.5 1.9 (0.8–4.7)
Nil/incomplete1government 125 25.1 2.6 (1.9–3.4)5 12 8.3 5.2 (2.5–10.6)5 14 21.4 3.6 (1.3–9.9)5
Nil/incomplete1nongovernment 68 12.1 3.2 (2.3–4.4)5 12 0.0 5.0 (2.5–10.1)5 5 60.0 1.3 (0.2–6.5)
HR, hazard ratio; CI, conﬁdence interval.
1Each factor above has been adjusted for the others in the model1morphology group.–2Each factor above has been adjusted for the others in the
model .–3Reference category.–4Values given in parentheses indicate 95% CIs.–5p  0.05.
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The incidence among boys is not very different between Chen-
nai and most developed countries, but the incidence among girls
in Chennai is signiﬁcantly less than in most developed countries.6
This is observed also in other registries in India and other develop-
ing countries.1,6 It has been suggested that such elevated sex ratios
among childhood cancers might reﬂect the socioeconomic level of
the society in which girls are more likely to be underdiagnosed
than boys, though the health care is free at the point of delivery.20
But, even in a more developed society with minimal socioeco-
nomic inequalities like Singapore, an elevated sex ratio in the
childhood cancer incidence among Singapore Indians (49 girls to
100 boys) was observed compared to 93:100 among Singapore
Malay and 78:100 among Singapore Chinese.6 The Singapore In-
dian population is not ethnically any different from the population
of Tamil Nadu in India, whose capital city is Chennai. Thus, the
underlying nature and etiology of the disease may also be impor-
tant factors for this differential sex pattern observed in childhood
cancer incidence in Chennai. The age-standardized rate of Hodg-
kin’s disease among boys in Chennai (15 per million) was higher
than developed countries.1,6 The ﬁrst peak in the age-speciﬁc inci-
dence curve for Hodgkin’s disease was observed in the childhood
in Chennai, and it occurred much later in other developed coun-
tries.6 This is consistent either with different etiology or with dif-
ferent number of oncogenes or causes that activate them. Retino-
blastomas in Chennai and Delhi are either on par or more than
developed countries.5,8
Table V gives the comparison in absolute survival of childhood
cancers between Chennai, Bangalore, US-SEER and ACCIS stud-
ies.7,21–23 Absolute survival is lower by one-half in Chennai for
lymphoid leukemia, astrocytoma, retinoblastoma and Ewing’s sar-
coma compared to US-SEER and/or ACCIS studies. Absolute dif-
ferences in survival between Chennai and US-SEER and/or
ACCIS studies were more than 20 units for Hodgkin’s disease,
non-Hodgkin’s lymphoma, Wilm’s tumor and osteosarcoma, with
less survival in Chennai. Survival was comparable in all the stud-
ies for acute nonlymphoid leukemia, with the exception of Banga-
lore where it was the least. Comparison of absolute survival
between Chennai and Bangalore revealed only minimal differen-
ces for most cancers: survival was notably higher in Chennai for
acute nonlymphoid leukemia, Wilm’s tumor and rhabdomyosar-
coma, and less for retinoblastoma than Bangalore. This wide
variation in survival from childhood cancers between India and
difference, poorer than in developed countries, are likely due to
conditions for treatment and to the other differences in socioeco-
nomic status, cancer awareness and stage of disease. Therefore, it
is not possible to draw any conclusions on the relationship on eti-
ology and survival.
In Chennai, the infrastructure for treatment of childhood can-
cers in terms of development and accessibility are available to all
sections of the society. The Cancer Institute (WIA) is a nongo-
vernment institution and the ﬁrst Regional Cancer Centre in the
region with all state-of-art diagnostic and treatment facilities for
cancer, wherein more than two-third of its cases received highly
subsidized or free treatment. In the government sector, there are
(i) a specialty teaching hospital dedicated to children, with the
required infrastructure for management of all childhood cancers at
free of cost and (ii) 4 other teaching hospitals catering to all ages
with facilities for radiotherapy, surgery and chemotherapy, also at
free of cost. In the private sector, there is a specialty hospital dedi-
cated for children with cancer consultants, 6 other hospitals with
radiotherapy facility catering to cancer patients of all ages, and
many others with cancer treatment facilities excluding radiother-
apy. However, the burden of cancer cases catered to by these hos-
pitals is quite heavy and not restricted only to those cases that are
residents of Chennai city. Also, the pattern of care including treat-
ment protocols followed for common childhood cancers in the dif-
ferent hospitals in Chennai were not uniform. It is, however, not
clear how these factors affect the cancer survival by treatment sta-
tus and type of hospitals. But it seems that while the survival in
public hospitals in government sector was less than in hospitals in
nongovernment sector for patients with complete treatment, the
reverse was true for the incomplete treatment. This probably indi-
cates that economic constraints in living conditions affected the
completeness of treatment more than the cost of hospitalization
and treatment itself.
With this background, the multifactorial analysis of prognostic
factors for survival from all childhood cancers together and the
major childhood cancers in Chennai did not show any statistically
signiﬁcant differences by age at diagnosis and sex, as observed in
similar studies from developed countries.24,25 The increasing risk
of death from acute lymphoid leukemia by increasing age group
signifying an inverse relationship between survival and age at di-
agnosis was observed in this study as well as EUROCARE stud-
ies24 but not statistically signiﬁcant. In this study, signiﬁcant
changes in the risk of dying were observed for all childhood can-
cers together when treatment status and type of hospital were com-
bined and adjusted for the morphology group. However, the lack
of information on the following is conspicuous: (i) stage of dis-
ease, (ii) socioeconomic status, (iii) patient compliance to ﬁrst
course of treatment for the entire duration which is crucial, (iv)
type of treatment or protocols followed and (v) supportive care
given to speciﬁc cancer types or individual patients. Hence, the
observation on the statistically signiﬁcant risk estimates by type of
hospitals should be interpreted with caution.
In India and developing countries in general, the etiology of
many childhood cancers is likely to be different from that in more
developed countries. When all childhood cancers occurring in a
region are considered, treatment still remains sometimes incom-
plete, and survival in general is less in India than in more devel-
oped countries. However, for children completing treatment in the
comprehensive cancer centers, the survival approaches that in
Europe or USA. A Childhood Cancer Registry is indicated, with
emphasis on collection of high-resolution data for explaining the
variation.
TABLE V – COMPARISON OF 5-YEAR SURVIVAL FROM CHILDHOOD CANCERS IN CHENNAI, BANGALORE,7 ACCIS21 AND US-SEER18 STUDIES
ICCC morphology group ICCC code
Chennai Bangalore ACCIS US-SEER
1990–2001 1982–1989 1988–1997 1985–1989
Lymphoid leukemia Ia 39 36 79 77
Acute nonlymphoid leukemia Ib 31 10 49 34
Hodgkin’s disease IIa 65 73 931 90
Non-Hodgkin’s lymphoma IIb 47 33 85 73
Astrocytoma IIIb 39 41 75 72
Neuroblastoma and ganglioneuroblastoma IVa 37 29 59 57
Retinoblastoma V 48 73 93 87
Wilm’s Tumour VIa 64 28 83 90
Osteosarcoma VIIIa 44 45 59 68
Ewing’s sarcoma VIIIc 23 – 62 61
Rhabdomyosarcoma IXa 36 14 63 60
ICCC, international childhood cancer classiﬁcation; ACCIS, automated childhood cancer information system.
1Includes cases aged 1–14 only.
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Loss-adjusted survival of cervix cancer in Khon Kaen, Northeast
Thailand
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For incident cancers of the cervix uteri (601 cases) registered in the population-based cancer registry of Khon Kaen province,
Northeast Thailand, in 1985–1990 loss-adjusted survival probabilities were estimated by a logistic regression model with four
prognostic factors (age at diagnosis, stage of disease, place of residence and treatment), and compared with observed survival,
estimated by the actuarial method. All patients were followed up for a minimum of 5 years, using both passive and active methods. In
all, 27.6% of patients were lost to follow-up within 5 years of the index date. The overall observed survival at 5 years was 56.8% and
loss-adjusted survival was 54.7%. The difference between the loss-adjusted and observed survival at 5 years was small: 2.1% overall,
varying between 0.8 and 3.5 percent units for any prognostic group. The assumption of independence of loss to follow-up and death
in the calculation of survival by the actuarial method in this, and probably in other, population-based series, is reasonable and leads to
no material bias in the estimates.
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Population level survival is usually estimated by the life-table
method, in which cumulative probability of survival is calculated
at successive annual intervals after diagnosis (Cutler & Ederer,
1958; Ederer et al, 1961). Information from all cases is used,
including cases whose follow-up ends due to closure of the study,
and those lost to follow-up before closure. Survival estimates may
be biased if the proportion of cases lost to follow-up is substantial
(as in many developing countries, where health information
systems are not well developed), and if the loss to follow-up is
correlated with the probability of death (prognosis) of the patient
after he or she was lost.
Prognostic factors that may also predict loss to follow-up are
related to the clinical characteristics of the disease, the patient and
the social environment. For example, recurrence or relapse of the
disease and serious comorbidity are prognostic factors that may
cause the patient to move away (for treatment, or terminal care),
making them impossible to trace. Social status influences the
probability of survival from cancer (Kogevinas and Porta, 1997)
and may also affect the ability to follow-up of a subject.
Information on the association between prognostic factors and
loss to follow-up can be used to reduce the bias in estimates of
survival (Ganesh, 1995; Mathew, 1996). In this paper, we calculate
the absolute survival of cases of cancer of the cervix recorded by a
population-based cancer registry in Thailand, using the actuarial
method, and examine the effect of adjustment for differential loss
to follow-up within subgroups of patients at different risk of death
from the disease (‘loss adjustment’).
SUBJECTS AND METHODS
A total of 630 invasive incident cancers of the cervix were
registered during 1985–1990 in the population-based cancer
registry covering the province of Khon Kaen. Of these, 29 (4.6%)
were registered on the basis of a death certificate only, and were
excluded from the survival analysis. For the remaining 601 cases,
data on age at diagnosis, area (district) of residence, date of
incidence, topography, morphology, stage of disease, treatment
(whether treatment by surgery, radiation or chemotherapy was
recorded in the patient file), date and vital status (alive or dead) at
last contact were abstracted from the registry database.
Patients were followed up until death, or date of loss to follow-
up, or 31 December 1995 (closing date). Therefore, the potential
length of follow-up was 5 –10 years. The registry used both passive
and active measures to establish the vital status (alive/dead) of
cancer patients.
Passive follow-up
All death certificates (with a mention of any cancer (ICD-9: 140–
208) as underlying or contributing cause of death) were obtained
from the Provincial Health Department. The death certificates were
linked to the cancer registry database at annual intervals (using
national ID number, name, date of birth and address) and the date
of death updated for matching cases.
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Active follow-up
For the remaining unmatched cases, information on follow-up was
collected by visiting the various hospitals to scrutinise case
records, and by making enquiries of treating physicians and
general practitioners. Annual follow-up on the anniversary of the
date of incidence was attempted for presumed survivors by
sending a reply-paid postcard inquiring about the current status of
the patient. If no reply was received, a second postcard was sent to
the headman of the village requesting the same information. House
visits were also performed wherever feasible.
Analytical methods
Actuarial survival The estimation of survival probability for each
year was carried out by the actuarial method. The index date of
this study was the date of incidence. The duration of survival for
each case was calculated as the time elapsed from the index date to
the date of death or the last date of follow-up or closing date,
whichever was earlier. Cumulative absolute survival (Cutler and
Ederer, 1958) was estimated using the SURV3 analysis programme
(Dickman et al, 2002).
Loss-adjusted survival The method proposed by Ganesh (1995)
was used and is described in detail in the statistical appendix.
 Step 1 – Choice of potential confounding (prognostic) factors
(X1,y,X4), and strata (j) for each factor.
Cases were allocated to 64 strata within four factors: (i) age
(four levels: o40, 40–49, 50–59, 60þ ), (ii) stage of disease
(four levels: I, II, III and IV, unknown), (iii) cancer-directed
treatment (two levels: yes, no) and (iv) place of residence (two
levels: Muang and surrounding districts, other). Muang district
is in the centre of Khon Kaen province where Khon Kaen city is
located.
 Step 2 – Classification of study subjects into two main
categories: those with complete follow-up and those lost to
follow-up.
At a given survival time (annual), ‘i’¼ 1–5 (say), the subjects in
each stratum (nij) were classified into two groups: (1) those
‘completely followed up’, denoted by nij
0, comprising those dead
(dij) during the interval (i) or alive (wij) at the end of the annual
interval, and (2) those ‘lost to follow-up’, denoted by li), who
were last known to be alive in the annual interval and status
unknown thereafter.
 Step 3 – Computation of probability of death (qij0) for all i and j
for factors X1,y,X4 among cases with complete follow-up
(nij
0 ¼ nijli ).
The probability of death (qij
0) at each annual interval i, was
estimated by means of a logistic regression model, using cases
with complete follow-up only (nij
0), with all factors (j) taken into
account simultaneously in the model. Stata version 7.0 (2001)
software was used to estimate the regression coefficients.
 Step 4 – Computation of expected deaths (dij0) among cases lost
to follow-up (lij).
The expected deaths (dij
0) among the group of cases lost to
follow-up (lij) were estimated by assigning the same probability
(qij
0) of death.
 Step 5 – Computing the loss-adjusted survival for each interval i.
The computation of the conditional probability of dying (qi),
conditional probability of surviving (pi) and the cumulative
probability (Pi) of surviving the current and subsequent annual
intervals of time are estimated by accumulating the numbers dij,
dij
0, nij, nij0 over the confounders, j, and proceeding under the
modified actuarial framework of generating life table, as
described in the statistical appendix.
RESULTS
A total of 601 (95.4%) out of 630 cases of cancer of the cervix
diagnosed during 1985–1990 were included in the survival study;
all patients were followed to the end of 1995 or later. In all, 83%
were diagnosed microscopically. Table 1 shows the distribution of
cases by age, stage, treatment received and place of residence. In
Table 1 Number of cases, proportion and risk (odds ratio, OR) of death and loss to follow-up at 5 years from the index date and 95% confidence interval
(CI) by factors studied
Proportion at 5 years from index date Odds ratio (OR) and 95% CI
Factors studied Number of cases Lost (%) Dead (%) Lost ORa Deadb ORa
All cases 601 27.6 36.4
(1) Age group
o40 122 27.9 24.6 1.0 1.0
40–49 194 24.2 35.1 0.9 (0.5–1.5) 1.5 (0.8–2.7)
50–59 158 29.1 36.7 1.2 (0.7–2.0) 2.0 (1.1–3.7)
60+ 127 29.9 49.6 1.2 (0.7–2.1) 3.5 (1.8–6.9)
(2) Stage of diseases
Stage I 93 23.7 20.4 1.0 1.0
Stage II 134 28.4 29.1 1.2 (0.7–2.2) 1.8 (0.9–3.6)
Stage III and IV 222 21.6 53.6 0.8 (0.4–1.5) 5.0 (2.7–9.5)
Stage unknown 152 37.5 27.6 1.4 (0.7–2.6) 1.5 (0.7–3.1)
(3) Treatment
Received treatment 428 22.4 36.2 1.0 1.0
No treatment 173 39.9 37.0 2.0 (1.3–3.1) 2.0 (1.2–3.4)
(4) Residency
Muang and surrounding
Districts 274 28.1 32.9 1.0 1.0
Other districts 327 26.9 39.4 0.8 (0.6–1.2) 1.5 (1.0–2.3)
aORs of each factor adjusted for all other factors in the table. bEstimated among those with complete follow-up only.
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all, 316 cases (53%) were aged under 50 years, and 127 (21%) were
over 60; 93 cases (15.5%) were stage I, 22.3% stage II, 31.5% stage
III, 5.5% stage IV and 25.3% were of unknown stage at diagnosis. A
total of 45.6% of cases were residents of Muang and surrounding
districts; 71.2% of patients received treatment through either
surgery or radiation or chemotherapy.
Risk of loss to follow-up and death
The proportion and risk (odds ratio) of death and loss to follow-up
at 5 years from the index date, by prognostic factors, are presented
in Table 1. The proportion of patients lost to follow-up during the
5-year period was 27.6%, and of dying was 36.4%. The risk of loss
to follow-up varied 1.3-fold by age at diagnosis, 1.6-fold by stage of
disease and 1.2-fold by place of residence; the risk of loss to follow-
up among cases not treated was two-fold higher than those treated.
The risk of death increased 3.5-fold with increasing age at
diagnosis, and five-fold with stage of disease (Po0.001), with the
highest risk observed in stages III and IV. Those with stage
unknown also had a higher risk of death than those in stage I
(OR¼ 1.5). Patients with no treatment had a two-fold higher risk
of death and patients who lived far away from the centre of the
province had a 50% higher risk than those who lived nearby.
Survival from cervix cancer (actuarial and loss-adjusted)
The observed (actuarial) survival at 5 years was 56.8% (Table 2).
During this period, 27.6% of cases were lost to follow-up; 13.3% in
the first year, 5.1% of those remaining in the second and third
years, and 19.3% of the remainder in the fourth and fifth years
(Table 2).
Adjustment for loss of follow-up gave an estimated survival of
54.7% at 5 years from index date, 2.1% units less than the observed
(actuarial) survival. This suggests that the patients who were lost to
follow-up had a higher mortality than assumed in the actuarial
method of survival analysis, in which such deaths occur at the
same rate as among those with complete follow-up. Table 2 also
gives the estimate of loss-adjusted survival by age group, stage,
treatment and residence, each adjusted for differential loss to
follow-up by the other three factors.
Age An inverse relationship between survival and age at diagnosis
was evident: Patients aged less than 40 years had the best survival
and patients aged more than 60 years had the poorest survival by
both estimation methods. The degree of bias introduced into the
actuarial estimate by differential loss to follow-up was small, in the
range of 1.2–2.9% units, and the variation by age was somewhat less
than indicated by the actuarial estimates.
Stage of disease Patients with stage I had the best survival
(74.6%) and stage III and IV had the poorest survival (38.2%). The
reduction in the differences of survival between loss-adjusted and
actuarial estimates was the highest in patients with unknown stage
(3.5% units) and the smallest in patients with stage III and IV
disease (0.8% units).
Treatment Patients who received treatment had better survival
(57.5%) than those who had not (47.5%). The reduction in the
differences of survival between loss-adjusted survival and actuarial
estimates was higher in the untreated (2.4% units) than in those
who received treatment (1.7% units).
Place of residence Patients who lived in Muang and surrounding
districts had better survival (58.6%) than patients who lived in
other districts (51.4%). Loss-adjusted survival revealed a reduction
in estimated survival compared with that estimated by the
actuarial method, for both residence groups. The difference in
survival estimates was 2.5% units for residents of Muang and
surrounding districts and 1.8% units for those living in other
districts.
These small changes in the estimate of survival following the
loss-adjustment procedure indicate the presence of a small bias in
Table 2 Number of cases, proportion lost to follow-up at varying intervals of time and 5-year cumulative absolute and loss-adjusted survival of factors
studied
% lost to follow-up among persons at risk of death at
varying lengths of time (i) from index date % Absolute survival
Factors studied No. of cases o1 year 1rio3 years 3rio5 years Actuarial Loss-adjusteda
All cases 601 13.3 5.1 19.3 56.8 54.7
(1) Age group
o40 122 13.1 4.1 17.9 71.0 68.1
40–49 194 11.3 4.8 16.4 59.7 57.8
50–59 158 13.9 6.6 19.8 55.7 53.4
60+ 127 15.8 4.8 26.9 38.8 37.6
(2) Stage of diseases
Stage I 93 7.5 1.2 19.4 77.1 74.6
Stage II 134 9.7 9.0 18.3 65.5 63.0
Stage III and IV 222 9.0 5.8 20.2 39.0 38.2
Stage unknown 152 26.3 3.2 19.2 63.3 59.8
(3) Treatment
Received
treatment
428 6.8 6.4 17.2 59.2 57.5
No treatment 173 29.5 0.0 27.7 49.9 47.5
(4) Residency
Muang and
surrounding
districts
274 13.1 5.2 19.6 61.1 58.6
Other districts 327 13.5 5.1 19.0 53.2 51.4
aEach factor adjusted for differential loss to follow-up by other factors in the table.
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the actuarial estimate, resulting from the higher mortality among
cases lost to follow-up, than under the actuarial assumption.
DISCUSSION
The fundamental step in carrying out an end result study is to
ensure good and complete follow-up of patients. The actuarial (life
table) method uses information from all subjects, including those
censored before 5 years follow-up or death. Losses to follow-up
and withdrawals may have different effects on the estimates of
survival. The actuarial survival rate gives an unbiased estimate of
true survival only if censorship has the same distribution between
the groups being compared (Hakulinen, 1982) and is independent
of risk of the outcome studied (Ganesh, 1995). The bias in the
estimation of survival probability is dependent on both the
magnitude and nature of losses to follow-up, and may be in either
direction. For example, the true probability of death of patients
lost to follow-up may be greater than assumed if patients with poor
prognosis are more likely to be lost. In these circumstances, the
actuarial survival estimate is biased and too high.
If the vital status of all the cases included in a survival study is
known at the closing date, the estimation of survival probability by
the actuarial method is straightforward and unbiased. In the
present study, all subjects could be potentially followed for at least
5 years, so that there were no withdrawals, and all censoring was
due to loss to follow-up. In developing countries, it is difficult to
obtain complete follow-up information for all patients for various
reasons. Typically, cancer patients no longer being followed up in
hospital must be traced by active methods, involving postal
enquires or home visits. Patients frequently migrate from their
usual place of residence to that of their relatives and the hospital/
medical centre may not be informed of the change in address. This
makes tracing of patients at home difficult, since the new contact
address must be obtained from other sources, neighbours or
friends, for example. Migration is typically related to the
recurrence of the disease, that is, with factors of prognostic
significance; its magnitude depends on the nonrandom nature and
the extent of the loss to follow-up. It is therefore important in any
survival study to ascertain not only the extent of loss to follow-up,
but also its independence of the probability of death.
The first step in deciding whether bias in the actuarial estimate
of survival is likely is to examine whether loss to follow-up varies
according to prognostic variables such as age, stage, residence and
treatment group. Computation of loss-adjusted survival (Ganesh,
1995) then takes into consideration such differential losses, by
assuming that patients lost to follow-up within strata defined by
these variables have the same probability of death as those still
remaining under observation and belonging to the same stratum.
It is reasonable to expect survival experience in patients lost to
follow-up and with complete follow-up to be more similar within a
prognostic group, than when all patients are considered together.
The difference between the crude actuarial survival and the loss-
adjusted value indicates the magnitude of the effect of differential
loss to follow-up.
The small difference between the absolute (actuarial) survival
and the loss-adjusted survival observed in this study is much less
than in other studies (Ganesh, 1995; Mathew, 1996). Large
differences in LAR and actuarial estimates have been found in
hospital-based series of patients, coming from a wide geographic
area, where follow-up of patients no longer attending hospital
clinics by house visits was impractical and no postal enquiries
were made. In contrast, an international comparison of actuarial
and loss-adjusted survival of cervix cancer cases from different
population-based cancer registries in developing countries (Swa-
minathan et al. 2002) found that the maximum difference was
4.1%, with a loss to follow-up of 44% and presence of
nonrandomness. The observation was not confined to cancer of
the cervix; differences for other sites like female breast (data from
six registries from developing countries) and larynx (data from
Chennai and Mumbai cancer registries) were of similar (small)
size. This may be mainly because of the integration of mortality
data collection into the case-finding operations of population-
based cancer registries (on an annual basis in Khon Kaen). It
confirms the finding of the present study, that in a population-
based series the assumption of independency of loss to follow-up
and death was reasonable, so that calculation of survival by the
actuarial method without adjusting for losses to follow-up is likely
to have resulted in no material bias in the estimates. However, this
is not true in general; the experience of hospital-based series in
particular indicates that bias may be considerable, and requires
appropriate adjustment of survival estimates.
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STATISTICAL APPENDIX
Loss-adjusted survival
The procedure for estimating loss-adjusted survival by the stratified
method can be described step by step in the actuarial survival
estimation framework. However, there is also a different approach
which integrates estimation by a regression technique and the life
table approach. It is the latter that is sequentially described here:
In the follow-up interval i in prognostic stratum j, there will be
nij patients alive at the beginning of the interval, of whom dij will
die, wij will be withdrawn alive because of the closing date of
follow-up and lij will be lost to follow-up during the interval.
Assuming for simplicity that the potential follow-up exceeds i
intervals, wij¼ 0. The number with complete follow-up, nij0, is
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given by
nij
0 ¼ nij  lij
To overcome the problems in estimation by multifactorial methods
caused by sparse numbers in the stratified approach, loss-adjusted
survival can also be estimated by logistic regression methods
(Breslow and Day, 1980).
The proportion dying with complete follow-up, qi
0, given the
prognostic factors xi,y, xk, is first estimated for patients not lost
to follow-up, nij
0, in the interval i:
qi
0 ¼ expðm
0Þ
ð1 þ expðm0Þ
where mi
0 ¼ boi þ b1ix1i þ ::: þ bkixki,the hazard in interval i given
the prognostic factors. The proportion of deaths can be estimated
for each level of any prognostic variable xi adjusting for the
effect of the other prognostic variables. This is done for every
interval i.
The expected number of deaths among patients lost to follow-up
is then computed as d0ij¼ q0ijlij, and the expected proportion of
deaths among all nij cases is
qij ¼ dij þ dij
nij
¼ Dij
nij
The procedure is repeated for the next interval (i¼ iþ 1) with
nðiþ1Þj 0 ¼ nij  dij  lðiþ1Þj and with l0ðiþ1Þj ¼ lðiþ1Þj þ lij  d0ij; and
with d0ðiþ1Þj ¼ q0ðiþ1Þjl0ðiþ1Þjand for the other prognostic
strata.
Accumulating over prognostic strata will result in an annual
loss-adjusted rate:
qiðLoss AdjustedÞ ¼
P
j
Dij
P
j
nij
and the cumulative loss-adjusted (crude) survival rate is
piðLoss AdjustedÞ ¼ ð1  q1Þð1  q2Þ . . . ð1  qiÞ
If there are withdrawals (wij), the normal actuarial approxima-
tion is
qij ¼
Dij
nij  12 wij
The approach corresponds to adjustment by stratification.
The process described for the stratified analysis will be applied
for dij
0, qi(LAR) and ultimately for Pi(LAR), by repeating the
estimation of qi(LAR) over the first i intervals.
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Chapter 3
Loss-adjusted hospital and population-
based survival of cancer patients
Ganesh B, Swaminathan R, Mathew A, Sankaranarayanan R
and Hakama M
Introduction
Cancer survival is the main indicator of outcome of
cancer health services or treatment, and an
important component in maintaining cancer control
activities [1]. Cancer registries have long served as
potential sources of data for estimating survival.
Hospital-based cancer registries usually report
survival of a selected series of treated patients that
are registered in a hospital or group of hospitals
without specific coverage of geographical area or
background population. On the other hand,
population-based cancer registries, which include all
incident cases treated or not from a specific
geographical area, usually report average survival in
specific regions. Cancer survival reported from both
settings may have different perspectives, but
estimation of survival rates is routinely done using
standard life table approaches such as the actuarial
[2] or Kaplan-Meier [3] methods.
The actuarial method [2] of estimating survival by
follow-up time allows utilization of all information
independent of the length of follow-up of an
individual patient, so that even recently diagnosed 
patients contribute to long-term survival. Patients
who have a potential follow-up shorter than the time
of the maximum estimated survival are "censored"
cases. Censored cases are usually withdrawals,
surviving at date of last follow-up: this date can be
either individual for each patient or a common closing
date for all patients. However, censorship in terms of
losses to follow-up takes place if follow-up fails
before this potential withdrawal. There is a
qualitative difference between these two groups of
censored cases.
Losses to follow-up may cause major bias. This holds
true if the losses are common and correlated with the
patient prognosis or survival. In most low- or medium-
resource countries, such losses are common due to
deficiencies in health infrastructure and recording of
health statistics. The losses are also likely to be
related to the patient's prognosis: low social status is
related to lack of continuous patient surveillance;
extent of disease is related to the motivation of
follow-up, etc. Hence, this correlation, explained by
information on prognostic factors, can be utilized to
correct survival estimates.
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Abstract
This chapter presents formulae that methodologically adjust for losses, and gives examples describing
magnitude of bias in survival estimates without such adjustment. Loss-adjusted survival is estimated under the
assumption that survival of patients lost to follow-up is the same as that for patients with known follow-up
time and similar characteristics of different prognostic factors at first entry. The observed number of losses to
follow-up is then relocated into expected numbers of death and survivors on this basis. Standard methods, such
as the actuarial one, are then applied with the sum of observed and expected outcome events. A total of 336
hospital series of treated new breast cancer cases from Mumbai with 24% lost to follow-up revealed a
substantial bias of 7 per cent units for 3-year survival estimated with (54%) and without (61%) loss-adjustment.
Stepwise adjustment of losses established that increasing the number of prognostic factors explained the bias
better. Population-based series comprising 13 371 cases of top ranking cancers from Chennai, with loss to
follow-up ranging from 7−24%, revealed negligible bias, ranging from 0−2% in 5-year survival by the loss-
adjusted approach for different cancers. Data source seems to affect the need for loss-adjustment, and the
loss-adjusted approach is recommended when hospital-based cancer registry data of a low- or medium-
resource country are used to evaluate the outcome of cancer patients.
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A method to estimate loss-adjusted survival rates
corrected, for possible bias due to losses to follow-
up, is described here through two examples, one each
from hospital-based and population-based registry
settings. The loss-adjusted survival results are
compared with the crude actuarial estimate to
demonstrate the magnitude of bias.
Methods
Follow-up
Follow-up was carried out by passive and active
methods. The passive approach was by data linkage
either with patients' records on regular follow-up at
the outpatient clinic and/or with mortality data from
the vital statistics division. The active approach was
by contacting the patients or their families directly by
means of postal/telephone/e-mail/house visit
enquiries for information on survival status.
Determinants of loss to follow-up or survival
Categorical factors (like age, sex, literacy status,
tumour stage, treatment, etc.), each with reference
and subcategory levels, that have the potential to
influence either follow-up (complete or lost to follow-
up) or survival (alive or dead) were first determined
by using test of proportions (univariate only), logistic
regression (unifactorial or multifactorial) or Cox
proportional-hazard model (univariate or multi-
factorial using survival time information). A
differential pattern of follow-up or survival outcome,
either between factors or within subcategories of
factors, would indicate an association of non-random
nature.
Estimation of loss-adjusted survival rate - stratified
method
The life table method estimates annual survival
during a given follow-up year by specifying four types
of events including the outcome experienced by the
patient: surviving throughout the year; dying
(outcome) during the year; withdrawn alive, where
patient was known to be alive at closing date of
follow-up; and loss to follow-up, where the known
survival time terminates during the follow-up year,
but before closing date. Unlike traditional survival
analysis, which grouped withdrawals and losses
together, the proposed method for estimating loss-
adjusted survival differentiated the two. For the time
being, methods are developed for potential follow-up
time of all subjects equalling the time for which
survival is estimated. In other words, potential
follow-up time for all cases would have to be five
years to estimate 5-year loss-adjusted survival rate. 
Every prognostic stratum is composed of a unique
combination of subcategories of all identified
determinants of follow-up or survival. In the
estimation of loss-adjusted survival, it is assumed
that those lost to follow-up in specific prognostic
stratum have the same probability of death as others
still remaining under observation and belonging to the
same stratum. At any given follow-up time, the
observed numbers of losses to follow-up in each
stratum are relocated into expected numbers of
deaths, withdrawals and survivors on the basis of
observed survival in those without loss to follow-up in
the same stratum. The actuarial method, or any
other, is then applied to the sum of observed and
expected events.
In the follow-up interval i in prognostic stratum j,
there will be nij patients alive at beginning of
interval, of whom dij will die, wij will be withdrawn
alive and lij will be lost to follow-up during the
interval. Since potential follow-up exceeds i intervals
for all patients, wij = 0. The number with complete
follow-up,      , is then given by: 
The proportion dying with complete follow-up, 
given the prognostic factors xi,.....xk, is first
estimated for patients not lost to follow-up, , in
the interval i:
The expected number of deaths in patients lost for
follow-up in interval i is:
and the expected proportion of deaths in the 
nij cases is:
The procedure is repeated for the next interval 
(i = i +1) as follows:
and with
with
and for the other
prognostic strata.
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Accumulating over prognostic strata will result in an
annual loss-adjusted rate:
and the cumulative loss-adjusted survival 
probability is:
Logistic regression approach to estimate expected
deaths among loss to follow-up
The correction of bias in survival estimation adjusted
for loss to follow-up is optimal when it is determined
by including as many factors as possible. An increase
in number of determinants (factors with
subcategories) of follow-up or survival would result in
a corresponding increase in the number of prognostic
strata. Cross-tabulation of all of these factors
simultaneously would require adequate sample size to
keep a majority of prognostic strata non-empty.
Adjusting all factors simultaneously by logistic
regression is a simplification of the computational
procedure to estimate expected deaths among lost to
follow-up and offers maximal effect in reducing the
bias. 
The proportion dying in the patients followed 
completely during the interval is:
where
is a linear combination of the determinant or
prognostic factors. The above methods are described
in detail elsewhere [4,5].
Other approaches
Loss-adjusted survival can also be estimated using the
Kaplan-Meier approach [6]. Stratum-specific
expected deaths are estimated and the Kaplan-Meier
curve is corrected at time points when the expected
deaths occur.
Results
Example 1: Hospital-based cancer registry series
A total of 336 new cases of female breast cancer
cases that were diagnosed and received complete
treatment at Tata Memorial Hospital, Mumbai
(Bombay), India, in 1985 and followed-up until 1988
formed the study population. These cases were
allocated to 64 strata involving four factors
associated with follow-up or prognosis: age (in
completed years: <45, 45−54, 55−64, 65+ years);
stage of disease (TNM staging classification: I, II, III,
IV); type of treatment (chemotherapy: without,
with); place of residence (Mumbai: residents, non-
residents). Outcome event with respect to follow-up
was loss to follow-up <3 years from diagnosis, and
outcome event for loss-adjusted survival was death
due to any cause. 
Patients below 55 years of age comprised 65%, with
an overall mean of 49 years (Table 1). There was an
equal distribution of resident and non-resident
patients from Mumbai city. A majority were diagnosed
in stage II (48%) followed by stage III (37%) of the
disease. About 58% of the patients were treated with
either surgery or radiotherapy or in combination but
not with chemotherapy, while the remaining 42% were
treated with chemotherapy either alone or in
combination with other modalities. Differential
pattern of proportion (%) or risk (odds ratio) of loss to
follow-up by different prognostic factor categories
was forthcoming. The proportion of patients lost to
follow-up was not very different between
subcategories of age and type of treatment, with 0 to
30% increased risk over corresponding reference
categories that was statistically not significant. The
proportion lost to follow-up was doubled among non-
residents versus residents of Mumbai, with two- to
three-fold increased risk that was statistically
significant. The risk was two to three times higher
among stage III or IV patients and 50% higher among
stage II compared to stage I patients, but not
statistically significant (Table 1). The findings suggest
an association between these prognostic factors and
loss to follow-up. 
The data was further analysed to estimate loss-
adjusted survival by stratification of two or three
factors at a time and by logistic regression
approaches. Survival was estimated at the end of 
3-year follow-up by actuarial method without and
with adjustment for loss to follow-up (Table 2). The 
3-year survival obtained by loss-adjustment showed
lower survival compared to rates obtained by
standard actuarial assumption without specific
adjustment for loss to follow-up. The bias in survival
estimation is represented as the difference in per
cent units of survival rates (%) without and with loss-
http://survcan.iarc.fr
adjustment for each factor. This varied from 5.4 for
patients aged 55 to 64 years to 8.6 for those aged <45
years. The bias was lesser among Mumbai residents
(3.2) than non-residents (8.8). Three-year loss-
adjusted survival was higher among residents (56.2%)
than non-residents (54.4%), but this was the opposite
for corresponding survival figures without loss-
adjustment (59.4% and 63.2%), respectively. 
A decrease in survival (Table 2) and increase in
proportion of lost to follow-up (Table 1) with severity
of disease was forthcoming, which indicated a
positive association between risk of dying and loss to
follow-up in all disease stages. Loss-adjusted survival
was greater in stage I patients, but lesser in other
stages, compared to respective survival estimates
without loss-adjustment. Following the elimination of
bias by loss-adjustment, the difference in loss-
adjusted survival between stages I and III patients
increased from 51 per cent units to 61 per cent units
(Table 2). The proportion of deaths in the
chemotherapy group was twofold more than in the
non-chemotherapy group. The comparison between
actuarial and loss-adjusted survival showed that the
adjusted unbiased difference between the two groups
was bigger (43 per cent units) than the unadjusted
ones (38 per cent units). 
The variable extent of bias in survival estimation that
could be elicited in the presence of loss to follow-up
by utilizing information from one to four prognostic
factors is shown stepwise for all cases in Table 3. The
unadjusted actuarial 3-year survival was 61%. The
loss-adjustment yielded a decrease of 7 per cent units
in survival when all four prognostic factors were
considered simultaneously by logistic regression
method. The stepwise introduction of each of the
prognostic factors into the adjustment procedure, by
stratified method of estimating loss-adjusted
survival, increased the correction of bias as follows:
1.7 per cent units when adjusted only for residential
status; 2 per cent units when age was added; 3.8 per
cent units when stage was added to the previous two
factors; and 4.7 per cent units when all factors were
adjusted.
Example 2: Case series from Chennai population-
based cancer registry
A total of 13 371 cases comprising cancers of the
uterine cervix (3134), female breast (1923), stomach
(1845), oesophagus (1403), lung (1237), mouth
(1202), lymphomas (768), tongue (670), leukaemias
(668), and of ovary (521) ranked within the top ten in
Chapter 3
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Table 1. Number and proportion (%) of patients and losses at 3 years and risk (odds ratio) of loss to follow-up with 
95% confidence interval by patient characteristics among female breast cancer patients diagnosed in 
Tata Memorial Hospital, Mumbai, India, in 1985 and followed through 1988
Age at diagnosis
44 years 101 30 22 22 1.0*
45−54 117 35 29 25 1.2 (0.6−2.3)
55−64 77 23 19 25 1.2 (0.6−2.5)
65+ years 41 12 10 24 (0.5−2.9)
Residential status
(Mumbai city)
Residents 169 50 26 15 1.0*
Non-residents 167 50 54 32 2.6 (1.5−4.6)$
Stage of disease
(TNM summary)
I 29 9 4 14 1.0*
II 160 48 30 19 1.5 (0.5−5.6)
III 126 37 40 32 2.9 (0.9−10.6)
IV 21 6 6 29 2.5 (0.5−12.9)
Treatment
With chemotherapy 194 58 42 22 1.0*
Without chemotherapy 142 42 38 27 1.3 (0.8−2.3)
Patient characteristics Patients Lost to follow-up Odds ratio
(n=336) (n=80; 24%) (95% CI)
Number %a Number %b
a Percentage of total breast cancer cases; 
b Percentage of total cases in respective categories;
CI: Confidence interval;
* Reference category; 
$p=0.05. 
Loss-adjusted hospital and population-based survival of cancer patients
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Table 2. Number and proportion (%) of patients and deaths and comparison of 3-year survival with and without 
adjustment for loss to follow-up by patient characteristics among female breast cancer patients diagnosed
in Tata Memorial Hospital, Mumbai, India, in 1985 and followed through 1988
Patient characteristics Number of Deaths 3-year survival %
patients Number %a Actuarial Loss-adjusted
assumption by logistic
regression*
Age at diagnosis
44 years 101 34 34 60.1 51.5
45−54 117 42 36 56.7 48.7
55−64 77 20 26 67.7 62.3
65+ years 41 12 29 65.4 58.5
Residential status
(Mumbai city)
Residents 169 60 35 59.4 56.2
Non-residents 167 48 29 63.2 54.4
Stage of disease
(TNM summary)
I 29 2 9 92.2 93.2
II 160 36 22 74.4 71.2
III 126 55 44 41.2 31.8
IV 21 15 71 0.0 0.0
Treatment
With chemotherapy 194 39 20 76.6 71.2
Without chemotherapy 142 69 48 38.1 28.2
a Percentage of total cases in respective categories;
* Adjusted for other factors in the table.
Table 3. Comparison of 3-year survival without loss-adjustment by actuarial assumption, stepwise loss- adjustment
of factors using stratified method and loss-adjustment using all factors together by logistic regression for 
all female breast cancer patients diagnosed in Tata Memorial Hospital, Mumbai, India, in 1985 and followed 
through 1988
Without loss-adjustment and using actuarial assumption only 61.2
Loss-adjustment done by stratification
Residential status 59.5
Residential status and age at diagnosis 59.2
Residential status, age at diagnosis and stage of disease 57.4
Residential status, age at diagnosis, stage of disease and treatment 56.5
Loss-adjustment done by logistic regression
Residential status, age at diagnosis, stage of disease and treatment 54.5
Loss-adjustedment of factors 3-year survival %
the Population-Based Cancer Registry, Chennai, India,
during 1990−1996 and followed-up until 2001 formed
the study population.
The determinants of loss to follow-up at less than 5
years from diagnosis for each site were identified
using Cox proportional-hazard model by following the
method outlined in Chapter 2 of this publication.
Five-year loss-adjusted absolute survival of patients
through stratified method was estimated by
allocating cases to 128 strata defined by 4 factors
(with reference and subcategories): age at diagnosis
(<45, 45−54, 55−64 and 65+ years); literacy status
based on years of education (Nil, 5, 6−12 and    12
years); clinical extent of disease as a surrogate for
tumour stage (localized, regional, distant metastasis
and unknown); treatment status (no or unknown and
yes). Outcome event was death due to any cause.
Table 4 gives the proportion of cases lost to follow-up
and comparison of 5-year absolute survival estimated
with and without adjustment for loss to follow-up for
each cancer site. The losses ranged between 7%
(oesophagus) and 24% (ovary) for different sites. Loss-
adjusted survival was consistently lesser than the
corresponding unadjusted estimate for all sites. Bias
in survival estimation in the presence of non-random
loss to follow-up, expressed in terms of absolute
difference between survival (%) estimates obtained
with and without loss-adjustment was minimal,
ranging between 0.2 to 1.7 per cent units for
different cancer sites.
Discussion
The success of cancer treatment is, as a rule,
measured by survival. Population-based survival
reflects the availability, development of and
accessibility to cancer health services in a region.
Survival based on hospital series reflects the impact
of clinical services specific to the hospital. In both
instances, high-level completeness of ascertainment
of mortality data is an important prerequisite, and
when such completeness cannot be assured, survival
rates should be carefully interpreted [7,8]. 
Conventionally, estimation of survival was done using
life table approaches by either actuarial [2] or
Kaplan-Meier [3] methods. Both methods utilize
observed survival time independently of whether it
ends at the death of a patient. Patients withdrawn
alive at closing date provide censored information
that is unbiased, since closing date is independent
from probability of death. If this is not true,
Hakulinen [9] and Brenner [10] give means to adjust
for withdrawal pattern and to correct for effects of
improvement of survival by time.
Losses to follow-up because of reasons other than
closing date (e.g., migration) are often few in
developed countries and are dealt with identically as
withdrawals. This is not justified if the losses are
many and are correlated with risk of death. Distance
from clinical care facility increases the likelihood of
not undergoing a follow-up examination, as does
serious morbidity and poverty. The factors in failure
to obtain follow-up data are the same. Therefore, it
is likely that patients lost to follow-up have poor
prognosis and could not be compared with those
under follow-up and surveillance. The direction in
bias may also be the other way: those lost to follow-
up have a better survival than those under follow-up,
as was shown in our example on stage I breast cancer
hospital series patients.
Our example from a hospital series shows that the
bias due to losses may be substantial. Mathew[6]
showed similar differences by applying loss-
adjustment in the Kaplan-Meier survival method for
hospital series ovarian cancer patients. Much of the
original deficiencies in the hospital data were,
however, removed by active follow-up using a
postcard enquiring the vital status of patient. Only
marginal adjustment effect appeared after the
enquiry. However, in the example involving breast
cancer hospital series, a large bias still existed after
such attempts of active follow-up. On the other hand,
the example involving population-based series of
several cancers revealed negligible bias. In both
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Table 4. Number of incident cases, proportion (%) lost to follow-up and comparison of 5-year absolute survival with
and without loss-adjustment for top-ranking cancers in a population-based cancer registry, Chennai, 
during 1990−1996 and followed through 2001
Cancer site/type Number of Lost to 5-year survival % Absolute
incident follow-up No loss- With loss- difference
cases % adjustment adjustment in survival
Cervix 3134 21.8 52.1 50.4 1.7
Breast 1923 20.7 39.5 39.1 0.4
Stomach 1845 8.0 9.4 8.7 0.7
Oesophagus 1403 6.7 7.7 7.5 0.2
Lung 1237 7.8 8.2 8.1 0.1
Mouth 1202 11.6 30.1 29.1 1.0
Lymphomas 768 11.5 26.5 25.6 0.9
Tongue 670 13.0 20.2 18.9 1.3
Leukaemias 668 8.2 19.8 19.2 0.6
Ovary 521 24.0 25.7 24.2 1.5
Loss-adjusted hospital and population-based survival of cancer patients
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instances, loss-adjusted survival was lesser than the
actuarial estimate without adjustment indicating that
under-ascertainment of deaths among loss to follow-
up cases may be the problem. Most population-based
cancer registries are based on systems that integrate
linkage or collection of mortality data as a routine
and hence result in small differential bias only [5].
Hence, the data source seems to affect the need for
loss-adjustment, and the problem may be more
substantial in hospital-based cancer registries and
clinical series. The loss-adjusted approach is likely to
be useful especially when hospital-based cancer
registry data of a low- or medium-resource country
are used to evaluate the outcomes of cancer patients.
One may conclude that if routine follow-up is poor,
the first priority is to increase the actual follow-up
visits on humanitarian and scientific grounds. The
second is to improve the data by instituting rigorous
active follow-up measures. The improvement of data
by these means may indirectly improve routine
follow-up activity. Analytical methods to correct the
survival data with adjusting for losses are to be used
in surveillance and evaluation and in scientific
comparisons. However, such means do not directly
improve human health, but have the potential to
improve the organization itself.
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Global Variations in Cancer 
Survival 
R. Sankaranarayanan, M.D.' 
R. Swaminathan, M.s.c.~ 
R. J. Black, M.A.' 
for the Study Group on Cancer Survival in Developing Countries 
' Unit of Descriptive Epidemiology, International Agency for Research on Cancer, Lyon, 
France. 
Cancer Institute (WIA~, Adyar, Madras, India. 
Population-based cancer registries from Algeria, China, Costa Rica, Cuba, India, 
the Philippines, and Thailand are collaborating with the International Agency for 
Research on Cancer in a study of cancer survival in developing countries. Compari- 
sons with the SEER program results of the National Cancer Institute in the United 
States, and the EUROCARE study of survival in European countries revealed con- 
siderable differences in the survival of patients with certain tumors associated with 
intensive chemotherapeutic treatment regimes (Hodgkin's disease and testicular 
tumors), more modest differences in the survival of patients with tumors for which 
early diagnosis and treatment confer an improved prognosis (carcinomas of the 
large bowel, breast, and cervix), and only slight differences for tumors associated 
with poor prognosis (carcinomas of the stomach, pancreas, and lung). With limited 
resources to meet the challenge of the increasing incidence of cancer expected in 
the next few decades, health authorities in developing countries should be aware 
of the importance of investing in a range of cancer control activities, including 
primary prevention and early detection programs as well as treatment. Cancer 
1996; 782461-4. 0 1996 American Cancer Society. 
KEYWORDS: survival, cancer, control, developed countries, developing countries. 
ost cancers occur in developing countries; 61% of the global M incidence in 1985.' However, few data are available on cancer 
incidence, mortality, and, especially, survival in such countries. The 
reasons for this are clear. Cancer information systems, such as medi- 
cal records, hospital cancer registries, population-based cancer regis- 
tries, and mortality registration, are not well established in most in 
developing countries. Even where some of these are present, difficult- 
ies remain in obtaining adequate follow-up information on the vital 
status of cancer patients. The International Agency for Research on 
Cancer (IARC) is coordinating a study that aims to provide, for the 
first time, systematic, population-based information on survival in 
developing countries, and to compare results obtained in developed 
countries, especially in Europe and the United States. The IARC study 
is also providing a context in which to investigate the special problems 
of cancer registration and patient follow-up, as well as statistical 
methods for the estimation of survival in developing countries. 
0 1996 American Cancer Society 
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TABLE 1 
Age-Standardizeda 5-Year Relative Survival of Patients with Selected Cancers (Age, Birth to 74 Yrs) 
% of patients surviving 
Developing countries 
Site or type of cancer U.S. (1967-1973) U.S. (1974-1986)h U.S. (1986-1991) Europe (1978-1985) (late 1980s) 
Stomach 13 17 20 23 7-17 
Large bowel 46 55 60 43 29-37 
Pancreas 3‘ 4 6 6 6-7 
Lung 10 15 15 10 3-10 
Breast ti5 76 82 69 43-63 
Cervix 59 68 68 ti1 27-65 
Testis 69 92‘ 93 83 42-61 
Hodgkin’s disease 62 71d 79 71 30-55 
“Age siaiidardizution invoked direcr standardization of the site-specific age distributions of the estimated global incidence uf major cancers in 14KS IParkin el al., 1993).’ 
I’ Includes white patients only. 
Represenls 3.year smiva l .  
‘I Represents data for 1981-198fi. 
RESULTS 
The methodology and full results will be published in 
the IARC Scientific Publications Series. The range of 
preliminary results obtained from cancer registries in 
China, Cuba, India, the Philippines, and Thailand are 
shown in Table 1, alongside previously published data 
for the and Europe.’ Three broad categories of 
results can be identified. For tumors associated with 
poor prognosis (stomach, pancreas, and lung), the ab- 
solute differences in survival between developed and 
developing countries were slight. There were greater 
absolute differences for tumors of the large bowel, 
breast, and cervix, all of which are associated with a 
moderate to good prognosis if detected and treated 
early. For all the tumors in this second group, patient 
survival was greater in the U.S. than in Europe, at least 
in the late 1970s to early 1980s, the only period for 
which comparable data were available. There were 
also substantial variations among the developing 
countries themselves, most notably for carcinoma of 
the breast and cervix. Finally, the greatest differences 
in survival between the U S .  and developing countries 
were found for testicular tumors and Hodgkin’s dis- 
ease. Again, there was some evidence of variations 
among developing countries themselves. Survival of 
patients with this third group of cancers was only 
slightly lower in Europe than in the U.S. In general, 
survival in developing countries was similar to or a 
little lower than survival in the U S .  in the late 1960s 
and early 1970s. 
INTERPRETATION OF COMPARATIVE 
SURVIVAL DATA 
Population-based survival for patients with a particular 
cancer represents the “average” outcome achieved in a 
population of individuals whose prognosis is influenced 
by a range of host factors (e.g., age, sex, or risk of death 
from other diseases), tumor-related factors ( e g ,  extent 
of disease), and factors relating to cancer control activi- 
ties at the population level (e.g., availability and quality 
of diagnosis and treatment services). Estimates of the 
survival probability in a group may also be affected by 
artifacts of case ascertainment by cancer registries, fol- 
low-up, and statistical methodology. In comparing re- 
sults for developed and developing countries, it is im- 
portant to realize that some or all of these factors may 
be involved. However, we believe that we have mini- 
mized the effects of artifacts in the data by using stan- 
dardized cancer registration definitions and data collec- 
tion techniques. Furthermore, some of the host factors 
could be accounted for by standardizing for age and 
using relative survival methodology, which adjusts for 
differences in competing risks of mortality in the popula- 
tions compared. For tumors associated with poor prog- 
nosis (carcinomas of the lung and pancreas), the low 
rates of survival estimated for developing countries offer 
some reassurance about the completeness of at least 
short term follow-up. The remaining differences in sur- 
vival are likely to be due mainly to the disease being in 
a later stage at diagnosis and a lack of availability of 
appropriate treatment for at least some sectors of the 
populations of developing countries. It should be noted 
that because the present study is descriptive, the follow- 
ing remarks are somewhat speculative. 
The survival of patients with testicular tumors and 
Hodgkin’s disease in developed countries has in- 
creased substantially since the introduction of effec- 
tive chemotherapy and multimodal therapy in the last 
25 years. The lack of well-established first-line medical 
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FIGURE 1. Differences in survival of patients with certain cancers between developed and developing countries, in relation to the 
potential benefits of primary prevention, early detection and treatment, or some combination of these, in reducing cancer mortality in 
developing countries. 
treatment in some developing countries may lead to 
later diagnosis and referral of patients with these con- 
ditions, but it seems likely that the major determinant 
of survival is the availability of treatment. 
For carcinomas of the large bowel, breast, and 
cervix, the relative importance of the stage of disease 
at diagnosis and the availability of treatment in devel- 
oping countries is less evident. The differences in the 
survival of patients with carcinoma of the large bowel 
between the U S .  and Europe are probably due to ear- 
lier diagnosis in the U.S. through extensive use of fecal 
occult blood testing and endoscopy, which began in 
the early 1 9 8 0 ~ . ~  With less extensive use of these early 
detection methods in Europe, at least in the early 
1980s, the survival rates achieved were not substan- 
tially greater than in some developing countries. This 
suggests that stage of disease is the most important 
factor affecting survival. The mainstay of the treatment 
of colorectal carcinoma is surgical management, and 
developing countries have at least a basic level of facil- 
ities available for surgery. 
The 5-year relative survival for women younger than 
75 years with breast carcinoma was 43-63% in devel- 
oping countries, as compared with 65% (in 1967- 19731, 
76% (in 1974-1986), and 82% (in 1986-1991) in the US.  
‘There has been considerable progress in the early detec- 
tion and treatment of breast carcinoma in the last 3 
decades. There is a debate about the relative contribu- 
tion of early detection and treatment to the improve- 
ment in survival and to the recently observed reductions 
in breast carcinoma mortality in some developed coun- 
tries. Systematic mammographic screening for breast 
carcinoma was not practiced in any of the developing 
countries during the period of data collection. Moreover, 
neither was opportunistic screening widely practiced in 
developing countries in contrast to many developed 
countries in the 1980s. It seems likely that the survival 
differences are due to both late stage of disease at pre- 
sentation as well as the availability and quality of adju- 
vant treatment. 
Compared with the survival of patients with some 
other cancers, the differences in patient survival among 
the registries of most developing countries, the US., and 
Europe were quite modest for cervical carcinoma. This 
may be because the key elements of control of this dis- 
ease, early detection and surgical and radiotherapeutic 
treatment, are within the technologic scope of the health 
authorities of most developing countries included in this 
study. Opportunistic cervical screening was practiced in 
the registry areas of all developing countries during the 
period of data collection, giving at least some sectors of 
those populations the opportunity to be treated when 
disease was in an early stage. The lack of systematic 
screening of all women at risk means that the overall 
distribution of stage of disease for patients is less favorable 
in developing countries (for example, in India’) than in 
the US. and Europe. 
CONCLUSIONS 
Despite concerns about data quality and comparabil- 
ity, and despite the descriptive nature of this initial 
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study, we believe that the results are noteworthy and 
informative. Survival results for developed countries 
demonstrate what can be achieved. Our study repre- 
sents a first step toward identifying the elements of 
cancer control, including primary prevention, early 
detection initiatives, and treatment, which are most 
likely to contribute to the reduction of cancer mortality 
in developing countries. 
Figure 1 shows the magnitude of differences in 
survival for patients with certain common cancers be- 
tween developing countries and developed countries, 
plotted against an axis representing the different 
phases of cancer control (primary prevention; early 
detection, including screening; and treatment). For tu- 
mors associated with poor prognosis, there is a lack 
of effective screening tests, and treatment has a low 
success rate even for the small proportion of tumors 
detected at an early stage. For these, primary preven- 
tion is currently the only viable strategy. At the other 
extreme, the considerable differences in survival ob- 
served for patients with carcinoma of the testis and 
Hodgkin’s disease are most likely to be reduced by 
improved treatment in developing countries. Between 
the extremes, there are a number of tumors for which 
there is effective treatment of early disease. For these, 
some combination of early detection measures allied 
to treatment services offers the best hope of improving 
survival in developing countries. However, more infor- 
mation is required to identify the most suitable poli- 
cies. Two types of studies are required. First, “high- 
resolution” studies of the diagnosis, treatment, and 
outcome for samples of patients from population- 
based cancer registries in developing countries are 
needed to identify the subgroups of the populations 
with poor survival (this is the approach taken in fol- 
lowing up the EUROCARE descriptive study of survival 
in Europe, which showed significant differences 
among European countries in patient survival of cer- 
tain major cancers). Second, population-based trials 
are required to identify technologically and economi- 
cally viable programs of screening allied to accessible 
treatment facilities. 
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Chapter 2
Stastistical methods for cancer survival
analysis
Swaminathan R and Brenner H
Introduction and background
The life table, one of the basic tools in the
description of mortality experience of a population,
was first developed as early as 1693 by E. Halley in
England. It forms the basis for calculation of the life
table estimate of the survivor function, which is still
widely used today in the analysis of data from
epidemiological studies. Information on survival has
long been recognized as an important component in
monitoring cancer control activities [1]. Like all other
health indices, survival statistics are useful primarily
as comparative measures. It is these comparisons that
help us to suggest possible reasons for the variations
and provide targets for improvement and a means of
monitoring progress towards them [2]. Survival data
obtained from a population-based cancer registry
ideally portrays the average outcome of the disease in
the pertaining region covered since it is based on an
unselected series of incident cancer cases [3].
Follow-up 
Adequate and complete follow-up is a prerequisite to
conducting a survival study. Lengthy periods of time
may be required until the event of interest (any death
is the outcome studied in this publication) occurs in
all cases studied and maintenance of surveillance on
patients may be extremely difficult. Hence, a closing
date for follow-up is typically imposed keeping in
mind the adequacy of follow-up information needed
to estimate the survival at a specified time. Complete
follow-up is deemed to have been achieved when the
vital status (alive/dead) at closing date is known for
an individual. If not known, then the follow-up is
incomplete.
With passive follow-up, information on deaths is
routinely received either by-law or via an
arrangement with the vital statistics division. Using
this procedure, those patients for whom no
information of death has been received may be
considered to be "alive" until that point of time. The
main requirement for this method to work efficiently
is that there is a high quality of registration of
mortality data and unique data linkage possibilities
which ensure the follow-up of cases to be complete
with the exception of migration or rare losses. A few
of the registries contributing data to this scientific
publication have relied almost entirely on this means
of obtaining follow-up information.
Active follow-up is necessary in the absence of a
reliable health information system, and it may
supplement the latter in case of incomplete passive
follow-up. Most registries that contributed data to
7
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Adequate and complete follow-up is a prerequisite for the conduct of any survival study. Passive follow-up
relies on routine availability of mortality data through unique data linkage possibilities, while active follow-up
supplements mortality ascertainment, for which there are a variety of methods. Cox proportional-hazard
model was employed to test whether censoring was random in presence of loss to follow-up. Absolute survival
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period approach was also used wherever possible. Expected survival probability for registries was estimated
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this scientific publication generally resorted to this
method after the routine matching of the incident
cancer cases with the available mortality information
was completed. The different ways by which this is
accomplished are by repeated scrutiny of medical
records in hospitals, enquiries with attending
physicians, scanning the population registers (city
directories), health registers of national health
services, health insurance registers, electoral lists,
postal/telephone enquiries and visits to the homes of
the cases or persons known to them.
Censoring
It is impractical to continue follow-up until all cases
under study are dead. With a closing date of follow-
up in place, for the subjects who are withdrawn
wilfully, drop out or are lost from the study before
this date and for those who are still alive at this date,
only a lower limit on lifetime is available. This is not
to conclude that no information is available on them,
but that the information is partial. This unique
feature in lifetime data analysis, which occurs when
exact lifetimes until death are known for only a
portion of the individuals in the study and known to
exceed certain values in the remainder, is called
"censoring". 
When censoring occurs, either due to the termination
of study at the closing date which is solely technical
or due to loss to follow-up that is 'unrelated' to the
outcome studied, e.g. death, it is said to be random
or non-informative censoring. When censoring occurs
due to loss of follow-up which is 'related' to death, it
is known as non-random or informative censoring.
Test for random censoring
Little reliance can be placed on the estimated
survival assuming random censoring when the
magnitude of loss to follow-up is high. In such
instances, it is desirable to investigate deviation from
randomness of censoring. In this publication, the Cox
proportional-hazard model [4] was used whenever the
censoring before closure of study or loss to follow-up
exceeded 10% of total cases. For this purpose, the
outcome studied is the "loss to follow-up" within a
specified time from the index date. Since the survival
is estimated at five years for the majority of cancer
registries in this publication, the time is fixed as five
years. All cases censored before closure of the study
and having had a follow-up of less than five years
constitute the loss to follow-up group, and the rest of
the cases who are either dead or known to be alive on
the closing date of follow-up are treated as censored
for this analysis to detect the presence of informative
censoring. Since the Cox model deals with survival
time dynamically, the varying patterns of every loss to
follow-up at different intervals on the survival time
scale are well accounted for. Based on the general
availability, the variables or determinants that are
tested for association with loss to follow-up are age
at diagnosis, sex and extent of disease. An example of
this type of analysis is given in Table 1, where the
proportion of patients lost to follow-up ranges
between 7−16% among categories of age at diagnosis
and 0−27% among categories of extent of disease. A
statistically significant differential risk of loss to
follow-up is observed. This suggests the presence of
non-randomness of loss to follow-up and, therefore,
Chapter 2
8
http://survcan.iarc.fr
Table 1. Example of test for randomness of loss to follow-up: Cox proportional-hazards model
Registry : Mumbai
Site of cancer : Female breast
Period of registration of cases : 1992−1994
Period of follow-up : 1992−1999
Event studied : Lost to follow-up before 31st December 1999 and having a follow-up of <5 years
% Loss to follow-up : 10.9%
Age at diagnosis
44 years 53 6.9 1.00 -
45−54 75 10.4 1.63 1.14−2.31*
55−64 89 16.2 2.47 1.76−3.47*
65−74 47 13.7 2.25 1.52−3.33*
75+ 9 7.4 1.26 0.62−2.56
Extent of disease
Localized 129 14.6 1.00 -
Regional 98 8.2 0.54 0.41−0.71*
Distant metastasis 1 0.4 0.05 0.01−0.35*
Unknown 45 26.9 2.40 1.70−3.38*
Determinants of Lost to follow-up Relative hazard of loss to follow-up$
loss to follow-up Number % Hazard ratio 95% CI
$ Each factor is adjusted for the other in the table; CI: Confidence interval; * p   0.05.
Stastistical methods for cancer survival analysis
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the survival estimates assuming random censoring
should be interpreted with caution.
Actuarial method of estimation of absolute survival
probability
It is rare to find a closed group of subjects in a
survival study without censoring, except possibly in
an artificial situation such as the construction of a life
table. The actuarial method of estimating survival
probability [5] handles censoring by assuming it to be
random. This method involves the construction of a
life table that permits the calculation of the
cumulative probability of survival at time ti+1 from
the conditional probabilities of survival during
consecutive intervals of follow-up time up to < ti+1.
This method has been used in this publication to
estimate the absolute survival probability. The layout
and method of calculation of the elements of a life
table are illustrated in Table 2 [6].
For each time period ti to ti+1, ni is the number of
subjects at risk of outcome at the beginning of the
time interval. The number of cases censored during
the interval, because they are lost to follow- up or
withdrawn alive at the end of the follow-up period, is
shown as wi. The symbol di denotes subjects who
experienced the outcome during each interval. The
effective number of subjects at risk during each
interval is calculated as:
In this way, subjects who are alive and at risk of
experiencing the outcome during the interval ti to ti+1,
but who are censored at some point of time during
the interval, are assumed to have been followed up
for, on average, half of the interval. This actuarial
assumption is based on the censorings being
independent of the outcome studied (i.e., any death,
in this publication). The probability of occurrence of
the outcome during the interval is given by
The probability of survival during the interval
beginning ti is then calculated as 
from which the cumulative probability of survival up
to time ti+1 is derived from the product of the pi's
This quantity pi+1 is often multiplied by 100 to give
the "percentage survival" at time ti+1. 
Different approaches
There are several approaches to estimating the
absolute survival at a given time by varying the
registration and follow-up periods of time. These are
discussed below and illustrated in Figure 1. 
Cohort analysis
The simplest way of computing survival probability is
to compute the ratio or percentage of the number of
subjects alive at the end of, e.g., 5 years from the
index date by the total number of subjects in the
study at the beginning of the study, excluding those
who did not have a chance to be followed for 5 years
http://survcan.iarc.fr
Table 2. Illustration of the layout of the life table and calculation of cumulative survival probability by 
the actuarial method
0−1 3289 166 365 3206.0 0.114 0.886 0.886
1−2 2758 275 301 2620.5 0.115 0.885 0.784
2−3 2182 37 278 2163.5 0.128 0.872 0.683
3−4 1867 30 191 1852.0 0.103 0.897 0.613
4−5 1646 20 106 1636.0 0.065 0.935 0.573
Interval Alive at Last known No. of Effective Conditional Conditional Cumulative
beginning alive during deaths number probability probability probability
of interval interval during at risk of death of survival of survival
(consored) interval (to end of
interval)
ti - ti+1 ni wi di Ni qi pi Pi+1
Source: Black and Swaminathan (1998)
after diagnosis. For this purpose, only subjects
potentially under observation for at least 5 years and
having a potentially complete follow-up of five years
are taken into consideration. This approach, which
has been called cohort analysis [7] has the
disadvantage that even the most recent survival
estimates are exclusively based on patients diagnosed
many years ago. For example, with a database that
includes patients diagnosed between 1989 and 1999
with a closing date of follow-up at the end of 1999, a
cohort estimate of 5-year survival could be obtained
from patients diagnosed in 1994 at the latest,
because patients diagnosed in later years could not
possibly have 5-year follow-up by the end of 1999.
This approach is illustrated by the solid black frame in
Figure 1.
Complete analysis
This is the approach to be used when there is no
restriction on the potential follow-up time to equal,
e.g., five years from the index date for which the
survival is estimated. Rather, all subjects who are
diagnosed as incident cancers until the closing date of
the follow-up period qualify for inclusion in the
analysis. Apart from the subjects with a complete
follow-up of five years, those under observation for a
variable period of time and having an incomplete
follow-up of less than five years are included [7]. In
the example given above, all patients diagnosed in
1995−1999 could be included in addition to those
diagnosed in earlier years for the derivation of a
complete estimate of 5-year survival. This approach is
illustrated by the dashed black frame in Figure 1.
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Figure 1. Types of analysis to derive up-to-date 5-year survival estimates based on data of patients
diagnosed in 1989−1999 and followed until the end of 1999
Cohort analysis: solid black frame; 
Complete analysis: dashed black frame; 
Semi or partially complete analysis: dotted black frame; 
Period analysis: solid blue frame.
The numbers within the cells indicate the years since diagnosis.
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Semi or partially complete analysis
This approach is widely practised in the estimation of
survival by cancer registries. It was adopted in the
previous publication on cancer survival [6], and is
used for most analyses in this publication as well.
Here, not all patients diagnosed until the closing date
of follow-up are included. Rather, only patients who
have had some minimum potential follow-up time at
the closing date of follow-up, such as two or three
years, are included. In our example, a partially
complete estimate of 5-year survival may be obtained
from patients diagnosed in or before 1997 and who
have had a minimum of two potential years of follow-
up at the end of 1999. This approach, which is in
between the pure cohort and pure complete analysis,
is illustrated by the dotted black frame in Figure 1.
Period analysis 
This is an alternative approach [8] to deriving more
up-to-date estimates of cancer patient survival by
exclusively utilising the survival information
pertaining to the most recent incidence and follow-up
periods. The period of interest could be a single
calendar year or more. Period analysis exclusively
reflects the survival experience of subjects within the
most recent calendar period for which the follow-up
is available. This is achieved by left truncation of
observations at the beginning of this period in
addition to censoring at its end [9].
In our example, assume that a period estimate of 
5-year survival is to be derived for the 1995−1999
period, the most recent period for which pertinent
data are available, then all observations are left
truncated at the beginning of 1995 in addition to
being censored at the end of 1999. The 5-year period
estimate of survival would be obtained from patients
diagnosed in 1990−1999 for whom some proportion of
5-year follow-up might have fallen in the 1995−1999
period. With this approach, illustrated by the solid
blue frame in Figure 1, different parts of the survival
function would be derived from patients diagnosed in
various calendar years. Survival during the first year
following diagnosis would be estimated for patients
diagnosed in 1994−1999, survival during the second
year following diagnosis would be estimated for
patients diagnosed in 1993−1998, and so on, until
survival experience during the fifth year following
diagnosis which would be obtained for patients
diagnosed in 1990−1995. These conditional survival
probabilities are then combined in the usual way to
generate 5-year cumulative survival estimates for the
1995−1999 period. It has been shown that period
analysis is the approach that clearly provides the
most up-to-date estimates of cancer patient survival,
and that period estimates of survival for some given
period quite closely predict survival experience of
patients diagnosed during that period [10]. In this
publication, however, period analysis could not
routinely be used because incidence data had not
been collected up to the closing date of follow-up by
most registries. That said, period analysis was used
with data from registries in Qidong and Tianjin,
China, and Singapore. A comparison of the survival
estimates by cohort and period approaches has been
done and the trends over calendar time were
depicted.
Relative survival
Berkson [11] in 1942 introduced the concept of
relative survival. The relative survival (Ri) for a group
of patients at the end of an interval beginning at time
ti is defined as 
where Si is the absolute survival for subjects with a
particular cancer and Si* is the expected survival of a
group of individuals with the same demographic
characteristics (age, sex, etc.) who are at risk of
death only from causes other than the cancer under
study [12]. Berkson and Gage [13] suggested that the
observed proportion of survivors of cancer can be
compared with an expected proportion of survivors
derived from similar people from the general
population, most of whom do not have the disease
under study. The concept of relative survival
methodology has primarily been designed for cancer
survival studies to exclude the effect arising from
different background mortalities.
Estimation of expected survival probabilities
Expected survival probabilities are usually estimated
from age- and sex-specific (sometimes also race-
specific) life tables of the general population for the
registry area. At least three different methods have
been proposed to estimate expected survival, the so-
called Ederer I [12], Ederer II [14] and Hakulinen [15]
methods. For follow-up times up to 5 years (as
reported in this publication) they generally give very
similar results. In this study, expected survival
probabilities are estimated from country-, age- and
sex-specific abridged life tables [16] according to the
Ederer II method [14] (for 5-year survival) and the
Hakulinen method [15] (for 10- and 15-year survival),
the latter of which corrects for potential
heterogeneity in patient withdrawal over long
potential follow-up times. The estimation of
expected survival for earlier calendar periods is done
using the country-, age- and sex-specific life tables of
the respective calendar periods.
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Age-standardization of survival
Most biological phenomena are related to age; there
is no reason to expect that survival is not. It is
important to note that use of relative rather than
absolute survival does not make age-standardization
unnecessary. For many types of cancer, the risk of
dying as a result of the cancer itself is clearly
associated with a subject's age at diagnosis. The ages
at diagnosis of cases of any cancer in the developing
and developed countries are vastly different [17].
When comparing survival in different groups of
patients from different regions, there is a definite
need to standardize both absolute and relative
survival estimates for age.
For this purpose, direct standardization of survival
estimates has been advocated [18]. This is commonly
done by using direct standardization of age-specific
survival estimates to derive summary statistics called
age-standardized absolute survival (ASAS) or age-
standardized relative survival (ASRS). For example,
ASAS at the end of some follow-up period i is given by
where the aix are age-specific (x:0−4;5−9; etc.)
absolute survival estimates at the end of follow-up
period ti and stx are the age-specific proportions used
as "standard or weight" for standardization. The stx
could be arbitrary. Traditionally, the weights have
been chosen to reflect the age distribution at
diagnosis of some standard cancer population, such as
the world standard cancer population [19].
However, for relative survival, the traditional age-
standardization, as outlined above, provides results
that are conceptually different from crude survival
data [20]. Furthermore, traditional age-
standardization is often difficult if not impossible to
carry out in the presence of sparse and censored
data. Hence, in this publication, an alternative
approach to age-standardization [21] has been
adopted. In this approach, one first assigns the
weights to the individual patients depending on their
age and then carries out conventional survival
analyses using the "weighted individual data". The
weights are defined as the ratio of the proportion of
patients in the respective age group (x) in the
standard population (st) divided by the proportion of
patients in the respective age group in the study
population. Whereas in the unadjusted (crude
analyses), each patient in the study population and
her/his contributions to the numbers of persons at
risk and deaths are (implicitly) entered with a weight
of 1, the proposed form of age-adjustment gives
weights higher (lower) than 1 to patients in age
groups which are under-represented (over-
represented) in the study population compared to the
standard population. The advantages of doing this
type of adjustment are: (i) it remains feasible with
sparse data, even in situations where survival
estimates cannot be derived for certain age groups,
and (ii) it provides age-adjusted estimates of relative
survival that are conceptually consistent with the
crude estimates. In particular, age-adjustment to the
study population's own age structure yields a
standardized relative survival that is identical to the
crude one.
In this study, the weights are defined as the ratio of
the proportion of patients in the respective age group
in the standard population as summarized in
GLOBOCAN 2002 [22], divided by the proportion of
patients in the respective age group in the study
population registry for every classified cancer
site/type.
Software used
While absolute survival can be estimated with any of
a large number of commercially available statistical
software packages, there are only few specialized
programs for relative survival analysis. In this study,
analyses are done using the publicly available SAS
macros "period" or "periodh" (age-specific and crude
analysis, [10]) or "adperiod" or "adperiodh" (age-
adjusted analysis, [21]) , which can be used to
calculate both absolute and relative survival (Ederer
and Hakulinen methods) with either the cohort, semi-
complete or period approach.
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